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SUMMARY
Inflammation of the joint, arthritis, is a major problem in human 
society, affecting large numbers of individuals, including a large 
number of those aged 60 and over. A principle event in development 
of inflammation is an increase in blood flow. Different factors are 
involved with neurocirculatory control of which the neurokinins and 
calcitonin gene-related peptide (CGRP) may have an important role 
and the work described in this thesis is directed at investigating this.
There are few reports about the role of neurokinins in joint 
inflammation and how neurokinin receptors are affected and thus 
animal models of inflammation were used for these investigations, 
based on the rat knee joint.
Two techniques were used to measure joint inflammation:
a) microturbidimetry was used to examine knee joint perfusate 
to evaluate its protein content due to the extravasation effect of CGRP.
b) laser Doppler imaging (LDI) was employed to give an 
estimate of blood flow changes in response to application of 
neurokinins
In normal knee joints:
1) Intra articular injection of 10~6 mol of CGRP produced 
protein extravasation which was sustained throughout the period of 
infusion. This was a specific effect of CGRP and not merely a 
consequence of its potent vasodilator effect.
xxn
2) SP on its own induced a dose dependent and transient 
vasodilatation, this being mediated via NK1 and NK2 receptors.
3) NKA at higher doses induced vasodilatation and this 
vasodilator effect was chiefly mediated via NK2 receptors and a 
smaller part mediated via NK1 receptors.
4) NKB produced a potent and significant vasodilatation. This 
effect was mediated chiefly via NEC1 and NK2 receptors and it is 
unlikely that NK3 receptors are present.
5) The neurokinin receptors in the rat knee joints are of the B 
type of NK2 and a possible subtype of NK1 receptors.
6) SP and perhaps other neurokinins are normally released from 
sensory nerves mediating and participating in regulation of vascular 
tone and basal blood flow.
B) In inflamed knee joints:
1) In the carrageenan-induced inflammation, there is a hyper­
sensitivity to the neurokinin response with a significant increase in SP- 
induced vasodilatation.
2) In the acute capsaicin treated knee, an acute vasoconstriction 
occurred at different doses of capsaicin which in lower doses was 
followed by a vasodilatation which could be due to release of 
neurokinins from sensory nerve endings. Vasoconstriction by 2% 
capsaicin is irreversible over the time course of the experiments.
XXIII
3) With acute and chronic inflammation induced by capsaicin, 
there is an alteration in the response to neurokinins and there is an 
attenuated response to the SP vasodilator effect on blood flow.
4) In adjuvant-induced arthritis, one week post induction the 
effect of SP was completely abolished with no response to SP at any 
dose. This attenuation changes to a vasoconstriction effect at week 3.
5) There is a contralateral effect of adjuvant-induced arthritis, 
the response to SP being significantly attenuated in the contralateral 
knee. This response revealed a neurogenic effect of inflammation in 
one knee being exerted on the contralateral joint.
6) In all three different models of inflammation, the response to the 
neurokinins was altered but there was not any change to the 5HT and 
adrenaline response in adjuvant-induced inflammation.
7) In all of these three models of inflammation neuropeptides 
have a key role in initiating of the signs of inflammation. The further 
joints changes will depend on the nature of the inflammatory agent and 
individual treatments would be required to reduce inflammation and 
joint damage.
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CHAPTER ONE
GENERAL INTRODUCTION
AND
LITERATURE REVIEW
1
1.1.1 INTRODUCTION
Inflammation is an important component of disease in many 
clinical conditions, and it is generally associated with disordered blood 
flow. Arthritis, inflammation of the joints is a specific example in 
which changes in blood flow are an important factor in disease 
development. In the healthy state joints permit a controlled and almost 
frictionless movement, and this depends upon integrity of the joint and 
nutrition of synovial tissue. Four elements of synovial tissues need 
consideration: the compact surface zone, the surface zone layer, 
packing tissue and the vasculature (Edwards 1988). Synovial nutrition 
critically depends on the circulation and microcirculation (Me Kibbin 
& Maroudas 1979). All vascular beds in the body leak a small amount 
of water to the surrounding tissue, which enters the lymphatic drainage 
system. Synovial tissue is unusual in that some of the water passes in 
and out of the cavity (and hyaline cartilage) before becoming lymph 
(Edwards 1988). Since any change in the circulation could have 
serious effects on joint movement, increased vascular permeability in 
inflamed synovial tissue could lead to an imbalance in Starling forces 
with resulting oedema and stiffness of movement (Edwards 1988).
The control of microcirculatory flow is complex, but recently 
neurokinins and calcitonin gene related peptide (CGRP) have been 
found in sensory nerve endings. These peptides have significant effects 
on the vasculature bed and their permeability (Maggi et al 1993a; 
Otsuka & Youhioka 1993; Poyner 1992) and so may have role in the 
pathogenesis of inflammation.
2
To examine microcirculatory changes, many methods of 
measuring blood flow have been developed (Liew & Dick 1981). 
Laser Doppler Imaging (LDI) is the most recent technique which is a 
development of single point laser Doppler flowmetery, allowing large 
areas to be scanned in a relatively short time.
1.1.2 AIMS OF THE STUDY:
Neurokinins and CGRP are newly discovered peptides but many 
physiological and pathological aspects of these peptides remain 
unclear especially regarding joints and the effect of these peptides in 
inflammation. CGRP is a potent vasodilator peptide which potentiates 
other neurokinin vasodilator effects (Cambridge & Brain 1992), but 
little is known of its effect on protein extravasation, and so the first 
objective is to examine this.
The second objective is characterize the neurokinin receptors 
mediating the effect of neurokinins on blood flow in the normal knee 
joint and to find out which neurokinins are involved in the normal 
regulation of articular blood flow.
The effect of neurokinins in different models of inflammation 
and arthritis is unclear, and so a third objective is to study the 
effect of neurokinins on the inflamed knee microcirculation and also 
evaluate the contralateral effect of inflammation. In the second and 
third parts of this study LDI was used and found to be an effective and 
user-friendly tool for the measurement of blood flow.
3
LITERATURE REVIEW
1.2 JOINTS
All bones are interconnected by articulations or joints to form 
the skeleton. These joint are composed of wide variety of connective 
tissue structures that permit varying degree of movement between 
adjacent bones. Three groups of joints are recognised and these are a) 
Synathrotic, b) Amphiarthrotic, c) Diarthrotic. There are also other 
types of classification based on the form of connective tissue which 
can be used. (Gray 1973).
1.2.1 Synathrosis: These joints are generally found in the skull 
and the contributing bony plates that compose them are held firmly 
together by fibrous or cartilagous elements (Mankin & Radin 1989). 
These joints are generally immovable or have a very limited 
movement, and can be further differentiated into three subclasses by 
the type of tissue involved in the union ( Junqueira & Cameiro 1992). 
These joints, also called fibrous joints,, are temporary joints because 
the fibrous tissues become ossified and synostosis will develop over 
time.
1.2.2 Amphiarthrosis: These joints are characterised by the 
presence of broad, flattened discs of fibrocartilage connecting the 
articulating surfaces. The bony portion of the joints is usually covered 
by hyaline cartilage and the entire structure is invested with a fibrous 
capsule. Examples of such joints are those between the vertebra, the 
distal tibiofibular articulation and the pubic symphysis. The hyaline 
cartilage joints become ossified in adulthood and so have no 
movement, but fibrocartilaginous ones retain limited movement.
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1.2.3 Diarthrosis: These joints include most of the body joints 
and have great mobility, such as the elbow and knee joints which have 
diarthrosis ligaments and a capsule of connective tissue to maintain the 
contact at the end of the bone (fig. 1.1). The capsule encloses a sealed 
articulating cavity that contains synovial fluid, a colourless transparent 
viscous fluid like egg white which is dialysed blood plasma with a 
high concentration of hyaluronic acid, a glycosaminoglycan of high 
molecular weight produced by B cells of the synovial layer (McCarty 
1989). These joints are also called synovial joints, the capsule is 
composed of two layers, one external (fibrous layer) and one internal 
(synovial layer). The internal surface of the synovial membrane is 
usually lined by a layer of squamous or cubical cells. Underneath this 
cellular layer is loose or dense connective tissue with areas of adipose 
tissue. These layers are separated from each other by a small amount 
of connective tissue (fig. 1.2).
It has been shown that there are two type of cells lining the 
synovial membrane: a) A cells, similar to mononuclear phagocytes 
with a large golgi complex, endoplasmic reticulum, but only small 
number of lysosomes.
b) B cells which are similar to a fibroblast (fig. 1.3) (Junqueira 
& Cameiro 1992).
This thesis is particularly concerned with the knee joint, one of 
the largest of the diarthrodial joints, and one which is commonly 
affected in joint diseases.
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Fig 1.2: Histologic structure o f the synovial membrane, 
with its lining connective cells in epithelioid arrangement. 
There is no basal lamina between the lining cells and the 
underlying connective tissue.(From Junquera 1992, in 
Basic histology)
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Fig 1.3: Schematic representation o f the ultra-structure o f the 
synovial membrane. A and B cell types are separated by a 
small amount o f connective tissue ground substance. (From 
Junquera 1992, in Basic histology)
1.3 GROSS ANATOMY OF THE RAT KNEE JOINT:
On the flexor surface of the distal end of the femur just proximal 
to the condyles are two small but well defined articular surfaces for the 
sesamoid bones, the medial and lateral fabella, which develop in 
connection with the tendons originating at the head of triceps surae. 
The semilunar cartilages of the knee joint are also ossified in the rat 
(Chace 1955)
1.3.1 Arterial supply:
The femoral artery (fig. 1. 4) is a continuation of the external 
iliac which travels in the medial aspect of the thigh. It extends from the 
inguinal ligament to the point where the vessel passes between 
adductor brevis and caudo femoralis to the popliteal fossa where is it 
known as the popliteal artery. It has six branches, the superficial 
circumflex iliac, the highest genicular, the sapheneous (great 
saphenous), the profunda femoralis and perforating, the muscular, and 
the superficial branches.
The highest genicular artery (genu suprema) arises from the 
deep surface of femoral artery. In the majority of cases its origin is 
above the muscular branch to the adductor and superficial epigastric, 
but in some it may leave the femoral artery just above the knee. In the 
rat, this artery represents the combined muscular and articular 
branches of the highest genicular, and occasionally the muscular 
branches spring directly from the femoral artery, and in such cases the 
articular branch may arise with the superficial circumflex iliac branch 
of femoral or the superficial epigastric (fig. 1.4) (Chace 1955).
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1.3.2 Venous drainage:
Joint drainage, from the medial inferior genicular, lateral 
inferior genicular, and middle genicular veins and tributaris vein is 
achieved by all of these veins. Ventral drainage begins with the 
junction of the anterior and posterior tibial vein at the upper margin of 
the popliteus muscle, and ends with drainage into the femoral vein. 
The femoral vein comes to a superficial position on the medial surface 
of the thigh and runs upward with the femoral arteries and leaves the 
tight by passing under the inguinal ligament and becoming the external 
iliac vein (Chace 1955)(fig. 1.4).
1.3.3 Nerve supply:
The femoral nerve, from the third and fourth lumbar nerves, 
appears from between psoas minor and iliacus and runs under the 
inguinal ligament in the company of the external iliac vessels before 
entering the thigh. It is divided into the posterior and anterior, the 
anterior comprising muscular branches. After giving various branches 
to the quadriceps femoris, it continues to the saphenous nerve (long 
saphonous) and runs superficially down the medial surface of the thigh 
and lower leg, accompanied by the saphenous artery and large 
saphenous nerve which takes the place of the medial sural branch of 
tibial nerve. (Chace 1955)(fig.l.5).
Joints are supplied by articular nerves the branches descending 
from main nerve trunks. Both the anterior and posterior articular 
nerves contains myelinated and unmyelinated afferent fibres and 
unmyelinated sympathetic post ganglionic fibres. The total number of 
nerve fibres has been determined by electron microscopy and, for
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Fig 1.4: Superficial blood vessels o f the medial aspect of 
the thigh. The femoral artery and vein. (From Chace, 
Green Eunic 1955, in Rat anatomy)
Fig 1.5: Divisions o f left femoral artery (From Chace, 
Green Eunic 1955, in Rat anatomy)
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Fig 1.5: Divisions o f the sciatic nerve
example the rat posterior atricular nerve (PAN) has 400 axons of 
which 20% are myelinated and 80% are unmyelinated and about half 
of the unmyelinated fibres are sympathetic efferents (Schaible & 
Grubb 1993).
1.4 CONTROL OF BLOOD FLOW
The peripheral circulation is essentially controlled by: neural 
(sympathetic, peptidergic), hormonal (cathecholamines etc.) and local 
factors at the tissue level.
The vessels that regulate blood flow throughout the body are 
called resistance vessels (arterioles) and these are very important in 
the central control of blood pressure regulation and blood flow (Berne 
& Levy 1991). The central nervous system regulates and controls 
systemic blood pressure.
The regulation of blood flow through each organs depends upon 
its moment to moment function and metabolic needs and local 
mechanisms override neural control in some situations, although the 
precise mechanisms are unknown. Four major hypotheses have been 
but forward to explain the local control of blood flow; 1) The 
myogenic hypothesis, which is related to degree of stretch of the 
smooth muscle which is the actuator in producing alternations in 
vascular resistance. 2) The metabolic hypothesis, in which it is 
believed that under conditions of consumption of oxygen, vasodilator 
metabolites are being produced at a constant rate, a transient increase 
in flow would wash out the metabolites at a more rapid rate and reduce 
their concentration thereby increasing vascular resistance. Conversely 
if perfusion pressure dropped the metabolites would be washed out at a
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reduced rate and locally increase their concentration and thus decrease 
vascular resistance(West 1990). 3) tissue pressure hypothesis and 4) 
the flow dependent dilatation which acts in the certain tissues like 
kidney and arcade arterioles (Berne & levy 1991; West 1990). The 
local circulation is also affected by active and reactive hyperaemia, 
response to injury which activates various tissues components, low 
P02, high PC02, lactic acid, adenosine, bradykinin, histamine, 
hydrogen ion, and as recently reported sensory neuropeptides (Vander 
et al 1990). Most of the vasodilator theories assume that the 
vasodilator substance is released from the tissue mainly in response to 
oxygen deficiency (Guyton 1991). It is likely that a combination of all 
these determinants regulate local flow.
There is now good reason to believe that chemical mediators 
-neuropeptide hormones- are likely to be a dominant factor in 
regulation and under special conditions are produced at a constant rate. 
In general the joint blood vessels behave like those of the skin 
(Cobbold & Lewis 1956).
1.5 REGULATION OF JOINT BLOOD FLOW:
Blood flow through a microcirculatory bed varies from tissue to 
tissue depending on metabolic need. There is a large variation in 
capillary density for example, in muscle it is 2000 capillaries per mm^ 
while in the skin it is about 50 capillaries per mm^ (Stem et al 1977). 
All the factors which are involved in the control of local blood flow 
regulation, including central and local factors, are also involved in the 
regulation of joint blood flow. In peripheral areas local control of joint
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blood flow is likely to be more important than central control because 
nutritional needs can alter so quickly.
Apart from all these factors, there are other important factors 
which affect joint flow and which are important for nutrition. These 
are:
a) Changes in intra articular pressure. Phelps et al (1989) 
showed that the synovial microcirculation is reduced by moderate 
increases in hydrostatic pressure and that small changes in intra- 
articular pressure (9-12 mm/Hg) can cause an appreciable decrease in 
blood flow as measured by 133xe clearance. The clearance doubled if 
only 10 ml of effusate material was aspirated (Liew & Dick 1981). In 
patient with rheumatoid arthritis (RA) intra-articular pressure is 
related to local hemodynamics of the knee and to regional blood 
perfusion. Elevation of the intra-articular pressure may affect the 
hemodynamics of the knee joint (Bunger et al 1986).
b) Heat: When temperature increases either locally or centrally, 
blood flow is increased and this also applies to the knee (Liew & Dick 
1981).
c) Exercise: blood flow through the knee segment increases 
during exercise, and it has been shown that there is an increase in 
blood flow in the calf muscles during resistive rhythmic contraction 
(Liew & Dick 1981). St'onge et al (1971) indicated that in the knee, 
there is a reduction in the clearance rate of Na+ during the exercise, 
but the exact mechanism is unclear.
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d) At rest, there is a generalised reduction in blood flow to the 
resting part both in the number and calibre of the blood vessels and 
this is probably the beneficial mechanism behind bed rest in acute 
rheumatoid arthritis (Liew & Dick 1981).
e) During inflammation: Inflammation induces marked 
increase in articular blood flow and this can be measured by 
techniques such as 133xe clearance '(Liew & Dick 1981).
1.6 CELL MEMBRANE RECEPTORS
In recent years a large number of neuropeptide hormones have 
been identified including sensory neuropeptides and neurotransmitters 
(Utosoka & Masanavi 1993; Mussap et al 1993) and each peptide is 
recognised by a specific and distinct cell surface receptor which 
translates hormone recognition into a biological response (Nuki et al 
1994). Each hormone receptor is a unique molecular species, and there 
are certain features which are similar among peptide receptors:
A) a mono binding region exposed on the external cell surface
B) a hydrophobic region which anchors them within the lipid 
bilayer of cell membrane
C) an activation site which interacts either with other membrane 
component or with the interior of the cell wall (West 1990).
Peptide hormone receptors are glycosilated and often contain 
more than one subunit and require phospholipid or a membrane
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environment for optimum biological activity. Two general structures 
for cell surface hormone receptors have been identified:
I) first structure consists of seven hydrophobic membrane 
spanning helical surface loops between membrane segment from the 
ligand binding domain
II) The second structure consist of a single membrane spanning 
domain which separates the extracellular domain from intracellular 
domain (Kubo et al 1986).
There are approximately lO^-lO^ receptors on a target cell and 
they have a continuous turnover and a potential half life and 
participation in the recycling period. Also, they are dynamic molecules 
and extensively regulated by the cell; for example long term exposure 
to a hormone causes decrease in receptor concentration (down 
regulation) while a low concentration of hormone causes an increase in 
receptor number and hypersensitivity (up regulation). (West 1990). 
Functionally there are four kind of receptors:
a) receptors for fast neurotransmitters, which directly couple to 
an ion channel.
b) receptors for many hormones and slow transmitters which 
couple to a effector system.
c) receptors which directly link to tyrosine kinase.
d) and finally steroid receptors.(Fig. 1.6)(Rang & Dale 1991)
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A. Direct ligand-gated channel type
Binding dom ain
x 4 or 5
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B. G-protein-coupled type
Binding dom ain
G-protein
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DNA-binding dom ain 
(‘zinc fingers’)
Fig 1.6: General structure of four receptor families (Rang and 
Dale 1991, in Pharmacology
The next step after association between hormone and receptor is 
signal generation, and here the mechanism is different depending on 
the coupling mechanism:
I) Activation of cyclic adenosine monophosphate, which has 
three subunits: a stimulating regulatory component, a catalytic 
component, and an inhibiting regulatory component
In the case of the activation of the stimulatory component, a 
catalytic unit will activate and this increases the formation rate of 
cyclic AMP , Mg AMP & GTP and production of ATP initiating a 
chain reaction to start up (Baldwin 1994).
In other cases activation of the inhibitory component leads to 
deactivation and decreases of formation cAMP and ATP (fig. 1.7).
II) Calcium calmodulin: the activated receptor can open 
calcium channels and mobilise calcium into the cell, binding to 
calmodulin which is a free protein. This complex is a powerful 
regulator of the activity of many enzymes (Fig. 1.8).
Ill) Phospholipid products: About 10% of the lipid portion of 
membrane contains phosphatidyl inositol, a hormone receptor 
component which activates phospholipase, and consequently 
phosphatidyl inositole 4,5 phosphate splits into the two component: 
diacylglycerol and inositol tri-phosphate (IP3) which, with calcium 
ions, can activate protein kinase C and consequently activate the 
metabolic pathway.
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Fig 1.7: Activation of cyclic AMP and consequent chain 
reactions. From Vander et al. (1990). in Human physiology
Fig 1.8: Mechanism of hormones action via calcium as 
second messenger. From Vander et al (1990). in Human 
physiology
Hormone
Hormone
A d e n y la te  cy c la se
C ataly tic
unit
In h ib ito ry
un it
Piosma
membrane
Cytoplasm
GTP GDP Mg-ATP cAMP GDP GTP
V  ^  m ^  V
Protein kinase 
(inactive)
Enzyme kinase 
(inactive)
Enzyme
(inactive)
Substra te
Protein kinase 
(active)
Enzyme kinase 
(active)
Enzyme
(active)
Product✓J>
Sto rag e  Release
Further
metabolism
▼Hormone
Endoplasmic
reticulum
U Secretory activities, etc.
Ca + +
Plasma
membrane
Cytoplasm
Ca
Ca + + + Calmodulin
Ca + +— Calmodulin
4 -
U Enzyme  activities
4
U Metabol i c  p a thw ays
▼Hormone
P l a i m a
m«mbran«
P h o sp h o llp a s* ■=>P h ot p h a tid y  lin otito l*
Cy top las m
P ros tag land ins 2 D ia cy lg ly ce ro l  Inositol  t r iphosphate
□ o0
H %>LJ ^  N A_____ -*»im u iikJT
n  t Protein k inase  C a * *  \  J
□ c acAvi,y Z >
Modu la t ion  of  
cell r e sp on se s
t l  E n z y m e  activities
Endop lasmic  
t i  M e ta b o l i c  p a t h w a y s  reticulum
Fig 1.9: Mechanism o f hormone action via membrane 
phospholipids. From Vander et al. (1990). in Human 
physiology
Fig 1.10 a: Mechanism of action of vitamin D, steroid and 
thyroid hormones. The hormone combine with a nuclear 
protein receptor. From Vander et a i (1990). in Human 
physiology
Fig 1.10 b: Types of receptor-effector linkage. (R= receptor: 
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IV) In some cases the receptor itself activates after binding to a 
hormone and after phosphorylation it can activate a cascade of 
metabolic pathways. (Fig. 1.9)
V) Some hormones can freely enter a cell and activate a 
transformation process in the nucleus by coupling with a cytoplasmic 
receptor through transformation and activation of DNA production, 
starting a cascade of production (Fig. 1.10A)(Beme & Levy 1990). All 
these mechanism are summarised in fig. 1.1 OB).
1.7. TACHYKININS
The first report of the discovery of tachykinins was given by 
Von Euler and Gaddum (Von Euler & Gaddum 1931). Substance P 
was the first neuropeptide discovered and was described as "a 
substance which lowered arterial blood pressure of an atropinised 
rabbit by peripheral vasodilatation". Later, in 1964, Gaddum named it 
substance P (SP), in which the "P" stands for the powder obtained after 
the extraction procedure. The chemical formula of SP remained 
unknown until 1970 when Leeman et al reported the amino acid 
sequence of SP (Pemow 1983). In this period some other peptides with 
effects similar to SP were extracted from amphibian tissues. Erspamer 
and colleagues observed that SP and non-mammalian newly 
discovered peptides, (like Eledosin from octopus salivary glands), 
have similar biological activity (Erspamer 1981). Following this, other 
homologues of SP have been discovered, and all these peptides have a 
common c terminal with a phe-xaa-gly-leu-met,NH2 sequence. In 
1985 two other peptides of this family were discovered, these are now
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known as Neurokinin A (NKA) and Neurokinin B (NKB)(Erspamer 
1981 ; Pemow 1983).
1.7.1 nomenclature:
After the discovery of each peptide, a specific name relating to 
its action was given to it, and so there was a different name for each 
peptide. Finally Erspamer and co-workers suggested the term of 
"Tachykinins” for these peptides, because their effect on the guinea 
pig ileum contraction was much quicker than of other peptides such as 
bradykinin (Bertaccini 1976). Later, the term "Neurokinin" came to be 
used for these peptide because all these peptides are derived from 
neurones. Presently the term 'tachykinins' is used for non-mammalian 
neuropeptides and ’neuropeptides' for mammalian neuropeptides 
(Regoli et al 1987a). At the Montreal IUPS satelite symposium, 
"Substance P and neurokinin" (1986) the following names were 
adopted for neuropeptides: 'SP' for Substance P, 'NKA' for Neurokinin 
A (also known as Neurokinin Alpha or neuromedin L or substance K), 
'NKB' for Neurokinin B (also known as Neurokinin beta or 
neuromedin K ) and 'TK' for tachykinins as a group defined by the C 
terminal (Henry 1987). Some newer neuropeptides with a common C 
terminal sequence have been isolated since and these are called "NPY" 
for neuropeptide Y and "NPK" for neuropeptide K ( Leeman 1987).
1.7.2 Synthesis:
Two genes which encode the peptide sequence of neurokinins in 
mammals have been identified. The preprotachykininl (PPT1, also 
known as PPTa) encodes the sequence of SP and Neurokinin A, and 
preprotachykinin II (PPT2 or PPTb) encodes Neurokinin B (Nawa et al
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1983; Bonner et al 1987; Nakanishi 1991). In translation different 
mRNA are produced by genes and these different mRNAs produce 
three different precursors, before finally, different neurokinins can be 
produced (Helke et al 1990). Neurones are the major source of 
tachykinin both in the CNS and in the peripheral nerves, but the major 
sources for tachykinins are in the peripheral endings of capsaicin- 
sensitive primary afferent neurones. TK synthesis occurs in the cell 
bodies of the capsaicin-sensitive primary afferent neurones which are 
located in the dorsal root ganglia (DRG) by the expression of PPTI. 
There is not enough evidence for the presence of PPT II in DRG 
(Mussab et al 1993; Maggi et al 1993a). Tachykinin-like 
immmunoreactivity has been detected in other tissues and cells, for 
example in the enteric neurone system (Deacon & Colon 1987), the 
heart (Hoover 1987), the primary afferents of the knee joint (Hanesch 
et al 1991), the upper and lower part of airway (Maggi 1990), the 
carotid artery (Kusakabe 1994) and in urinary bladder (Maggi et al 
1993a; Ekstrom et al 1994;)(Fig. 1.1 la & b).
1.7.3 Storage: Tachykinins are stored in large granules in 
synaptic vesicles of diameter up to 100 nm in diameter (Otsuka & 
Youhioka 1993). Substance P is found only in small or intermediate 
size vesicles (less than 50 nm) which indicates that it can be found in 
the unmyelinated fibres (Hanesch et al 1991).
1.7.4 Release: The mechanism of NK release is not fully 
understood, but an active calcium dependent release, high frequency 
dependent release, low K+ ion concentration dependent release and 
finally capsaicin induced release have all been demonstrated (Maggi
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SI’ H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH?
NKA H-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NHj
NKB H-Asp-Met-His-Asp-Phc-Phe-Val-Gly-Leu-Mel-NHy
Kassinin H-Asp-Val-Pro-Lys-Scr-Asp-Gln-Plic-Val-Gly-Leu-Mct-Nl 1»
Elcdoisin Pyr-Pro-Scr-Lys-Asp-Ala-Plie-llc-Gly-Lcu-Mct-NH?
Physalaemin Pyr-Ala-Asp-Pro-Asn-Lys-Phe-T yr-Gly-Lcu-Mct-N H T
Neuropeptide K H-Asp-Ala-Asp-Ser-Ser-Ile-Glu-Lys-Gln-Val-Ala-Leu-Leu-Lys- Ala-Leu-
Tyr-Gly-His-Glv-Gln-Ile-Ser-His-Lys-Arg-His-Lys-Thr-Asp-Ser-Phe-
Val-Gly-Leu-Met-NH?
Neuropeptide y H-Asp-Ala-Gly-His-Gly-Gln-Ile-Ser-His-Lys-Arg-His-Lys-Thr-Asp-Ser-
Phe-Val-Gly-Leu-Met-NH,
Fig 1.1 IB: Amino acid sequences of natural Tachykinins. 
The C-terminal sequence common to the peptides of 
tachykinin family is underlined. From Maggi 1993a
1993a). There is no report of physiological release of neurokinins 
except in the gut (Otsaka & Youhioka 1993; Maggi et al 1993a)
1.7.5 Degradation:
These peptides are highly susceptible to hydrolysis by tissues 
and cytosolic and membrane peptidases. Neuronal uptake has a minor 
role in terminating of the effect of tachykinins (Mussap et al 1993), 
therefore many of body organs are capable of the breaking down the 
tachykinins. The kidneys are the most effective organs and the spleen 
and liver are also effective organs in eliminating SP (Pemow 1983). 
Neutral endopeptidase (NEP) is widespread in brain, respiratory tract 
and gut (Maggi et al 1993a), and NEP breaks downs SP at three 
different hydrolysed bonds, 6, 7 and 9, these bonds are in amino acid 
group of hydrophobic residuaes (Matsas et al 1984). It has been shown 
that Neurokinin A and B are a good substrate for endopeptidases 
(Turner & Hooper 1987). Angiotensin converting enzyme can also 
hydrolyse neuropeptides in the C terminal region and certain other 
areas ( Matsas 1984; Turner & Hooper 1987).
1.8.1 TACHYKININ RECEPTORS:
After the discovery of neurokinins a vast effort was begun to 
identify the Neurokinin receptors. Erspamer reported the first receptor 
for SP in 1981 (Erspamer 1981) and further research lead to the 
discovery of NKA and NKB receptors. There are now known to be 
multiple receptor and binding sites for tachykinins (Iverson et al 1987; 
Lee et al 1987). The nomenclature for these receptors is based on three 
tachykinins; NK1 is for receptors with highest affinity to substance P 
rather than NKA and B, NK2 has a higher affinity to NKA and NK3
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has a higher affinity to NKB rather than the others (Maggi et al 
1993a)(fig. 1.12a). These three neurokinins are therefore full agonists 
for these three receptors but with different affinities (Regoli et al 
1987b).
NK1 which has 407 amino acid sequences has the highest 
affinity for SP and has been isolated from different tissues. There is a 
heterogenicity in neurokinin receptors which is based on; a) the 
affinity of the agonist for the receptor, b) metabolic breakdown and c) 
whether the glycosilated or non-glycosilated form of NK1 receptor is 
present (Lew et al 1990; Liu & Quirion 1991). This heterogenicity led 
to the development of very specific antagonists and the discovery of 
NK1 subtypes (Hall et al 1994; Meini et al 1994). NK1 receptor 
subtypes have been found in visceral smooth muscle and glands, 
respiratory, and urogenital system, blood vessel muscle, epithelium, 
exocrine cells and lymph nodules (Mussab et al 1993; Maggi et al 
1993a)(fig. 1.12b).
Compared to other receptors, NK2 is the most responsive 
receptor for NKA. The first NK2 receptor was found in the bovine 
stomach with 384 amino acids and other forms of NK2 receptor have 
been found, for example in the rat stomach (390 amino acid sequence), 
human trachea (398 amino acid), human jejunum (398 amino acid) and 
in mouse genome (384 amino acid sequence) (Maggi et al 1993a). 
Different NK2 subtypes have been found, in hamster pulmonary artery 
(Maggi et al 1989), in human bronchus (Astofi et al 1994), and rat 
spinal cord. In general two subtypes of NK2 receptor have been 
described, NK2a and NK2b (Mussab et al 1993).
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NK3 which has a 452 amino acid sequence is the most 
responsive receptor for NKB (Helke et al 1990 ). Recent findings 
about the human human NK3 receptor have revealed that 68% of its 
amino acid sequence is similar with NK1 and NK2 receptors (Buel et 
al 1992). Like other receptors, there is heterogenicity in NK3 
receptors (Murray et al 1987 ). The NK3 receptor only has been found 
in the myoenteric plexus of guinea pig and the rat portal vein (Maggi 
et al 1993a) and in the gastro intestinal tract, oesophagus and urinary 
system (Mussab et al 1992; Maggi et al 1993a) but the numbers of 
receptors are much lower than other receptors.
1.8.2 Mechanism: the mechanism of action of neurokinin 
receptors are based on activation of the phosphoinositol pathway. 
Neurokinins activate this pathway via G proteins in the membrane and 
consequently there is increase in intracellular calcium (Ca2+) (Hall 
1987; Dam 1987). Neurokinins evoke membrane depolarisation, due to 
decrease of K+ ion conductance and inhibit the Ca^+ activated 
potassium channel (Otsuka 1993).
1.8.3 Agonists:
The natural agonist, SP has the highest affinity for the NK1 
receptors and the most responsive agonist for the NK2 receptors is 
NKA, and NKB having the highest affinity for NK3 receptors. There is 
cross reactivity between these receptors and they respond to all of 
these peptides, but there are different levels of response (Drapeau et al 
1987; Ireland et al 1991) . A great deal of effort went into the 
development of specific agonists and Watson (1983) developed the 
first SP agonist (Watling & Guardi 992). Later different agonists for
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tachykinin receptors were found, for example; GR73632 was 
developed as NK1 selective agonist which is a potent NK1 agonist 
either in vivo or in vitro. GR64349 was developed and confirmed as a 
potent and selective NK2 agonist. Senktide [( succinyl 1 -asp6 , 
mephe^ ) SP ] was developed as a NK3 agonist and this is very potent 
and selective for the NK3 receptor; it is 10^ times more potent on 
NK3 receptors than NK1 and NK2 receptors (Buell et al 1992; 
Watling & Guard 1992 ) .
1.8.4 Antagonists:
The first attempt at developing a special neurokinin antagonist 
was by Leander (Leander et al 1981) by inserting a D amino acid in 
the backbone of the natural peptide. At this time different NK1 
antagonists had been developed but most of them had low affinity for 
the receptor, and so attempts to find more specific antagonists led to a 
second generation of antagonists. The first antagonist of this 
generation was L659877 (L659874 ) which had a linear structure 
(Dion et al 1990), and then MEN 10207 was developed by Maggi et 
al (Maggi et al 1993a; Quartara et al 1992). Recently the Fujisawa 
group developed a selective tripeptide NK1 receptor antagonist, 
FR113680 (whose amino acid sequence is AC THR-DTRP (CHO) 
PH-NMEB21) (Maggi et al 1993a). this compound originated from the 
octapeptide [d-pro4D-TRp7-9-10 phe l 1]SP 4-11. FR 113680 acts as a 
selective and competitive NK1 receptor antagonist. Later Fujisawa 
developed FK888 or 2-(N_ME) indolil-CO-HYP-NAL-NMEBZl, 
from FR113680 which is an extremely potent and selective NK1 
antagonist (Watling & Guard 1992; Fugi et al 1992)(fig. 1 .,13). The 
Fujisawa group developed FK224 from a strain of streptomyces
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violaceo niger. This is a natural macrocyclic peptide, which is a NK1 
and NK2 antagonist and inhibits the effect of both SP and NKA in 
vivo and in vitro (Morimoto et al 1992; Murrai et al 1992). These 
second generation antagonists generally were potent antagonists and 
were suitable for identifying neurokinin receptors. The third generation 
were defined as a nonpeptide antagonists, the advantage of these over 
the peptide antagonists being their resistance to degradation by tissue 
peptidases (Mussab et al 1993). Non peptide antagonists commenced 
with CP 96345 which is a potent and selective NK1 receptor 
antagonist (Maggi et al 1993a). A non peptide NK2 receptor 
antagonist (S) - N - Methyl-N [4-4 Acetyl Amino-4-Pheoxyl 
piperidinol - 2 - (3-4)] dichloro-phenyl benzamide or SR48968 was 
developed by Emonds (Emonds et al 1992; Advenier et al 1992) and is 
a very highly potent and specific NK2 receptor antagonist. This 
antagonist is a competitive antagonist with 100 fold higher affinity for 
NK2 receptors than other receptors (fig.l.l3)(Watling & Guard 1992).
There has been little progress in developing NK3 antagonists 
and there are few reports in the literature (Petitet et al 1993). Recently 
[D-Pro^, D - Trp6 ,8 ? N le^  ] Neurokinin B has been reported as a 
NK3 antagonist, but a potent and selective NK3 antagonist has yet to 
be developed (Petitet et al 1993).
1.9 BIOLOGICAL ACTION
Neurokinin receptors are widespread and distributed in all body 
organs and they show different biological actions depending on the 
position of the receptor and the type of organ (Pemow 1983; Maggi et 
al 1993a; Otsuka & Youhioka 1993). SP acts as neurotransmitter in
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peripheral afferent neurones and spinal cord. Release of SP is mediated 
by high concentrations of calcium and magnesium or by application of 
capsaicin or by noxious stimulation. SP elicits EPSP’s (excitatory post 
synaptic potentials) and slow EPSP's in the second order neurone in 
the spinal cord and also in the mesenteric ganglionic cell. It is widely 
distributed in the central nervous system (CNS) and acts as stimulatory 
mediator in different parts of the CNS. There is a widespread presence 
of SP in salivary glands with a potent stimulatory action and in the GI 
tract where it affects movement via depolarisation of smooth muscle 
(Holzer et al 1980; Holzer et al 1981). SP also exists in nerves around 
the GI tract blood vessels and it can cause neurogenic inflammation in 
the GI tract. There is presence of SP in other parts of the GI tract, such 
as the liver, gall bladder, and pancreas (Otsuka & Youhioka 1993). 
NK1 receptors and SP are present in the respiratory system and have a 
role in vascular permeability control, sneezing, mucosal secretion and 
mucociliary activities (Maggi et al 1993b) NK1 agonists and SP are 
the most potent bronchoconstrictor agents known (Ireland et al 1991). 
Numerous SP immunoreactive nerve fibre have been found in the 
heart, and SP has a role in cardiovascular pain transmission, and in the 
carotid body, where it mediates the hypoxic response (Otsuka & 
Youkioka 1993). SP containing fibres have been observed in the 
adventitia and between the adventitia and medial border and it elicit a 
potent endothelium dependent vasodilatation which can lead to protein 
extravasation (Saito et al 1990). SP immunoreactive nerves are present 
in blood vessels around the renal cortex. SP is one of the most potent 
vasodilators and intra renal infusion of SP produce an increase in renal 
blood flow, urine volume, sodium excretion, increase in glomerular 
filtration rate and suppresses renin release. SP immunoreactive
neurones are also present in the pyelouretral region and with noxious 
mechanical or chemical stimuli, release of SP not only induces 
inflammatory vasodilatation but also enhances motility of the 
pyelouretral musculature and facilitates removal of the irritant (Maggi 
et al 1992; Otsuka & Youhioka 1993). Neurokinins are present in the 
male and female reproductive system, in the umbilical and placental 
fluid, and it seems that SP also has a regulatory role in foetal blood 
flow during development. The role of other neurokinins are as yet 
undiscovered (Di Tommoso et al 1987; Papka & Trauring 1987).
Neurokinins are present in the skin, muscles, and joints and have 
a role in controlling blood flow. In response to irritation and 
stimulation, they can be one of the majors factor mediating 
inflammation in the skin and in the joint by their action at nerve 
endings (Yaksh 1988).
1.10 NEUROKININS AND 
NEUROGENIC INFLAMMATION
Arthritis is a disease of unknown aetiology that manifests itself 
as a chronic inflammatory disorder of the synovial joints (Ferrell & 
Lam 1995). This inflammation can be generalised and spreads to 
multiple joints. (Rheumatoid arthritisi is an auto-immune disease which 
has characteristics other than joint inflammation, and the inflammation 
which results from peripheral release of neurokinins is termed 
neurogenic inflammation (Mapp et al 1993). It has been suggested that 
neurokinins could contribute to joint inflammation (Scottet al 1994)
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There is a vast network of myelinated and unmyelinated neurones in 
the articular capsule with free complex or encapsulated nerve endings. 
In normal joints small nerves are found and these are immunoreactive 
for neuropeptides. Calcitonin gene related peptide (CGRP), SP and 
NKA (Deizguerra et al. 1988) exist in the perivascular area. Twenty 
percent of these neurones, which are sensitive to capsaicin, are 
myelinated and the remainder are unmyelinated. It is generally thought 
that unmyelinated fibres are capsaicin sensitive (Kidd et al 1990). 
These unmyelinated neurones play an important role in inflammation 
and release of SP can be activated by electrical stimulation, noxious 
stimulation, heat and chemical irritation (White & White 1985; Otsuka 
& Youkioka 1993). The extravasation effect of neurokinins has been 
reported previously by Lam & Ferrell (1991a). Electrical stimulation 
of C fibres in posterior articular nerve (PAN), evokes plasma 
extravasation which is reduced by application of a SP antagonist 
(Ferrell & Russell 1985). Later, the involvement of neuropeptide and 
peptide containing neurones in inflammation and inflammatory disease 
became clearer, and the existence of post ganglionic nerve terminal 
substances as pro-inflammatory agents has been suggested (Basbaum 
& Levine 1991). SP has its effects partly via a direct effect on blood 
vessels and partly by an effect on mast cells (Basbaum & Levine 1991). 
Further reports have indicated that SP intensifies experimental synovitis 
suggesting that SP is a potent and specific stimulus for many of the 
features of RA in vitro and possibly in vivo SP can contribute to the 
development of several of the pathological findings in RA (Lotz et al 
1987). Lam & Ferrell (1990) reported that SP can directly induce 
inflammation and that this effect is mediated by NK1 receptors (Lam 
& Ferrell 1993a). Inflammation is, in general, accompanied by protein
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extravasation and it has been shown that neurokinins are involved as 
they can induce and enhance protein extravasation in joints (Lam & 
Ferrell 1991a) and both NK1 and NK2 receptors can mediate this 
protein extravasation in joints (Scott et al 1994). In the bronchial tree, 
NKA has been shown to induce a dose dependent leakage of 1^25 
labelled plasma protein and fibrinogen extravasation which is 
completely inhibited by the non peptide NK2 antagonist SR48968. 
This shows the powerful role of NK2 receptors in mediating plasma 
extravasation, and this effect is a direct one on NK2 receptors and is 
not by activation of histamine release. In the guinea pig dura, NK1 
receptors induce plasma protein extravasation (O Shaughnessy & 
Conneer 1993). These effects can be accompanied by vasodilatation 
and increasing blood flow both in the skin (Brain & Williams 1989) 
and knee joint (Lam & Ferrell 1993b). This effect is exaggerated in 
inflammation and this suggested the presence of multiple neurokinin 
receptors in the knee joint which could mediate the inflammatory 
response (Scott et al. 1992; Tousingnant et al 1994). There are some 
reports of the bilateral effects of neurogenic inflammation of 
neuropeptides, which can contribute to the bilateral inflammation 
process (Bileviciute et al 1993; Mapp et al 1993; Kidd et al 1989). 
This symmetrical effect suggests that this is mediated by a neuronal 
pathway with a precise topographic projection (Kidd et al 1989). 
Mono arthritis most commonly leads to the induction of bilateral 
arthritis which implies the involvement of the nervous system and 
sensory neuropeptides in this condition (Mapp et al 1993). In arthritis 
and inflammation the distribution and response of receptors to 
neurokinins will change. In acute inflammation there is an increase in 
response to neurokinins but in chronic arthritis the response to
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neuropeptide is attenuated (Scott et al 1992; Lam & Ferrell 1993b; 
McDougall et a l 1994).
1.11 CALCITONIN GENE RELATED PEPTIDE
(CGRP)
The first indication of the existence of CGRP, in the rat, was 
obtained in 1983 (Rosenfield 1983). Later, a similar peptide was 
discovered in humans (Morris et al 1984) and after this other reports 
were published about CGRP with a slightly different structural 
sequence.
The discovery of CGRP was one of the first examples of a 
biologically active agent to be discovered by application of 
recombinant DNA technology in the absence of prior biological 
information (Holzer et al 1994). CGRP is a 37 amino acid polypeptide 
and the amino acid sequence varies in different species of mammals 
and birds. In some species for example the rat and man, two different 
types of CGRP have been isolated (fig. 1.14).
In man, the CGRP gene is transcribed from a larger precursor 
RNA with 6 Exons which subsequently split into a -  CGRP and p- 
CGRP. The primary expression is the same in neural tissues; splicing 
to each CGRP is fully and precisely regulated by the CGRP producing 
tissues, and translations from RNA are in different pathways 
depending on tissue specificity and tissue factors (Bennett & Amara
1992). CGRP can be found in body fluids and tissues, but the 
molecular weights differs in each (Fig. 1.15) (Wimalawansa 1993).
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Fig 1.14: Structure o f human and rat a  and P CGRP, 
chicken CGRP, human amylin and salmon calcitonin. 
Area of sequence identity are shaded From Paynor 1992)
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Rosenfleld 1983 in Nature
1.11.1 CGRP receptors:
CGRP receptors have been isolated from different organs. The 
molecular weight of the CGRP receptor is 66000 D and it consists of 
one subunit. The suggestion that there may be of different types of 
CGRP receptor, because of different responses in different organs, has 
not yet been proved but it is possible that there is more than one class 
of receptor for CGRP (Wimalawansa 1993). Quirrion et al (1992) 
suggested the existence of at least two classes of CGRP receptor which 
he has named CGRPl and CGRP2. CGRPl receptors appear to be 
sensitive to antagonistic activity of extended C terminals, and CGRP2 
receptors possesses high affinity to a linear analogue of [cys 
(ACM)2,7] aCGRP and a third subtype now can be recognised by its 
low affinity to both of the others (Quirrion et al 1992 ). Poyner (1992) 
classified four subtypes of CGRP receptors:
a) CGRPla, which is antagonised by CGRP(8-37). Rat a  CGRP 
is equipotent with human a  CGRP at this receptor
b) CGRPlb, which is sensitive to CGRP (8-37), and is 10 fold 
more potent than human a  CGRP
c) CGRP2, with a low sensitivity to CGRP (8-37)
d) CGRP3, which is CGRP and Calcitonin equipotent and 
detected only in binding studies (Poynor 1992).
1.11.2 Distribution and mechanism of action
Different mechanisms of action have been suggested for the 
effect of CGRP. Quirrion et al (1992) believes that it acts by coupling
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with G proteins, and by activating other mechanism in the cell. 
Anderson & Clasent (1989) reported that CGRP in the soleus muscle 
stimulates active Na+- K+ transport and causes a decrease of intra­
cellular Na+ and a minor increase in K+ and a hyperpolarization which 
can be blocked by ouabain. Kageyama et al (1993) reported that, in 
the porcine coronary artery, CGRP acts via a cAMP dependent 
mechanism and Momse et al (1993) reported a similar mechanism in 
the gubemaculum of the urinary tract.
1.11.3 Agonist and antagonist: In addition to natural CGRP, 
CGRP of the [ cys (Acm)2,7] type are selective agonists, and only 
CGRP(8-37) and (12-37)CGRP, which act on different CGRP receptor 
subtypes have been shown to be antagonists (Poyner 1992; Hayes
1993).
CGRP is co-localised and co-released with Calcitonin in 
parafollicular C cells of the thyroid gland, and with SP in sensory 
nerves (Quirrion et al 1992), and also with acetylcholine in 
motoneurones (Csillik et al 1992). This assumes a regulation of the 
number and function of actylecholine receptor molecules. CGRP is 
present in variety of central and peripheral neurones and also seems to 
accumulate at the motor end plate (Kashihara et al 1989) and in a very 
wide range of body organs, such as gut and in mesentric resistance 
vessels, and it also regulates further CGRP release via a negative feed 
back mechanism (Nuki et al 1994). It also inhibits pancreatic enzyme 
secretion via the vagal nerve (Ying et al 1993), and has a regulatory 
function in the respiratory system (Tung cheng et al 1993), circulatory 
system, muscle, joints and in the brain (Sarina et al 1992).
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CGRP shows diversity in its effects. It is likely to have role as a 
neurotransmitter, neuromedulator, local hormone, and as a trophic 
factor which causes rapid changes in neuronal activity, and relaxation 
of many types of smooth muscle. It also has a role in metabolism, and 
changes in gene expression (Royner 1992). CGRP is a potent 
vasodilator, acting on blood vessel smooth muscle and inducing 
hypotension in conscious animals (Abdehrahman et al 1992). The 
vasodilatation and hypotentsive effect of CGRP acts via endothelium 
derived nitric oxide (NO), and not via opening K+ ATP channels and 
so can be attenuated by L NAME (Abdehrahman et al 1992). In 
muscle CGRP has a potent effect on glycogen synthetase activity and 
muscle glucose metabolism and has a physiologic role in skeletal 
muscle glucose metabolism (Rosseti et al 1993) . In the bloodstream 
there is a large concentration of CGRP with an unknown source and it 
may have an important role in the regulation of both systemic and 
local blood flow, since it is stored in the peripheral terminals of 
sensory nerves. It is possible that in ischaemia it will be released and 
regulate blood flow (Goto et al 1992). Recently CGRP has been 
implicated as one of the major factor in menopausal flushes (Tung 
Cheng et al 1993). CGRP is the most potent vasodilator known (Brain 
et al 1985) and this effect is a direct action of CGRP and does not 
involve any other vasodilator mediator. This vasodilator effect of 
CGRP in some vessel in rat aorta is dependent on endothelium (Brain 
et al. 1985) and in other vessels is independent of endothelium ( rat 
coronary artery)(Hiraty et a l 1988).
In endothelium independent relaxation, CGRP acts directly on 
vascular smooth muscle receptors and it has been demonstrated that it
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can stimulate adenyl cyclase in these tissues and provides a 
biochemical pathway leading to relaxation of smooth muscle (Hiraty et 
al. 1988), or open the ATP sensitive K+ channel which leeds to 
hyperpolarization and relaxation of the muscle (Nelson et al 1990)
In the endothelium dependent vasodilator effect of CGRP, 
activation of CGRP receptors in certain vascular beds releases Nitric 
oxide (NO), which dilates vessels by stimulation of the guanylate 
cyclase (Holzer 1994).
1.11.4 CGRP in inflammation:
It is now well established that CGRP containing neurones exist 
in the knee joint (Hanesch et al 1992). There is an increase in the 
release of CGRP during inflammation (Donnerer et al 1992), 
compared with normal conditions. CGRP on its own can participate in 
the formation of intra-articular oedema (Cruwys et al 1992), and even 
enhances the vasodilator action of other peptides by positive feed back 
(Lam and Ferrell 1993b). In conclusion CGRP can be an effective 
mediator of inflammation.
1.12. MEASUREMENT OF BLOOD FLOW
Measurement of blood flow in different organs became a 
necessity after the discovery of the circulation but measurement of 
joint blood flow with its special anatomical compartment has proven to 
be much more complicated. A variety of methods have so far been 
tried and the first to try to estimate joint blood flow was Horwath & 
Hallander (1949) who used a calorimetry method involving
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intraarticular temperature. Skin temperature depends on the balance 
between two type of processes, those by which heat is dissipated from 
skin surface to the atmosphere (conduction, convection, evaporation 
and radiation) and those which deliver heat from the body to the skin 
surface by tissue conduction and flow transport. The heat coming to 
surface of skin comes from the deeper tissues which are warmer due to 
the reactions of cellular metabolism, and the flow rate of the heat 
depends upon tissue heat generation and thermal conductivity which 
varies in different situations. The advantage of this method was its 
simplicity and ease of measurement but its disadvantage was the large 
variation in the skin temperature and the poor correlation between 
temperature and blood flow.
Venous occlusion plethysmography has been used to measure 
blood flow, the non invasive nature of this method makes it mostly 
applicable in man. This is a classical method which was first studied 
by Brudie and Russell (1905) for measuring regional limb blood flow. 
The basic principle is that changes in regional volume of a limb or 
organ are directly related to changes in blood flow. The usual protocol 
is to perform venous occlusion with a proximal cuff inflated to 40-60 
mmHg so that induced changes in volume are directly related to 
arterial inflow only. The limitation of technique is obvious, the usage 
being limited to those whole areas which can be occluded 
measurement is not continuous and also it is not possible to tell from 
which tissue the flow is mainly derived (Bonny et al 1952). Cobbold & 
Liewis . (1952) measured knee joint blood flow by the bubble method, 
first introduced by Bronner et al (1949). They studied the effect of
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heating and cooling and of adrenaline on blood flow, and found a 
correspondence between the blood flow and these stimuli.
Transcutaneous P02, originally designed for neonatal 
monitoring of arterial P02, measures only flow to the skin and 
flourescein angiography (Oberge et al 1982) in which sodium 
flourescein is injected intravenously to study skin illuminated with UV 
light, is similarly limited (Cobbold & Leiwis 1956).
Radioisotopic methods for example radioactive xenon (133xe) 
and technetium (99tc) have been used for local skin blood flow 
measurement and their washout rates are proportional to flow. The 
radioactive 133xe technique has also been used to measure blood flow 
through many organs (Dick et al 1970a) including joints (Liewick & 
Dick 1981) and 99jc has been used in many organs in order to 
measure blood flow which is based on uptake of the isotope 99jc 
(Dick etal 1970b).
Recently a radiolabeled microsphere technique has been used to 
measure of joint blood flow in animals. By this method the number of 
microsphere flowing into an area provided an estimate of blood flow 
(Ferrells al 1990).
In the past 10 years Laser Doppler Flowmetry (LDF) has been 
used to monitor blood flow in various tissue (Obeid et al 1990; Lam 
& Ferrell 1991b;Oberg et al 1982; Shepherd 1987). Since this 
technique is used in most experiment in this thesis, considerable space 
will be devoted to description of its operation and use. LDF relies on 
the Doppler shift effect, a shift in frequency which photons undergo 
when they collide with a moving object, in this case moving red blood
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cells. The Doppler shift is illustrated in practice by the change which 
can be heard in the sound of the siren of a moving train as it 
approaches and recedes.
1.12.1 History of Doppler : John Christian Doppler (1803- 
1850) delivered his famous theory in 1842, and in that theory, the 
correct elementary formula is derived from the motion between the 
source and the observer along a line between them. The extension of 
this theory to the motion of both source and observer at the same time 
appeared in 1846, in which he mentioned the application of the theory 
both in acoustic and optics (Woodruff 1971). This theory was later 
verified by Ballot (Woodruff 1971).
1.12.2 Discovery of Lasers: Townes (1951) knew that as the 
wavelength of microwave radiation grew shorter its interaction with 
molecules became stronger and made it a more powerful spectroscopic 
tool. Making a device to generate the required wavelength became 
possible in 1953, which was called a MASER (Microwave 
amplification by stimulated emission of radiation) but Townes realised 
that shorter wavelengths beyond the microwave, infrared and visible 
light, probably offered even more powerful tools for spectroscopy 
(Karles 1988). In 1957 Townes discussed this matter with Schawland 
and the possibility of making this device, and after eight months they 
made their first LASER (Light amplification by stimulated emission of 
radiation) device. In 1960 a more practical Laser, the Ruby Laser was 
built by Majman. The most commonly used Laser now a days is a 
Helium-Neon Laser first operated by Javan in 1961. Many years 
elapsed between the marriage of the Doppler theory and the discovery 
of the Laser.
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Attempts using this technique as a velocimeter started early in 
1964. The high intensity and narrow line width of the Laser quickly 
converted the light beating phenomenon into a standard laboratory 
technique and the final step in the development Laser Doppler 
Velocimeter (LDV) was combination of the laser beam with the 
Doppler effect. Light scattered by particles or impurities in a moving 
fluid will be Doppler shifted by an amount proportional to the local 
fluid velocity and by mixing the scattered light with unscattered light 
Yeh & Cummins (1964) succeeded in measuring reactive change in 
blood flow and Laser Doppler Flowmetry (LDF) was bom with this 
experiment (Shepherd 1990).
1.12.3 Principle of operation: The principle of LDF is based on 
the fact that a light beam from a low power laser source is directed via 
an optical fibre to the tissue, and the light scattered back from the 
tissue is collected by one or more other optical fibres and analysed. All 
the fibres are arranged in parallel within a single probe. Light which is 
scattered from moving blood cells undergoes Doppler shifting, the 
change in frequency depending upon the velocity of the cells. The red 
blood cell moves with a velocity of about 0.4-0.8 mm/second in 
capillaries (Fronken et al. 1977). Since the microvascular bed 
constitutes an intricate network of interlinking small blood vessels, the 
angle between the red blood cell velocity vectors and the beam 
propagation vector of the diffused scattered light can be regarded as 
randomised (Bonner & Nossal 1990). In cells which are moving away 
from the light source at velocity of 1 mm/sec, the frequency falls about 
4KHz and in the cells moving at the same rate in the opposite direction 
the frequency is increased the same amount (Kageyama et al 1993).
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From the alteration of the photon current, an output signal that is 
related to the flux of red cells in a specific tissue volume is generated. 
Fig. 1.16 presents a simples schematic diagram of the process. Special 
processing must be used to attenuate noises from the system and 
different adjustments must be made for the measurement of different 
ranges of blood flow (Obeid et al. 1990).
1.12.4 Depth of penetration: In human skin the red laser beam 
(wavelength 633nm) can penetrate and detect flow in vessels up to 1-2 
mm below the skin surface. In the gut, it has been shown that the 
beam can detect blood flow in vessels up to 6 mm below the gut wall 
surface. In the pulp of intact human teeth, with the combined thickness 
of the enamel and dentine, the depth of penetration is about 2-3.5 mm. 
There will not be a critical depth below which flow cannot be detected 
but the sensitivity of the detector will decrease progressively as the 
thickness of the overlying tissue increases (Wardell 1991).
1.12.5 Performance of the Laser Doppler Flowmeter :
Both the performance of the LDF in comparison with other 
methods for tissue blood flow evaluation and its value in clinical and 
research applications have been assessed in number of investigations. 
The LDF technique has been compared with xenon wash out in human 
skin and the correlation coefficient was found to be about 0.9 (Stem et 
al 1977 ), and also it was compared with heat clearance technique 
were the advantage of LDF was proved (Enkema et al. 1981). 
Comparison between LDF and the microsphere technique was 
performed by Win et al. (1994) and they found that LDF technique is a 
powerful and appropriate technique for the measurement of blood
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Laser
Fig 1.16: Laser- Doppler measurement of tissue perfusion. 
Laser light is typically delivered to tissue and returned to a 
detector by fibre optic light guides. Light in tissue is 
diffusely scattered by stationary tissue. Such light reaches 
the detector without being Doppler-shifted. Photons that 
encounter moving red blood cells experience a Doppler 
shift. From Shepherd 1990, in laser Doppler flowmetry
flow. Comparison between LDF and other techniques was performed 
to evaluate blood flow in different organs (VongSavon et a l 1993). 
LDF has also used for measurement of knee blood flow (Khoshbaten 
& Ferrell 1990; Najafipour & Ferrell 1993a; Najafipour & Ferrell 
1993b).
1.12.6 Advantages and limitation of LDF
Advantages of this technique are that it is easily learned, non 
invasive and repeatable, unlike methods such as isotope clearance and 
radiolabelled microspheres (Hales et al. 1978) Linearity in the relation 
between the flux and red cell velocity, along with long term stability 
and fast response time make flowmeters ideal for monitoring rapid 
blood flow changes.
Quantitative absolute measurement of microvascular flow is not 
easy to perform with any available method. LDF gives an output value 
depending on the flux of red blood cells which is in arbitrary units The 
meaning of this value as a true representation of blood flow is 
problematic since exact penetration depth, vessel diameter and the 
exact angle between the laser beam axis and the flow axis is uncertain 
at the given point in time.
Red blood cells are transported close to each other possibly in 
Rouleaux formation, which can act as a larger particle when meeting 
laser light causing greater forward scatter and consequently 
underestimating the flux of these cells in the larger vessel. And finally 
another limitation of this technique is the extreme sensitivity to 
movement artefacts (Bonner et al 1990).
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Despite these limitations, LDF demonstrates a good 
performance for the measurement of blood flow has been established 
as a good technique for this purpose and is being used in an ever 
increasing number of applications.
1.13.1 LASER DOPPLER PERFUSION IMAGING (LDI):
This is a system which allows multiple points on tissue to be 
scanned in a short space of time so that a larger area of tissue perfusion 
can be mapped. LDI is a new improved apparatus which can capture, 
analyse, process and display colour-coded images of tissue perfusion. 
A conventional scanner has two mirrors, the positions of which are 
controlled by two stepping motors, which guide a low power laser 
beam to the tissue surface (fig. 1.17) The mirrors move the laser beam 
sequentially over tissue, step by step, through a maximum of (64 X 
64) pixels, making a total number of 4046 pixels. This area can 
covered in 4.5 minutes and represents 12X12 cm2. At each point the 
beam penetrates tissues, depending on the power of the laser beam 
and the tissue structure, and light is scattered back and detected by a 
photo detector positioned in the scanner head. The detector transforms 
scattered light to equivalent electrical signals and each of these 
transformed values is stored in the computer memory for further signal 
processing and data analysis. After termination of the scanning 
procedure over the area, a colour-coded perfusion image can be 
displayed on a monitor and then the software generates perfusion 
values and allows statistical and data analysis (Wardell 1991). The 
system also comprises a personal computer equipped with an analogue
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Fig 1.17: Block diagram o f laser Doppler imager. From 
Wardell 1993
to digital converter board (DT2811 data translation Inc USA), a signal 
processing unit installed in the computer for control of the stepping 
motors and also a detector amplifier in the scanner head. The scanner 
head is fixed to a laser beam generator tube. This machine can be 
situated on a tripod for ease of adjustment over tissues. A colour 
plotter is connected to the computer for a hard copy of images. 
Because ambient light can interfere with the measurement lights must 
be switched off or tissues covered by black fabric when in operation.
1.13.2 Mode of action: At the end of a scan the following steps 
can be carried out:
A) Signal processing: After eliminating signal noises, the 
processed signal scales linearly with tissue perfusion and a correction 
factor is added, derived from the angle between the detector and 
measurement area( fig. 1.18) (Wardell 1991).
B) Image generation: The signal consist of two separate parts:
1) Total light intensity (TLI) which can be used to separate the 
background from the tissue
2) Perfusion image data which now can be displayed on a 
monitor. The image can be presented either in absolute colour code or 
relative colour code mode.
In relative colour code mode the highest value will be set to 
100% and other values will be scaled to that. In absolute colour code 
mode the operator can select the highest and lowest value. The 
selected upper value sets to 100% and lower value sets to 0 % and the 
resulting image will appear in six different colours and each point will
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detector
beam
Fig 1.18: The position of the detector in relation to the 
light spot on the tissue surface. From Wardell 1991
have its own specific value. Values between 80-100% are coded 
brown, 64-80% red, 48-64% yellow, 32-48% green, 16-32% blue and 
0-16% navy blue (fig. 1.19). Other additional information is also 
given on the final image.
Advantages of this technique are generally similar to LDF 
which was described earlier. Absence of continuous measurement of 
blood flow is however a limiting factor. Movement artefact can still be 
a problem but less so than with LDF.
1.13.3 Data analysis: A specially written software package can 
be used and different functions are available in this programme which 
can convert physiological perfusion data to the numerical data. In the 
statistics option, the area of the image can be selected and within the 
selected area, the total number of pixels can be measured and a plot 
(histogram) of colour-coded pixels can be shown and the mean, 
standard deviation and number in the sample are calculated and 
displayed. Further statistical analysis can be performed on this 
numerical data.
LDI is well correlated with perfusion, the sensitivity of LDI has 
been compared with other known techniques and in all comparisons 
there has been a close correspondence between LDI and those other 
techniques (Wardell et al 1993a) and correlation co-efficients have 
been greater than 0.97 (Warded et al 1993b). The use of this technique 
is now increasing and blood flow in different organs is now being 
assessed with this technique. It has been used in the oral cavity and GI 
(Troilious et al 1991) and also in animal research (Lam & Ferrell 
1993a; Lam et al 1993D; McDougall et al 1994).
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Fig 1.19: Laser Doppler perfusion image o f medial aspect o f 
the normal rat knee joint A) Diagramatic representation o f one 
o f the rat knee joint area scanned by the LDI. B) Colour coded 
perfusion image o f the scanned area. For all measurements, 
the area o f interest was outlined (black rectangle). 
Background values (grey areas) were ignored in these 
calculation. C) Colour coded for relative difference in 
perfusion, ranging from dark blue (lowest) to dark red 
(highest) and the corresponding voltage o f the LDI signal (0- 
10 V). The same range o f values were used in all scans 
including those illustrated in this thesis.
CHAPTER TWO
MATERIALS
AND
METHODS
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MATERIALS
2.1.1) Instruments: The following instruments were used during the 
experiments:
Dissecting microscope M650, Wild Heerbrugg (Switzerland) 
Dissecting table, Palmer (England)
Clock, Pye (England)
Balance Metier AE50, (Europe Instrument, Oxford)
Water bath, Grant instrument LTD (England)
Cordless cautery, Warecrest, C28(England)
Neurolog system, pressure amplifier, AC/DC, amplifier, Filter 
(England)
Laser Doppler Perfusion Imager, Lisca Developments (Sweden) 
Multi-trace polygraph, Lectromed (England)
Shaker, Heidolph (Germany)
Polythene cannula size 2 and 3 (England)
Syringes size 1-20 ml, Plastipack (Ireland)
Surgical instruments and operating table accessories (from different 
sources)
Infusion pump, Gilson Minipuls (France)
Rack drive (departmental design)
Micropipet, Labsystem (Finland)
Digital thermometer, model THGH, Harvard, USA 
Digital electronic micrometer, Mitomoto RS (Japan)
UV visible spectrophotometer model 4050, LKB (England)
Pressure transducer (Elcomatic EM 751)
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2.1.2)Drugs: In addition the following drugs were used: 
Freund’s complete Adjuvant (Sigma)
Alcohol (70% and 100%)
Benzethenium chloride (Sigma)
Captopril (Sigma)
Lambda Carrageenan (Sigma)
EDTA (Sigma)
FK 224 (Fujisawa Pharmaceutical Co, Japan)
Heparinised saline 
Neurokinin A (Novabiochem)
Neurokinin B (ICI)
Substance P (Cambridge research biochemical)
Calcitonin Gene-Related Peptide (Celtech; Bachem inc) 
Cremophore (Sigma)
Normal (0.9%) Saline
Phenoxybenzamine Hydrochloride (Smithkline and French) 
Capsaicin, (Fluka, Switzerland)
Hypnorm, (fentanyl fluanisone, Janssen)
Urethane, (ethyl carbamate, Sigma)
Valium (diazepam, Roche)
FK 888 (Fujisawa pharmaceutical Co, Japan)
SR 48968 (Sanofi research, France)
Isoproterenol (Sigma)
Euthetal - Pentobarbitone (120mg / ml)(May and Baker)
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METHODS
2.2: ANIMAL PREPARATION: All experiments were 
performed on adult male Wistar rats (Albus ratus norvegicus), 300- 
500g weight. In total 480 rats were used for the work of this thesis.
2.3: ANAESTHESIA: Two methods of anaesthesia were used 
in the experiments, terminal and recovery anaesthesia. In terminal 
anaesthesia a solution of 25% urethane (Ethyl carbamate) (1-1.5 g / kg 
/ IP) was injected into the peritoneal cavity, and in for recovery 
anaesthesia, Hypnorm 0.5 mg/kg /IM and diazepam 2mg/kg / IP were 
injected.
2.4: SURGICAL PROCEDURES
2.4.1: Carotid artery cannulation: In some experiments, the 
right common carotid arteiy was cannulated to monitor blood pressure 
during the experiment and for injection of drugs.
2.4.2: Anatomical aspect: The innominate artery, (brachio 
cephalic) derived from the aortic arch, extends anteriorly to the right as 
far as the level of the sternoclavicular joint where it is divided into the 
right common carotid and the right subclavian artery (Chess green 
1955). The left common carotid arises directly from aortic arch. Both 
carotids after leaving the thorax, extend anteriorly in parallel with the 
trachea up to the level of the thyroid glands, where is a division into 
external and internal carotid.
In order to cannulate, the carotid (right, left or both) was freed 
from surrounding connective tissue and adjacent vagus, then the distal 
part (rostral) was ligated by a thread. Two other threads were used to
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make two separate loops around the carotid and these were tied 
loosely, one proximal, the other distal. In order to stop blood flow a 
clamp could be used or it could be stopped by pulling up die free end 
of a third loop which had been placed previously. Then a small 
incision was made between these two ligatures, the heparinised 
cannula could then be inserted into the artery and secured in place by 
tightening the proximal thread. The cannula could be inserted deeper 
after removing clamp and then gently secured in its new place with the 
other pre-prepared threads.
The free end of the cannula was connected to a transducer which 
processed the signal which after amplification, was transferred to a 
chart recorder to give a continuous trace of blood pressure.
The pen recorder was calibrated between 0-200 mm Hg via a 
calibrating pressure pump.
2.4.3: Exposure of the knee joint: In all experiments where 
knee joint exposure was necessary, the anaesthetised rat was placed in 
dorsal recumbency and the fur over the knee joint shaved and the skin 
over the knee was excised in an oval shape, to expose the medial 
aspect of knee joint, and any connective tissues and fatty components 
over the knee joint were removed (fig. 2.1).
2.4.4: Denervation of the knee joint
In some experiments denervation of the knee joint was 
necessary. To achieve this, the anaesthetised rat was placed in dorsal 
recumbency and the fur over the thigh shaved and an incision made 
on the upper part of thigh. The skin was freed from underlying tissues
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Fig 2.1: Photographic illustration o f an exposed rat knee 
prepared for assessment o f knee jo int perfusion by laser 
D oppler imaging (LDI). (A) Drawing o f rat indicating the 
exposed medial aspect o f the knee joint which is 
photographically illustrated in (C). (B) Diagram shows the 
principal anatomical features o f the knee joint (from lam & 
Ferrell 1993b)
by blunt dissection. The fat pad of the thigh was removed by electro­
cautery and the saphenous nerve exposed. The nerve was freed from 
the adjacent artery and connective tissues and sectioned proximally. 
For rats in the recovery groups, the skin was sutured twice, once sub- 
cutaneously and then overlying skin to prevent wound reopening by 
the animal. In the terminal experiments the wound was closed by a 
Michell clips.
2.5: INTRA-ARTICULAR INFUSION
The anaesthetised rat was placed in dorsal recumbency, and the 
skin over the knee joints was shaved and carefully excised. Two 25 
gauge needles, connected to an infusion pump were inserted into the 
joint, the inflow needle positioned so that it passed through the joint 
cavity (between the femoral condyles) to lie in the posterior region of 
joint, and the outflow needle was inserted so that its tip lay in the 
anterior region of the knee joint cavity through the patella tendon, or it 
could also be inserted in the small cavity under the patellar ligament 
(Fig. 2.2).
Saline (0.9%) was perfused into the knee joint at the rate of 0.1 
ml /4 min. Joint aspirate was collected every 8 min with a collecting 
machine. A new sampling tube was placed every 8 min under the 
aspirate tube (fig. 2.3).
2.6: MICROTURBIDIMETRY.
This procedure is necessary to measure the amount of protein in 
the joint aspirate. After collecting samples, reagents were added to 
measure the protein content of each sample. The method is based on
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Fig 2.2: Schematic illustration of intra-articular infusion set­
up and collection of aspirated samples.
9Fig 2.3: Photograph shows the experimental set-up and position o f 
the animal at the end o f cannulation and insertion o f inflow and 
outflow needles. 1) m inipuls pump 2) Infusate and aspirate needles 
3) U V  visible spectrophotom eter 4) Carotid cannula 5) Aspirated 
sam ples 6) Blood pressure transducer 7) Stepping m otor tim er and 
controller 8) Pen recorder paper 9) Sample rack and driver 10) 
Blood pressure am plifier
the observation that, in alkaline solution, protein reacts with the 
quaternary ammonium salt, benzyl methyl {2 - [2 - ( p -1 ,1,3, 3 - tetra 
methyl buthyl phenoxy) ethoxy] ethyl} ammonium chloride 
(benzethonium chloride), to produce turbidity.
0.1 ml of the sample was mixed with 1 ml of 0.2% 
benzethonium chloride solution in distilled water plus 4 ml of 3.2% 
NaOH in 1.23% EDTA solution in distilled water. The solutions are 
vortexed and left for ten minutes for chemical processing and the 
amount of turbidimetry was measured by spectrophotometry at 360 
nm. The reading of the machine was adjusted to zero in solvent plus 
saline before sample reading. Standard protein samples (0-500 mg/1) 
were prepared for each set of experiments to minimise variability . The 
amount of the protein in the sample was detected by comparing the 
reading of the sample with the reading of each protein calibration 
curve. This method was described by Iwata & Nishikasa (1979), gives 
a linear and sensitive readings between 50-500 mg /I but cannot detect 
very low protein concentrations.
This technique was then modified and changed the 
concentration of the solutions. In the modified version, 0.2 ml of 
perfusate was mixed with a final solution of 0.4 ml of 0.2% 
benzethonium chloride plus 1.6 ml of 3.2% NaOH in 1.23% EDTA 
and the mixture was vortexed and left for 15 min for chemical 
processing. After this, the procedure was the same as the Iawata & 
Nishikasa (1979) method. In the modified method the sensitivity and 
linearity of the reading was increased between 5-500 mg A (fig. 2.4).
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Fig 2.4: Modified protein calibration curve between 5-500 
mg/1
2.7: GENERAL METHOD FOR INDUCTION OF
INFLAMMATION
Different models of inflammation were required in different sets 
of experiments. To induce inflammation, rats were anaesthetised and 
the fur over the knee joint was shaved and the skin disinfected. The 
sterile inflammatory agent used e.g. (Carrageenan, Capsaicin or 
Freund’s Adjuvant) was prepared and 0.2 ml (of one of these,) was 
injected through a 25 G hypodermic needle. Passing through the 
patellar tendon into the joint cavity, 0.1 ml was injected into the 
posterior region and 0.1 ml injected to the anterior region of the joint 
cavity. After a period (depending on the nature of the inflammatory 
agent) inflammation will develop in the joint.
2.8: DRUG ADMINISTRATION: In all of these experiments, 
vasoactive drugs were applied topically. The drugs were prepared and 
warmed and then applied as a bolus on the knee joint with a 
Micropipet. Warmed saline applied to the joint surface was used 
during the experiment to prevent dehydration and a fall in the knee 
temperature.
2.9: MEASUREMENT OF KNEE BLOOD FLOW
As mentioned in chapter one, knee joint and synovial circulation 
have been evaluated by different techniques such as, measurement of 
skin temperature, synovial fluid temperature, plethysmography, bubble 
flowmetry, isotope clearance, vital microscopy and the microsphere 
technique. There are disadvantages to most of these methods, for 
example in the temperature measurement technique variability is high
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and there is a strong influence from environmental temperature 
(Greeenfield et al 1951). In the Xenon method, lipid solubility is 
one of the limiting factors in blood flow measurement ( Dick et al 
1970a). and in some of these techniques (eg. isotope clearance) the 
long time of measurement is a limiting factor. Furthermore, almost all 
of these methods are not suitable for measuring rapid changes in blood 
flow. With the Laser Doppler flowmetery (LDF) method, blood flow 
can measured continuously, but only at single point and in a small 
volume of tissue, and slight changes in probe position may cause a 
very big change in measured blood flow because of variation in tissue 
architecture.
Laser Doppler Imaging (LDI) is newly developed technique. 
The principle of the technique has been described in chapter one and is 
based on collecting back scattered Doppler- shifted laser light, to 
create an image of blood flow distribution in an area over 
approximately 12 cm2 {n approximately 4.5 minute (fig. 2.5).
2.9.1: Experimental set-up: The LDI instrument was fixed on a 
tripod 10 inches above the operating table. LDI has a low power He- 
Ne laser source of a class two type which produces a 633 nm red 
beam. The laser beam is controlled by a software program (PIM, Lisca 
AB) which controls the stepping mirrors and guides the laser beam 
(800 pm ) over the tissue. The scan starts from the top right of the 
selected area and terminates in the bottom left. The scan can be taken 
in high or low resolution mode which allows for zooming in on a 
specific area. The maximum size of scan area is 150 cm2- ^  this 
format, the machine will scan 64 pixels in both X and Y axes making 
an area of 4064 scanned pixels with a scanning period of 240 sec. The
48
Fig 2.5: Photograph shows the experimental set-up and position 
of the animal at the end of the preparation 1) Stimulator 2) 
Laser tube 3)laser Doppler scanner head 4) Printer 5) Computer 
linked to the set-up 6) Stimulating electrodes 7) PIM 
programme on the monitor 8) Rats exposed knee joint

size of scan area can be adjusted by the operator by selecting a smaller 
area to scan, and the required scan time becomes shorter. This allows 
simultaneous scanning of the opposite knee of two separate rats placed 
in close proximity. Background threshold is also adjustable and may 
be altered, depending on the type of experiment. In these experiments 
the normal back ground threshold was set to 5.81, and the scans were 
operated in high resolution mode.
In the presence of moving red blood cell in the capillaries, 
partially back-scattered Doppler-shifted light is detected by a photo 
detector in the scanner head. It converts instaneous light intensity into 
an electrical signal (volts) that is proportional tissue perfusion. A 
colour-coded perfusion image is then displayed on the monitor which 
can be output to a colour printer. For display purpose these images use 
six colours to encode perfusion (see chapter one), but the actual 
voltage values at each image are held in the memory or stored on disk 
and utilised for further statistical calculation of perfusion within a 
given area. Additional statistical analysis can be performed by the 
"VIEW” statistical programme which was exclusively written for 
image analysis.
2.9.2: Analysis: Statistical analysis of the scans was done using 
VIEW software (Moor Instruments). Statistical analysis of a selected 
rectangular area is possible in this programme and the data is shown in 
a bar chart form and numeric values (^ SD) as a percentage change in 
blood flow. The size of the rectangular area selected can be changed to 
include most of the articular tissue with minimal inclusion of 
surrounding muscle. In each set of experiments the scan was taken 
before administration of drug, as a control scan, and immediately after
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administration of drugs to minimise variation and error. Further scans 
could be taken subsequently as a time dependent response. A residual 
signal is generated from tissue even when circulation is occluded and 
flow stopped completely (biological zero)(Holloway 1980; Tenland et 
al. 1983) and it has been recommended that this value should be 
subtracted from all observed values (Fargell 1990; Nilson 1990). Thus 
at the end of experiments a scan was taken of the joint in a dead animal 
as the biological zero (i e LDI signal when flow is absent). The value 
obtained for this biological zero was subtracted from the other values 
to allow calculation of pure blood flow changes (Nilson 1990). Values 
below the background threshold value are excluded from the 
calculation of voltage values.
2.93: Penetration depth: To evaluate depth of penetration of 
the red laser beam, a scan was taken prior an intra-articular injection of 
10 PM adrenaline, (a potent vasoconstrictor) and another scan was 
taken after one minute and then ten minutes post injection. The scans 
showed blood flow changes in the articular and synovial vessels but 
the surrounding tissue was unaffected (fig. 2.6).
At each measurement site the beam penetrates the tissue to a 
depth of at least 250 pm (Wardell 1991). It has been shown that 90% 
of capillaries in the joint capsule are located in the thin strip of 
synovium which lines the synovial cavity and many of these capillaries 
are within 20 microns of the joint space (Knight & Levick 1983), 
therefore the above result suggests that the red laser penetrates 
through the capsule to detect synovial blood flow, as underlying 
cartilage is avascular and laser penetration to the dense cortical bone is
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Fig 2.6: Laser Doppler perfusion images of rat knee joints.
A) colour-coded system for showing perfusion values 
rang from dark blue (lowest) to dark red (highest), along 
with corresponding voltages (0-10V) of the LDI signal. 
The same range of values were used in all scans.
B) Photograph of the exposed medial aspect of a rat left 
knee joint, showing the high degree of vascularity of the 
region. The white area lateral to the large branching 
blood vessel corresponds roughly to the joint capsule.
C) Perfusion image of the medial aspect of the left knee 
joint of a normal animal prior to any experimental 
procedure.
D) Image from the same knee 1 minute after intra- 
articular injection of 10 pmol of adrenaline (Adr). A 
reduction in perfusion is present over the capsule region.
E) 10 minutes after injection of adrenaline, the 
underperfused area is somewhat larger, but surrounding 
regions are unaffected, suggesting that there has been no 
diffusion of adrenaline from the joint.
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negligible, any changes in blood flow detected by LDI exclusive refer 
to changes in synovial perfusion.
2.9.4: Stability of LDI measurement:
The flux reading in the first scan after initial preparation is 
relatively high because of the surgical procedures and tissue reaction, 
but the blood flow slowly comes down and after 15-20 min achieved a 
stable base line. This base line blood flow was stable during the 
experiments. The control scan reading after each drug application 
was the same as previous control scan. Statistical analyses were 
performed between controls of different sets of experiments and none 
of them were significantly different (one-way anova p=0637, 
n=30)(fig. 2.7).
2.9.5: Validity of the LDI technique: The LDI technique 
provides a convenient means of sampling a large volume of tissue in a 
relatively short time-frame thereby allowing the determination of the 
spatial distribution of tissue perfusion. This is particularly useful for 
analysis of joint capsule perfusion because of the complex geometry of 
joints, the highly anastomotic blood supply and the heterogeneous 
nature of the tissues which constitute the capsule. A significant 
advantage of LDI over laser Doppler flowmetery (LDF) is related to 
the heterogeneity of the responses observed. From the perfusion 
images (fig. 2.8) it is obvious that there is considerable variation in 
perfusion in adjacent areas, but closer inspection (fig. 2.8 b & c) shows 
that the response to SP is also heterogeneous, with perfusion at some 
points showing no change whilst other points show an increase in 
perfusion in excess of 300%. By taking measurements over an area of
51
5  1
C/5
"3
D£#C
-5
8u
control s prior to application drugs
Fig 2.7: Flux reading (volts) o f control scans prior to drug 
application (mean ±SEM, n=35) obtained during dose response 
curve. Differences between the readings are not significant (see 
text).
Fig 2.8: Laser Doppler perfusion images of rat knee joints.
A) colour-coded system for showing perfusion values
B) Perfusion image of medial aspect of 2 rat knee joints prior 
to any experiment.
Cl) Image from same knees after topical administration of SP 
at 10“9 mol.
C2 &3) Image from other knees to the same dose of SP
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the joint capsule, LDI provides a clear view of the overall response of 
the tissue whereas LDF, as it only samples at a single point, is less 
likely to yield a representative sample. Past experience of LDF has 
shown that a great deal of sampling is required to find a site on the 
capsule which gives a similar response to a given drug between 
different animals (W. R. Ferrell personal communication). Without 
such standardisation, in a tissue such as the joint capsule, the values 
obtained with LDF would be veiy difficult to interpret. By contrast, 
LDI makes such standardisation unnecessaiy, and has the added 
advantage that any variation in the pattern of joint perfusion could be 
readily detected. This could prove to be useful in examination of the 
pattern of perfusion in acutely or chronically inflamed joints. One clear 
disadvantage of LDI compared to LDF is the poorer temporal 
resolution of the former. LDF provides a continuous measure of 
perfusion at a single point whereas LDI to some extent "integrates” the 
response over time, depending on the area of tissue scanned. This 
could be particular problem when examining transient events. In 
previous work using laser Doppler flowmetry to continuously monitor 
blood flow, it was observed that application of SP produced a transient 
dilatation, reaching a peak in about 40 sec and returning to baseline at 
about 110 sec (Lam and Ferrell 1993b). Thus, with a scan time of 100 
sec, as typically used in the present study, it is possible that some of 
the response could be missed. To check this, images from rats were 
examined, placing small windows at the upper and lower borders of 
the knee joint and the vasodilator effect of SP examined. As scanning 
proceeded in a proximal to distal direction, if a significant temporal 
effect of SP were present, it would be expected that the percentage 
change in perfusion at the upper window would be greater than the
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value for the lower window i.e. vasodilatation would be greater at the 
upper border of the knee as the response to SP would have waned by 
the time the scan reached the lower border. However, the mean 
percentage difference in perfusion between the two areas was only 
2.8±3.3% and this difference was not significant ( P=0.395; paired t- 
test; n=41 paired measurements). This suggests that the response to SP 
lasted long enough to be substantially captured during the scan. This 
may in fact be due to the fact that during the LDI scan time of -100 
sec, about the first 20 sec covers extra-articular tissues proximal the 
joint and about the last 20 sec also covers extra-articular tissues distal 
to the knee. Thus, the joint capsule, sandwiched in the middle, is 
reached at a near-optimal time.
2.10: TERMINATION OF THE EXPERIMENT:
At the end of the experiment the rat was painlessly killed by 
Euthetal (Pentobarbital 120 mg/ ml) via the IP route.
2.11: STATISTICAL ANALYSIS: Data analysis was 
performed on the values obtained from image analysis. "Minitab" 
software was used, and a modified version of the Shapiro Wilk test 
was used to test whether the data were normal distributed. Two 
statistical techniques were used, the Student t-test and ANOVA .
Two-tailed paired t test was used to compare the result of a 
special treatment of a group of image data with control image data in 
the same group of rats.
ANOVA was used to compare the data from two sets of 
experiments with different treatment and concentration of drugs. One
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or two factor ANOVA (depending on experiments) was used and in 
both tests , the difference between two compared groups was 
considered significant when P values were less than or equal to 0.05.
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CHAPTER THREE
PLASMA PROTEIN EXTRAVASATION 
INTO THE RAT KNEE JOINT 
INDUCED BY 
CALCITONIN GENE-RELATED PEPTIDE
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3-1 SU M M A RY
1) Calcitonin Gene-Related Peptide (CGRP) is a 37 amino acid 
peptide which is the most potent vasodilator known, but there is no 
report of CGRP-induced protein extravasation, which could be due to 
the insensitive methods previously used to measure plasma protein 
extravasation.
2) Experiments were performed to investigate the protein 
extravasation effect of CGRP in the rat knee joint.
3) Intra-articular infusion of 1(H> M CGRP induced protein 
extravasation which was sustained throughout the period of infusion.
4) Both lower (10“5) and higher (10"7) concentrations of CGRP 
failed to produce extravasation. Failure at the highest concentration of 
CGRP was the likely consequence of a significant fall in arterial blood 
pressure which occurred with administration of CGRP at this 
concentration. In the presence of arterial hypotension (induced by the 
a i, <X2, adenoreceptor antagonist, phenoxybenzamine) 1(M> M CGRP 
failed to induce plasma protein extravasation.
5) Plasma extravasation induced by CGRP was a specific effect 
of and not merely consequence of its potent vasodilator effect. A 
similar vasodilator response induced by a P adenoreceptor agonist, 
isoproterenol, failed to induce protein leakage.
6) These findings suggest that CGRP can also alter blood vessel 
permeability and therefore could contribute to neurally-mediated 
inflammatory responses.
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3.2 IN T R O D U C T IO N
Calcitonin gene-related peptide (CGRP) is a 37 amino acid 
polypeptide which is encoded by the calcitonin gene. mRNA derived 
from this gene is processed so that it contains sequences coding either 
for calcitonin or CGRP, which is under the control of tissue dependent 
factors (Amara et al 1982). Translation of the mRNA results in a 
16000 Dalton (D) protein which is then cleaved to give a 3900 D a  
CGRP (Rosenfeld et al 1983). The second form is P CGRP which is a 
product of a separate gene and only the peptide produced by this gene 
is biologically active. The mRNA encoding this peptide which is 
referred to as P CGRP appears to be the only mature transcript of p 
CGRP gene. Hybridisation histochemically reveals a similar 
distribution of a  and p CGRP mRNA. This P CGRP is a new member 
of a family of related gene with a potential function in regulating the 
transduction of sensory and motor information (Amara et al 1985)
Neuropeptides such as substance P (SP) are known to increase 
blood vessel permeability and thereby result in plasma protein 
extravasation into the extra vascular space. In synovial joints this 
process results in protein appearing in synovial fluid (Cruwys et al 
1992; Lam & Ferrell 1991a; Scott et al 1991) which is normally an 
ultra filtrate of plasma. Thus, using a marker which labels plasma 
proteins and estimating its concentration in synovial fluid, an indirect 
measure of synovial blood vessel permeability can be obtained.
CGRP is known to be a potent vasodilator of synovial blood 
vessels (Cambridge & Brain 1992; Lam & Ferrell 1993a; Lam & 
Ferrell 1993b) but previous experiments have failed to demonstrate
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that CGRP can, of itself, elicit plasma extravasation (Cambridge & 
Brain 1991; Cruwys et al 1992). However, this may have been the 
result of the relative insensitivity of the techniques employed where 
markers such as Evans blue (Cruwys et al 1992, Lam & Ferrell 
1991b) and 125I labelled albumin (Cambridge & Brain 1992) were 
used. It has recently been shown that direct measurement of the protein 
content of synovial fluid by micro-turbidimetry is much more sensitive 
than plasma labelling methods (Scott, Lam & Ferrell 1991). Thus, the 
present study was performed, using the micro-turbidimetric method of 
protein assay, to re-evaluate whether CGRP can influence the 
permeability of synovial blood vessels.
3.3 MATERIAL AND METHOD
Experiments were performed in male Wistar rats (350-500g) 
deeply anaesthetised by intra peritoneal injection of urethane 
(1.13g/kg). The method for intra-articular injection was as described in 
chapter 2.4.1. In a sub-group of rats the carotid artery was canulated 
for monitoring blood pressure.
Normal saline (0.9%) was perfused into the synovial cavity 
(Gilson minipuls) at a rate of 25 pi / min and the effluent from the 
joint was collected every eight minutes. Saline perfusion was 
continued for up to one hour after which the perfusate was changed to 
one consisting of saline in which a-CGRP (Celltech) was dissolved in 
different concentrations, or another saline solution as a time control, 
and the second perfusion continued for up to one hour. In most animals 
both knees were used. After all the samples had been collected, 
reagents were added to measure the protein content of each sample.
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The technique used in this study was described in chapter 2.4.2.
Samples of infusate containing only CGRP in concentrations up 
to 10“5 M were analysed with this method, but yielded no measurable 
protein. In a smaller series of animals, synovial effluent was collected 
whilst synovial perfusion was monitored using laser Doppler 
flowmetry (Lam & Ferrell 1993b) Assessment of changes in vascular 
calibre was by calculating changes in vascular resistance (mean arterial 
blood pressure divided by blood flow). Statistical analysis of the data 
was performed using MINITAB software. A modified version of the 
Shapiro-Wilk test showed that the data were normally distributed. 
Comparisons between mean values was by student’s t-test or ANOVA 
where appropriate. Means ± standard error of the mean (SEM) are 
used throughout and all quoted P values are two-tailed.
3.4 RESULTS
Intra-articular perfusion of CGRP produced plasma protein 
extravasation into the synovial cavity of the rat knee, but only at a 
concentration of 10-6 M (fig. 3.1, n=24). Both lower (10“7 M) and 
higher (105 M) concentrations failed to elicit extravasation (fig. 3.2, 
n=ll and 3.3, n=17) and therefore the concentration/response 
relationship was not investigated beyond this range. The responses at 
these two concentrations did not differ significantly from the response 
to saline infusion (fig. 3.4).
It was noticeable that protein extravasation gradually declined 
during the experiment at both of the concentrations of CGRP and the 
saline infusion. By contrast, 10-6 M CGRP produced a sustained 
response throughout the one hour infusion period. Although protein
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Fig 3.1: time course o f plasm a protein extravasation into the rat 
knee joint in response to intra-articular infusion o f 0.9% saline, 
(black column, n=5) and CGRP at concentration o f 10-6 M, (red 
column, n=24).
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Fig 3.2: time course o f plasma protein extravasation into the rat 
knee joint in response to intra-articular infusion o f 0.9% saline, 
(black column, mean ±SEM , n=5) and CGRP at concentration of 
10"7 M, (red column, mean ±SEM , n=17).
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Fig 3.3: time course o f plasm a protein extravasation into the rat 
knee joint in response to intra-articular infusion o f 0.9% saline, 
(black column, mean ±SEM , n=5) and CGRF* at concentration of 
10"5 M, (red column, mean ±SEM , n=l 1).
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Fig 3.4 Protein concentration in synovial effusate during saline 
infusion (S) and 16 min after commencement of infusion of 
different concentrations of CGRP. * mean significantly different 
from saline infusion (p<0.05), + mean significantly different from 
lower and upper concentration (p< 0.05).
extravasation occurred at the 10“6 M concentration in each animal 
tested, the time course, particularly the time taken to reach the peak 
response, varied between animals, leading to large variations in protein 
measurements at the different times. Comparison of the time/response 
curves by ANOVA revealed a significant difference due to 
concentration (PO.OOOl, n=24), with the 10-6 M infusion of CGRP 
differing significantly from the saline infusion, the 10-7 M and the 10-5 
M CGRP infusions (P<0.001 in all cases).
The apparent lack of a dose-dependent effect of CGRP, as 
exemplified by the absence of protein extravasation by the 10“5 M 
infusion of CGRP, may have been due to the systemic vasodilator 
effects of CGRP. As shown in fig. 3.5 this dose produced a 
pronounced fall in mean arterial blood pressure and as synovial 
perfusion is directly related to the arterial perfusion pressure, it is 
likely that at this concentration of CGRP, the fall in synovial blood 
flow was sufficient to mask any protein extravasation.
Comparison of the time/response curves by ANOVA showed a 
significant difference due to treatment (P<0.0065). The fall in blood 
pressure induced by 10_5M CGRP differed significantly from that 
occurring with saline (P<0.05) and 10-7 M CGRP (P<0.05). Although 
it appeared that the lower concentrations of CGRP might produce a 
modest fall in blood pressure with time, overall, the responses at both 
10_6M and 10_7M CGRP did not differ significantly from that 
occurring with saline infusion. Plasma extravasation induced by 10-6 
M CGRP (98.8± 24mg/l; n=9) could be virtually abolished (27±10 mg/ 
1; n=4) in the presence of hypotension induced by intravenous 
administration of the ai, a 2-adrenoceptor antagonist
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Fig 3.5 Percentage change in mean arterial blood pressure in 
response to intra-articular infusion of 0.9%  saline (□ ) and CGRP at 
concentrations o f 10“7 M ( A ) , 1 0 ‘ 6  m  (H), and 10'5 M (# ). Mean 
±SEM , n= 4-5.
phenoxybenzamine prior to intra-articular infusion of 10-6 M CGRP. 
Phenoxybenzamine, in producing a 27± 4% (n=4) fall in blood 
pressure which was similar to that occurring with 10~5 M CGRP 
(67.6±1.5% of control; n=4), did not itself produce significant protein 
extravasation (27± 10mg/l).
It was also observed that vasodilatation of articular blood 
vessels induced by the Pi, P2-adrenoceptor agonist isoproterenol was 
not accompanied by significant protein extravasation. Infused into the 
joint at a concentration of 10“5 M, isoproterenol produced a 13.46± 
2.9% (n=6) fall in vascular resistance, but this was not accompanied by 
significant protein extravasation (29.8± 11 mg/1). This vasodilatation 
was similar to that occurring with 10-6 M CGRP which produced a
11.9±2.1% (n=6) fall in vascular resistance but, as described earlier, 
yielded significant protein extravasation (111.1±30.2 mg/1). These 
findings argue that CGRP-induced extravasation is a specific effect, 
and not merely a consequence of its vasodilator action.
3.5 DISCUSSION
The results of this investigation have shown that contrary to 
previous studies (Cambridge & Brain 1992; Cruwys et al 1992; Lam 
& Ferrell 1991a), CGRP can, in addition to its known vasodilator 
effects, also produce an increase in vascular permeability. It is unclear 
whether this is a direct effect on endothelial cells, but it is unlikely to 
be due to purely to its vasodilator effect as vasodilatation induced by 
the P-adrenoceptor agonist was not accompanied by plasma 
extravasation. Agents such as SP are known to have both a vasodilator 
effect (Lam & Ferrell 1993a; Lam & Ferrell 1993b) and to increase
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synovial blood vessel permeability (Cruwys et al. 1992, Lam & Ferrell 
1991a) In addition, at a concentration of 10~5M, although CGRP 
would have produced the greatest degree of vasodilatation of synovial 
blood vessels, plasma extravasation was nevertheless absent. As 
explained earlier, the absence of protein extravasation at this 
concentration is probably related to reduced synovial perfusion, and 
this is strengthened by the observation that there is absence of protein 
extravasation during intra-articular infusion of 10_6M CGRP in 
hypotensive animals. In addition, in a previous study it was shown that 
SP-induced plasma protein extravasation decreased at higher 
concentrations in acutely inflamed rat knee joints due to hypotension 
following systemic uptake of SP from the more permeable articular 
blood vessels (Scott, Lam & Ferrell 1992).
The progressive downward drift in protein concentration 
observed in the present study with saline, 10"5M and 10~7M CGRP 
probably reflects the gradual washout of protein from the knee joint 
cavity.
Another interesting feature to emerge from this study was the 
long-lasting nature of the extravasation induced by CGRP. It was 
shown that SP produced only transient increase in blood vessel 
permeability despite maintained intra-articular infusion (Scott, Lam & 
Ferrell 1991). In some respects this parallels the vasodilator effects of 
these two agents, with SP producing transient dilatation of synovial 
blood vessels whereas CGRP produces long-lasting dilatation (Lam & 
Ferrell 1993b). This difference is thought to reside in the rapid 
degradation of SP compared to CGRP (Brain & William 1989) but in 
the present experiments the intra-articular concentrations were
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maintained by continuous infusion and therefore this mechanism 
cannot explain the findings of the present study. It is possible that 
some other mechanism may be present to account for these differences 
in plasma extravasation and this requires further investigation.
The findings of this study indicate that CGRP can by itself 
enhance vascular permeability, in addition to its ability to potentiate 
the effects of other inflammatory mediators which induce plasma 
extravasation (Brain & Williams 1989; Cambridge & Brain 1992; 
Cruwys et ai 1992). As CGRP is present in many peripheral 
nociceptive afferents, it could contribute to neurogenically-mediated 
inflammatory responses both by producing vasodilatation and by 
increasing vascular permeability.
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CHAPTER FOUR
NEUROKININS
IN THE
RAT KNEE JOINT
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SECTION ONE
SUBSTANCE P AND ITS RECEPTORS
65
4.1.1 SU M M A RY
1) Experiments were performed to identify the type of Substance 
P (SP) receptors in the rat knee joint.
2) Laser Doppler Imaging (LDI) was used to investigate changes 
in blood flow.
3) FK888 (an NKI antagonist), SR48968 (an NK2 non peptide 
antagonist), and FK224 (an NKI and NK2 antagonist), in different 
doses were used in the experiments.
4) SP on its own induced a dose dependent transient (2 min) 
vasodilatation, (doses between 10“9 to 10" 13 mol). Maximum 
vasodilatation was 40±7% when a dose of lnmol was used. Higher 
doses failed to increase the vasodilator effect and the response 
decreased because of systemic vasodilatation and a fall in arterial 
blood pressure.
5) Both FK888 and SR48968 on their own failed to inhibit the 
vasodilator effect of SP in the rat knee joint.
6) FK224 dose dependently inhibited the vasodilator effect of 
SP in the rat knee joint. An equal combination of FK888 and SR48968 
also inhibited the vasodilator effect of SP.
7) These data suggest that the vasodilator effect of SP is 
mediated via NKI and NK2 receptors.
8) Captopril, an NEP inhibitor, reduced by 35% systemic blood 
pressure, and even in the presence of this low blood pressure SP still
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produced a small dose dependent vasodilatation which lasted over 15 
min
4.1.2 INTRODUCTION
SP is a peptide with an 11 amino acid sequence which was first 
discovered by Van Euler in 1931. This water soluble peptide is 
released from sensory nerve endings. SP containing sensory nerves are 
widely distributed in different organs, and participate in a variety of 
physiological and pathological events including inflammation (Lam & 
Ferrell 1990; Lam et al. 1993) and arthritis (Smiths 1989) and also 
activate neural pathways leading to rheumatoid synovitis (Lotz et al 
1987). Recently different receptors for the neurokinins have been 
recognised (Maggi et al 1993a; Maggi et al 1994) this being made 
possible by the discovery of neurokinin agonists and antagonists.
The distribution of neurokinin receptors varies in different 
organs and in different species of animals. In the rat knee joint it is not 
clear which type of neurokinin receptor mediates the effects of SP on 
blood flow. These experiments were therefore performed to clarify the 
receptors mediating the effects of SP.
4.1.3 MATERIALS AND METHOD
Male Wistar rats (each approximately 350-500g, in-house 
colony) were deeply anaesthetised by intra-peritoneal injection of 
urethane (2g/kg). Subsequently, the skin over the knee was excised to 
expose the medial aspect of the knee joint. Relative changes in capsule 
blood flow (voltage difference of test minus control were monitored by 
Laser Doppler Imaging (LDI). As described in chapter 2, perfusion of
67
the exposed joint capsule was monitored during application of SP or a 
combination of SP with one of the antagonists. A scan was taken as a 
control immediately prior to application of any drugs. The normal 
time interval between successive scans was 5 minutes, which allows 
enough time for the recovery from the effect of the previous 
application of SP.
The vasodilator effect of the neurokinins is transient with the 
peak response occurring at 40±5.35 sec and return to baseline level in
111.43±8.7 (Lam & Ferrell 1993b). Details of the preparation and 
method are described in chapter 2.
Wanned SP (Cambridge Research Biochemicals), FK888 
(Fujisawa), FK224 (Fujisawa), SR48986 (Sanofi) were administered as 
a bolus to the surface of the joint in a volume of 0.1 ml. SP was 
applied in 6 different doses from 10“ 13 to 10”8 mol, whilst three 
different doses (10” 12 mol, 10” 10 mol, 10“8 mol) of each antagonist 
were co-applied with SP. Warmed physiological saline (0.9% Cl Na) 
was regularly applied to the tissue surface to prevent dehydration.
Statistical analysis of the data was performed using ’’Minitab” 
software. A modified version of Shapiro Wilk test showed that the data 
were normally distributed . The comparisons between mean values 
was by ANOVA or ’’Student” t test where appropriate. Mean ± 
standard error of mean (SEM) was used and all quoted P values are 
two tail with P values equal or less than 0.05 being considered 
significant.
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4.1.4 R E SU L T S
Basal perfusion: Imaging of blood flow to the medial aspect of 
the rat knee joint revealed that this region is highly perfused and is 
very vascular compared with surrounding tissue and skeletal muscle at 
regions adjacent to the joint capsule. Also in the joint tissue there is 
considerable variation in blood perfusion (fig. 4.1.1).
As the initial measurements involve comparison of basal blood 
flow between different treatments, rectangular areas chosen for 
calculation of the mean voltage were of the same size (23x15 
measurement points). The rectangles selected comprise a total of 345 
pixels on each image sufficient to include most of the articular tissue 
with minimal inclusion of the surrounding tissue.
The effect of SP showed a significant dose dependent increase 
in blood flow (p<0.001, n=35, Anova). At a dose of 10-13 mol there 
was a slight non-significant increase in blood flow, but there were a 
significant vasodilator responses with application of higher doses. The 
greatest vasodilator response occurred with SP 10"9 mol which 
increased of blood flow by 45.1=*= 8.6 %, n=35 (fig. 4.1.2,).
The effect of antagonists: three different antagonist at three 
different doses were used to see whether these can block the 
vasodilator effect of SP.
SR48986 (a NK2 non peptide antagonist) at three different 
doses was applied topically with SP to the knee joint (10"12 mol, 10- 
mol, 10-8 mol). SR48968 failed to reduce SP induced 
vasodilatation at all applied doses. Application of SR48968 at 10"12
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Fig 4.1.1: Laser Doppler perfusion images of rat knee 
joints.
A) colour-coded system for showing perfusion values
B) Perfusion images in different knees prior to any 
experiment

log dose SP (mol)
Fig 4.1.2. Changes in synovial blood flow during topical 
application of SP to the knee jo in t capsule (mean ±SEM , n=35)
mol slightly reduced the response to SP but it was not significantly 
different from control (P=0.064, n=24, Anova) (fig. 4.1.3a).
Application of SR48968 at doses of 10“10 mol and 10"& mol did 
not reduce the vasodilator effect of SP, and seemed to slightly 
intensify it, but this effect was not significant (n = 12, p = 0.06 and n 
=8, p = 0.37 respectively) (fig. 4.1.3b, and c).
FK888 (an NK1 antagonist) was topically applied together with 
SP to the rat knee joint as described previously. Application of 10" 12 
mol FK888 with different doses of SP had no significant effect on 
vasodilatation. As seen in fig. 4.1.4a, 10“12 mol FK888 significantly 
reduced the vasodilator effect of 10-12 SP but failed at other doses of 
SP (p 0.513, n=12, Anova). This antagonistic effect of FK888 has been 
reported before (Lam et al 1993a).
Application of 10“ 10 mol FK888 with SP at different doses, 
except dose 10" 10 mol, failed to reduce the vasodilator effect of SP 
(p= 0.2, n=12, Anova) (fig. 4.1.4b).
10~8 mol FK888 failed to reduce the vasodilator effect of SP on 
the rat knee joint (p = 0.61, n=16, two way Anova) (fig. 4.1.4c). In 
general FK888 reduced SP vasodilator effects at some doses but 
overall this reduction was non-significant
Three different doses of FK224 (an NK1 and NK2 antagonist) 
were used together with SP. FK224 at a dose of 10"! 2 mol failed to 
reduce the SP- induced vasodilator effect (p=0.23, n=8, Anova) (fig. 
4.1.5a). This dose of FK224 inhibited the SP effect at some doses (10" 
12 mol), but overall the effect is unclear.
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Fig 4.1.3. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule alone, and with 
a non peptide NK2 antagonist, SR48968 at different doses. 
Values are mean ±SEM.
A) Application of SP alone (O, n=35) and together with 
SR48968 at 10-12 mol (A, n=24 )
B) Application of SP alone (O, n=35) and together with 
SR48968 at 10-10 mol (■, n=12 )
C) Application of SP alone (O, n=35) and together with 
SR48968 at 10-8 mol (« , n=8 )
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Fig 4.1.4. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, alone and with 
an NK1 antagonist, FK888 at different doses. Values are 
mean ±SEM.
A) Application of SP alone (O, n=35) and together with 
FK888 at 10-12 moi (A, n=12 )
B) Application of SP alone (O, n=35) and together with 
FK888 at 10-10 mol (■, n=12)
C) Application of SP alone (O, n=35) and together with 
FK888 at 10-8 moi (# , n=i6)
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FK224 at a dose of 10" 10 mol reduced the vasodilator effect of 
SP significantly (p=0.047, n=24, two way Anova). This dose reduced 
SP effects on blood flow and shifted the dose response curve to right. 
At some points of the dose response curve the reduction is not 
significant but overall the reduction is significant (fig. 4.1.5b).
Co-application of FK224 (10“8 mol) with SP at various doses, 
fully inhibited SP's effect on blood flow (P<0.0001, n=12, Anova) and 
shifted the SP dose response curve to right (fig. 4.1.5c). At this doses 
of FK224 there is not only no response to SP from 10“ 13 to 10“ 10 
mol but also there is a slight vasoconstrictor response. In general, 
FK224 dose dependently inhibited SP’s effect on blood flow.
Co-application of both FK888 and SR48968 each at a dose of 
10-8 mol with SP was performed and this significantly (p=0.01, n=8, 
Anova) reduced the vasodilator effect of SP at most doses, and shifted 
the dose response curve down (fig. 4.1.6).
4.1.5 DISCUSSION
SP, an inflammatory mediator, is a potent vasodilator with a 
widespread effect all over the body. Local injection of SP can induce 
inflammation and oedema in the rat knee joint (Lam & Ferrell 1990). 
SP can also induce plasma protein extravasation in the rat knee joint 
(Scott et a l 1991). Inhibiting the effect of SP on blood flow and 
permeability by an appropriate and selective antagonist would have an 
important role in preventing pathological effects of SP. SP induced a 
dose-dependent vasodilatation in the rat knee joint, from 10-12 to io-8 
mol. At a dose of 10-8 moi? there is fall in blood flow compared to 10“ 
9 mob which could be due to the systemic absorption of SP.
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Fig 4.1.5. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, alone and with 
an NK1 and NK2 antagonist, FK224 at different doses. 
Values are mean ±SEM.
A) Application of SP alone (O, n=35) and together with 
FK224 10-12 mol (▲, n=8)
B) Application of SP alone (O, n=35) and together with 
FK224 10-10 moi (* , n=24)
C) Application of SP alone (O, n=35) and together with 
FK224 10-8 mol ( • ,  n=12)
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Fig 4.1.6. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, alone (O, mean ±SEM, 
n=35) and during co-application with SR48968 and FK888, both 
at a dose of 10-8 mol, (■  , mean ±SEM, n=8)
II
Monitoring blood pressure showed about a 20% fall in the blood 
pressure at 10"8 mol which is enough to reduce blood flow in the knee 
joint (fig. 4.1.7). This effect is transient, lasts less than 110 sec (Lam & 
Ferrell 1993b) and blood flow subsequently returns to normal. Thus, as 
previously mentioned, five minute intervals between each application 
of SP is enough for blood flow to return back to baseline. Fig. 2.7 
indicates that control scan over 5 min are similar and there is no 
significant difference between these.
Three different neurokinin antagonists were applied in 
combination with SP to find out which neurokinin receptors mediate 
the vasodilator effects of SP.
SR48968 in general failed to inhibit the vasodilator effect of SP, 
although at one dose it could significantly reduce the SP vasodilator 
effect (SR.-12 with SP ‘1 !)■ At higher doses it even increased the SP 
vasodilator effect. As SR48968 is a potent and selective non peptide 
NK2 antagonist (Emonds et al. 1992), its failure to significantly reduce 
the vasodilator effect of SP at all doses suggests that these effects are 
not purely mediated by NK2 receptors.
Application of FK888 together with SP also failed to inhibit 
SP’s effects on blood flow. In a previous study by Lam and Ferrell 
(1993c), FK888 was found to be an appropriate antagonist and was 
able to inhibit vasodilator effect of SP in the rat knee joint, though they 
only used a single dose of FK888. As shown in fig.4, at some doses it 
significantly reduced SP effects on blood flow (FK888 10'10 mol 
with SP 10“10 moi ? p<0.01) but this was not consistent at other doses, 
and overall the effect was not significant. As FK888 is a selective and
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Fig 4.1.7. Percentage change in mean arterial blood pressure in 
response to topical application o f SP to the joint capsule, (mean 
±SEM, n=6)
potent NK1 antagonist (Murai et al. 1992), it’s failure to completely 
inhibit the effect of SP, suggests that these are not fully mediated by 
NK1 receptors.
FK224 at a dose of 10“10 mol significantly (p=0.047) blocked 
SP effects and shifted the dose response curve to right and at dose of 
10“8 mol it showed stronger inhibition of SP induced vasodilatation 
(p<0.0001). At doses of 10“ 13 to 10-10 mo}? the response to SP was 
completely blocked by this antagonist, and a vasoconstriction response 
compared control was observed (fig. 4.1.5 b and c).
In general these data suggest that SP exerts its vasodilator 
effects via both NK1 and NK2 receptors which can be blocked by an 
NK1 and NK2 receptor antagonist such as FK224. The 
vasoconstriction which occurred in the presence of full blocking of 
NK1 and NK2 receptors, suggests that in the absence of a SP effect, 
other vasoconstrictor influences supervene resulting in a reduction in 
blood flow below the baseline control value. It could be concluded that 
SP may have a physiological role in regulating blood flow.
To verify whether the effect of SP is mediated by NK1 and NK2 
receptors, a combination of a selective NK1 receptor antagonist 
(FK888) and selective NK2 receptor antagonist (SR48968) was used to 
try to block the vasodilator effect of SP. Application of both SR48968 
and FK888 together with SP significantly inhibited the vasodilator 
effect on blood flow (p=0.01) and shifted the SP dose response curve 
downwards. This may be due to the vasoconstriction effect of FK888 
and SR48968, as described in chapter 4.4
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These data confirm previous findings with FK224, although the 
inhibition with FK888/ SR48968 combination at 10"8 mol was less 
than that obtained with FK224. This difference could be due to 
existence of atypical neurokinin receptors or neurokinin receptor 
subtypes. Lee et al. (1982) and Piercey et al. (1982) reported that there 
are several subpopulation of SP receptors. Also, the existence of 
atypical NK1 tachykinin receptors in the rabbit iris sphincter (Hall et 
al. 1994) supports the idea of atypical receptors perhaps being also 
present in the rat knee joint. Also Meini et al. (1994) have described 
the existence of NK1 receptor subtypes in the rat urinary bladder.
The inhibitory effects of these antagonist are likely to be purely 
due to their specific effect on neurokinin receptors. Although Zum yi 
wang et al (1994a) and Karlson et al (1994) have reported that these 
antagonists can have non-specific sympathetic effects which can cause 
slight vasodilatation, this appears at 10“4 mol which is more than a 
thousand fold higher than the maximum dose which was used in the 
present experiments. In addition, the time course of such effects is 
much longer than the transient SP time course on blood flow.
In conclusion these data suggests that SP induced vasodilatation 
in the rat knee joint is mediated by NK1 and NK2 receptors which 
may be atypical or a subtype of these receptors. A physiological effect 
of SP in controlling local blood flow may also be present. Further 
investigation is required to clarify this .
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4.1. 6 SP IN H IB IT IO N  BY N E U T R A L  E N D O PE PT ID A S E
Neutral endopeptidase (NEP) and angiotensin converting 
enzyme (ACE), are well known to convert and degrade SP (Couture et 
al. 1981). Several organs are capable of inactivating SP, and the liver 
has highest capability (Lembeck et al 1978).
Captopril (also known as SQ. 14225) was introduced as a NEP 
inhibitor (Couture et al 1981), and it is also known as a hypotensive 
drug. Neurokinins will rapidly be degraded by NEP and eliminated 
The time course of vasodilatation by the neurokinins, with topical 
application, is less than 2 min. NEP inhibition in the tissues results in a 
long-lasting effect of neurokinins. In the experiments described below 
captopril was applied both topically and intravenously (IV) to 
evaluate changes in the neurokinin-induced vasodilatation in the rat 
knee joint.
4.1.6.1 Materials and methods: Six rats were cannulated to 
monitor blood pressure and drug administration. The procedures were 
as described in chapter 2. Captopril was applied topically or IV in a 
dose of 5.7 mg per kg (Shore et al 1992). SP was applied at different 
doses. The procedure and data analysis were as described in chapter 2 
and 4.1,2
4.1.6.2 Results: IV application of captopril reduced systemic 
blood pressure up to 35% and this reduction was consistent and 
irreversible over 60 min (n=13). Topical application of captopril 
showed the same effect on blood pressure and reduced blood flow by 
35% (n=5).
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Topical application of SP on the knee joint in the captopril pre­
treated rat revealed an attenuated response to SP. It was a weak 
response and also there was no significant difference between doses 
(p< 0.05). This attenuated response was consistent over 15 min.(fig. 
4.1.8, n = 13).
4.6.3 Discussion: The response of the normal knee joint to SP is 
dominantly affected by the fall in blood pressure. SP at dose of 10*8 
mol caused a <20% fall in the blood pressure and attenuated its local 
vasodilator effect on the knee joint (fig. 4.1.2,4.1.7). A 35% reduction 
in systemic blood pressure should have a strong attenuating effect on 
SP mediated vasodilatation, but in fact SP showed a small but non 
dose dependent vasodilatation on the knee joint over 15 min. However 
in the intact knee the normal degrading period for SP is 1.5 min. Fig. 
4.1.9 shows the time course of the effect of SP on blood flow after 0 , 
5,10 and 15 min post application of SP in the captopril pre-treated rat 
and compared with SP in the normal rat. SP in higher doses, even in 
captopril pre-treated rats, showed a further reduction in systemic blood 
pressure.
SP is a potent vasodilator peptide and it is synthetised and stored 
in a vast variety of tissues and body organs (Pemow 1983) This 
substance is immediately destroyed and inactivated by NEP and when 
this is inhibited an acute reduction in blood pressure can result from 
rapid vasodilatation. Therefore it could be concluded that the systemic 
hypotensive effect of captopril could be due to its inhibitory effect on 
NEP, thereby preventing the degradation of SP. SP has an essential 
role in controlling blood pressure and so slight changes in its 
metabolism can produce a vast changes in systemic blood pressure.
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Fig 4.1.8. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule in the intact 
knee and after IV. treatment with captopril (10“7 mol), at 
different times: Values are mean ±SEM.
A) Application of SP in intact knee (O, n=35) and 
immediately after treatment with captopril ( • ,  n=10 )
B) Application of SP in intact knee (O, n=35) and 5 min 
after treatment with captopril (■, n=10 )
C) Application of SP in intact knee (O, n=35) and 10 min 
after treatment with captopril (A, n=10 )
D) Application of SP in intact knee (O, n=35) and 15 min 
after treatment with captopril n=10 (A, n=10 )
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Due to marked systemic effect of captopril on blood pressure it 
was not possible to do further experiments .
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SECTION TWO
NEUROKININ A AND ITS RECEPTORS
78
4.2.1 SU M M A RY
1) Experiments were performed to identify the action of NKA 
on neurokinin receptors in the rat knee joint.
2) Laser Doppler Imaging (LDI) was used to investigate 
changes in blood flow.
3) FK888 (an NK1 antagonist), SR48968 (an NK2 non peptide 
antagonist), and FK224 (an NK1 and NK2 antagonist), in different 
doses were used in the experiments.
4) NKA on its own at lower doses slightly decreased blood flow 
but at higher doses it dose dependently increased blood flow (doses 
between 1(H0 to 1(H3 mol). Maximum vasodilatation achieved was 
59.25% ± 13.44 when a dose of 10"8 mol was used.
5) FK888 at higher doses inhibited the vasodilator effect of 
NKA in the rat knee joint.
6) FK224 at some doses inhibited the vasodilator effect of NKA 
but overall failed to reduce its effect on blood flow.
7) SR48968 at 10-8 mol partially, significantly and dose 
dependently reduced the vasodilator effect of NKA
8) These data suggest that the vasodilator effect of NKA is 
chiefly mediated via NK2 receptors which could be a subtype of these 
receptors, and a small part of its action is mediated via NK1 receptors.
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4.2 2 IN T R O D U C T IO N
The existence of NKA first was reported in 1983 by several 
groups (Kangaw et al 1983; Kimura et al. 1983; Manamino et al 
1984), and further investigation showed that this peptide is widely 
distributed in both central and peripheral nervous systems. NKA is 
released in response to noxious and other stimuli and has a variety of 
biological actions (Maggi et al 1993a) and is produced from a single 
preprotachykinin gene (SP/NKA gene: Nawa et al 1983). This peptide 
has a very wide distribution and synthesis occurs in different parts of 
the body (Pemow 1993, Deacon and Colonl987, Maggi 1993b) and 
gives rise to different physiological and pathological effects (Geppeti 
et al 1987; also see chapter 1). However there is only one reports about 
the effect of NKA on the rat knee joint vasculature (Lam & Ferrell 
1993B). These experiments were performed to clarify the effect of 
NKA on rat knee joint blood flow and the receptors mediating this 
response.
4.2.3 MATERIALS AND METHODS
Experiments were performed on 53 Wistar rats, the experimental 
procedures and data analysis were as described previously (chapter 2).
NKA was utilised at six different doses ( l(H 3-lO-8 mol) with 
and without three different antagonists, SR48968, FK888, FK224. 
Antagonists were applied over the same dose range and by the same 
route as described previously (see chapter 4.1.3). Statistical analysis 
was performed using minitab software, and the comparisons between 
mean values was by two way Anova or two tail Student t test (see 
chapter 4.1.3).
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4.2.4 R E SU L T S
Basal perfusion and selected rectangular measurement area is as 
described in chapter 4.1 .4.
The effect of NKA: NKA at lower doses had variable effect on 
blood flow. The 10"!3 mol dose increased non-significantly blood 
flow and doses of 10"l2 mol and 10-U mol slightly decreased blood 
flow compared to basal blood flow values. From 10" 1° mol blood flow 
increased dose dependently up to a maximum of 59.2±13.4%, n=14 
(fig. 4.2.1).
The effect of antagonists: Three different antagonists at three 
different doses were used (10"12 mol, 10"10 mol, 10’8 mol).
SR48968, which is a non-peptide NK2 antagonist, was applied 
topically with different doses of NKA. Co-application of SR48968 at 
10"12 mol with NKA failed to reduce the vasodilator effect of NKA 
and even intensified the vasodilator effect of NKA at 10"9 mol, but 
overall SR48968 failed to inhibit the effects of NKA (p = 0.96, n=8, 
Anova) ( fig. 4.2.2a).
Application of SR48968 at 10"l° mol with NKA showed 
different responses, with NKA at 10"12 mol to NKA 10"10 mol 
increasing NKA's effect on blood flow but at other doses of NKA, 
decreased its effect on blood flow. In general, SR48968 at 10"10 mol 
failed to reduce the vasodilator effect of NKA (p= 0.58, n= 8, Anova) 
(fig. 4.2.2b) and the dose response curves were not significantly 
different from control.
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Fig 4.2.1 Changes in synovial blood flow during topical 
application o f NKA to the knee joint capsule (mean ±SEM , n=14)
In contrast, SR48968 at 10“8 mol significantly (P=0.002, n=8, 
Anova) inhibited the effect of NKA (fig. 4.2.2c).
FK888 which is a specific NK1 receptor antagonist was applied 
at three different doses together with NKA. FK888 at 10“ 12 mol with 
different doses of NKA, not only failed to inhibit NKA but also 
increased significantly the NKA effect on blood flow (p<0.001, n=12, 
Anova)(fig. 4.2.3a).
FK888 at 10"10 mol applied with NKA also increased the 
vasodilator response of NKA and although this effect was less 
obvious than FK888 at 10“12 mol, and it too was significant (p=0.001, 
n=12. Anova) (fig. 4.2.3b).
Co-application of FK888 at 10“8 mol with NKA reduced the 
effect of NKA on blood flow at doses 10“13 to 10“9 mol but increased 
the vasodilator effect of NKA at a dose 10“8 mol (fig. 4.2.3c). In 
general, FK888 at 10-8 mol partially and significantly reduced the 
effect of NKA on blood flow (p=0.02, n=12, Anova).
FK224 is an NK1 and NK2 receptor antagonist. This antagonist 
was also used at three different doses. Application of FK224 at 10“12 
mol together with NKA not only inhibited NKA-induced 
vasodilatation, but also significantly increased its vasodilator effect 
(p=0.007, n= 8, Anova) (fig. 4.2.4a).
FK224 at 10“10 mol intensified the effects of NKA on blood 
flow at all doses, which was significant compared with NKA on its 
own (PO.OOOl, n=8, Anova) (fig. 4.2.4b)
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FK224 at a dose of 10"8 mol co-administered with NKA showed 
a variable effect on blood flow, at some doses increasing and at others 
decreasing the vasodilator effect of NKA. Overall it failed to reduce 
the effect of NKA on blood flow (p= 0.32, n=8, Anova) (fig. 4.2.4c).
Application of both FK888 and SR48968 at a dose of 10"8 mol 
with NKA, inhibited the vasodilator effect of NKA except at a dose of 
10"11 mol. This reduction of blood flow was significant (p=0.017. n=8, 
Anova) in compared to control (fig. 4.2.5).
4.2.5 DISCUSSION
NKA is a ten amino acid peptide which is produced by PPT1, 
the same gene which produces SP. NKA has a 4 amino acid sequence 
similar to SP (Helke et al 1990). This peptide exists with other 
neuropeptides in the sensory nerve endings of both central and 
peripheral nervous systems and participates in different biological 
responses (Maggi et al 1993a). NKA, beyond a dose of 10"10 mol, 
increases blood flow with a maximum effect at a dose 10-8 mol (59.2± 
13.4 % increase in blood flow). To find out which receptors mediate 
this effect three different antagonists at three different doses were 
topically co-applied with NKA.
SR48968 at a dose of 10“12 mol failed to reduce NKA induced 
vasodilatation and 10-10 mol SR48968 produced variable effects, and 
except at a dose NKA 10-8 mol, it failed to reduce the vasodilator 
effect of NKA. SR48968 at 10~8 mol significantly and dose 
dependently reduced effects of NKA on blood flow (two way Anova, 
p=0.002). This reduction in the NKA effect on blood flow is not strong 
and the dose response curve is only slightly shifted to right which
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Fig 4.2.2. Changes in synovial blood flow during topical 
application of NKA to the knee joint capsule alone, and 
with a non peptide NK2 antagonist, SR48968 at different 
doses: Values are mean ±SEM.
A) Application of NKA alone (A, n=14) and together with 
SR48968 at 10-12 mol (A, n=8 )
B) Application of NKA alone (A, n=14) and together with 
SR48968 at 10-10 mol (■, n=8 )
C) Application of NKA alone (A, n=14) and together with 
SR48968 at 10-8 mol (« , n=8 )
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Fig 4.2.3. Changes in synovial blood flow during topical 
application of NKA to the knee joint capsule alone, and 
with an NK1 antagonist, FK888 at different doses: Values 
are mean ±SEM.
A) Application of NKA alone (A, n=14) and together with 
FK888 at 10-12 mol (A, n=12 )
B) Application of NKA alone (A ,n=14) and together with 
FK888 at 10-10 mol (■, n=12 )
C) Application of NKA alone (A ,n=14) and together with 
FK888 at 10-8 moi (« , n=i2 )
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Fig 4.2.4. Changes in synovial blood flow during topical 
application of NKA to the knee joint capsule alone, and 
with an NK1 and NK2 antagonist, FK224 at different 
doses: Values are mean ±SEM,
A) Application of NKA alone (A , n=14) and together with 
FK224 at 10-12 mol (A, n= 8)
B) Application of NKA alone (A, n=14) and together with 
FK224 at 10-10 mol (■, n= 8 )
C) Application of NKA alone (A , n=14) and together with 
FK224 at 10-8 moi (« , n= 8)
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Fig 4.2.5. Changes in synovial blood flow during topical 
application of NKA to the knee joint capsule, alone (A, mean 
±SEM, n=14) and co-application with SR48968 and FK888, both 
at dose of 10-8 mo]? (■ ? mean ±SEM, n=8)
suggests a partial inhibition of NKA. As SR48968 is known to be a 
specific NK2 antagonist, these data suggest that NK2 receptors 
mediate a part of the vasodilator effect of NKA on blood flow.
Co-application of both 1(H2 and 10“10 mol FK888 with NKA, 
enhanced the vasodilator effect of NKA on blood flow, which was 
significant (P=0.01) for the 10“10 mol dose. This enhancing effect of 
antagonists at lower concentrations was observed also with the other 
antagonist SR48968. FK888 on its own does not have any effect on 
blood flow in doses of 10“12 and 10“8 and at 10-10 mol non 
significantly increased blood flow (see 4.4). Therefore the enhancing 
effect of NKA with co-application of FK888 could be due to a direct 
effect on blood vessels or activation and release of other vasodilator 
agents.
10“8 mol FK888 significantly reduced the vasodilator effect of 
NKA at lower doses and enhanced effects of NKA on blood flow at 
10“8 mol. These data suggest that FK888 can partially inhibit the 
vasodilator effect of NKA on blood flow, which indicates that NKA 
can also activate NK1 receptors and mediates a part of its effect via 
these..
FK224 at dose of 10“I2 and 10“10 mol was unable to reduce 
NKA-induced vasodilatation, and even significantly enhanced this 
effect. FK224 at 10-8 mol had a variable effect on NKA induced 
vasodilatation, at lower doses of NKA this effect is attenuated and at 
higher doses this effect is enhanced. At 10-10 mol this antagonist 
weakly inhibits NKA-induced vasodilatation but this was not 
significant.
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Combination of FK888 and SR48968 both at 10-8 mol 
significantly (P=0.017) reduced the NKA effect on blood flow. This 
reduction, except at a dose of 10“11 mob was dose dependent, and 
shifted the dose response curve to right. In conclusion, NKA has a 
higher affinity for NK2 receptors than NK1 receptors, and mediates its 
effect on blood flow generally via these receptors, although NKA can 
cross react on NK1 receptors. SR48968 showed a weak antagonistic 
response for NK2 type of receptors. Hallin et al (1994) suggested 
further classification for NK2 receptors in spinal cord, and Advenier et 
al (1992) described that SR48968 is more active on the NK2a receptor 
than the NK2b. As SR48968 did not show strong antagonistic effect in 
the rat knee joint, it seems that NK2b receptors mediate the 
vasodilator effect of NKA. There is cross reactivity with NK1 
receptors and a small portion of the NKA effect on blood flow is 
mediated via these receptors. Previous work has shown that 
bronchoconstriction in the conscious guinea pig is mediated 
predominantly by NK2 receptors with only a minor involvement of 
NK1 receptors (Chan etal 1994).
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SECTION THREE 
NEUROKININ B AND ITS RECEPTORS
86
4.3.1 SU M M ARY
1) Experiments were performed to identify the action of NKB on 
neurokinin receptors in the rat knee joint.
2) Laser Doppler Imaging (LDI) was used to investigate 
changes in blood flow.
3) FK888 (a NK1 antagonist), SR48968 (a NK2 non-peptide 
antagonist) and FK224 (a NK1 and NK2 antagonist), were used at 
different doses in these experiments.
4) NKB on its own produced a potent and significant dose 
dependent vasodilatation in the rat knee. The maximum vasodilatation 
achieved was 105% increase from base line with a dose of 10~8 mol 
NKB.
5) SR48968 at a dose of 10”8 mol significantly reduced the 
effect of NKB on blood flow.
6) FK888 in a dose of 10"8 mol slightly but non significantly 
reduced NKB-induced vasodilatation.
7) FK224 at 10~8 mol completely and significantly blocked the 
vasodil ator effect of NKB.
8) Combination of FK888 and SR48968 in a dose of 10’8 mol. 
completely and significantly blocked the effects of NKB on blood 
flow.
These data suggest that NKB mediates its vasodilator effects via 
NK1 and NK2 receptors in the knee joint, and it is unlikely that NK3 
receptors are present.
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4.3.2 IN T R O D U C T IO N
NKB is a ten amino acid peptide, which belongs to the 
tachykinin family with a common C terminus. NKB is the only 
tachykinin derived from pre-pro-tachykinin II (PPTII) (Bonner et al 
1987). In spite of expression of PPTI, in dorsal root ganglia (DRG), the 
PPTII gene is not expressed in DRG hence the absence of NKB in 
central or peripheral nerve terminals of capsaicin-sensitive primary 
afferents is expected (Maggi et al 1993a) and NKB is mainly found 
within the CNS. Some investigators have reported the existence of 
NKB in rat peripheral nerves (Tateishi et al 1990), but tissue levels are 
extremely low compared to SP or NKA and in many cases NKB is 
undetectable.
The release of this peptide is via an active calcium dependent 
mechanism (Bonner et al 1987), and it is thought to exert different 
physiological actions, but there are few reports about the specific 
effects of NKB in peripheral tissues.
Three different and distinct receptors, NK1, NK2 and NK3 
mediate the biological effects of the neurokinins. NK1 and NK3 are G 
protein coupled receptors with pharmacologically distinct profiles 
(Gether et al 1993). However there is little known about the effects of 
NKB in rat knee joint blood vessels and the receptors mediating these 
effects, and these experiments were performed to investigate these 
issues.
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4.3.3 M A T E R IA L S AND M E T H O D
The experiments were performed on 42 male Wistar rats (-350- 
500g). Anaesthetic procedures and preparation for experiments, 
technical and statistical methods were as described in chapter 4.1.3.
NKB at six different doses (10"13 to 10"8 mol), was used in 
these experiments Three different antagonists, FK888, FK224 and 
SR48968 at three different doses (10-12, 10" 10, 10-8 mol) were co­
applied with NKB. The rest of the methods have been described 
previously (chapter 2). Statistical analysis in this study was by two way 
Anova and student t test as described previously (see 4.1.3).
4.3.4 RESULTS
Basal perfusion and selected rectangular measurement area is as 
described in 4.1.4.
The effect of NKB: NKB on its own produced a potent and 
significant increase in blood flow. This vasodilatation began at a dose 
of 10"12 mol and the maximum response was at 10"8 mol with 105.7±
13.6 %, n=8, increase in blood flow over basal values (fig. 4.3.1).
The effect of antagonists: SR48968 at dose of 10"12 mol co­
applied with NKB, in some cases decreased and in some cases 
enhanced the vasodilator effect of the NKB, but overall these changes 
were not significant (p=0.24, n=8, Anova) (fig. 4.3.2a).
Application of 10"10 mol SR48968 with NKB not only failed to 
reduce NKB-induced vasodilatation but also significantly (p=0.01, 
n=8, Anova) increased its effect on blood flow at all doses (fig. 
4.3.2b).
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Fig 4.3.1 Changes in synovial blood flow during topical 
application o f NKB to the knee jo in t capsule (mean ±SEM, n=8)
SR48968 at a dose of 10-8 mol co-applied with NKB weakly 
but significantly (p=0.033, n=8, Anova) reduced NKB-induced 
vasodilatation (fig. 4.3.2c).
FK888 at all three doses failed to inhibit NKB-induced 
vasodilatation. FK888 at 10“12 and 10“10 mol had no effect on NKB- 
induced vasodilatation and at 10“8 mol non-significantly reduced the 
effect of NKB (p=0.8, n=8. p=0.5, n=8 and p=0.4, n=8 respectively) 
(fig. 4.3.3a, b and c respectively).
FK224 at a dose of 10“12 mol co-applied with NKB, reduced its 
effect on blood flow, but this reduction was not significant (p=0.1, 
n=8, Anova) ( fig. 4.3.4a).
FK224 at 10“10 mol significantly (p=0.012, n=8, Anova) 
inhibited NKB induced vasodilatation and slightly shifted the dose 
response curve to the right (fig. 4.3.4b).
The vasodilator effect of NKB was completely and significantly 
(p<0.001, n=10, Anova) blocked by FK224 at 10“8 mol, and except for 
the 10“8 mol dose which gave only 45% vasodilatation, the other 
doses did not evoke any response and blood flow remained at baseline 
values (fig. 4.3.4c).
Co-application of FK888 and SR48968 both at 10-8 mol with 
NKB completely blocked the effect of NKB on blood flow at lower 
doses and at higher doses. Significant (p<0.0001, n=8, Anova) and 
dose dependent inhibition of NKB occurred, shifting the dose response 
curve to the right (fig 4.3.5).
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Fig 4.3.2. Changes in synovial blood flow during topical 
application of NKB to the knee joint capsule alone, and 
with a non peptide NK2 antagonist, SR48968 at different 
doses: Values are mean ±SEM.
A) Application of NKB alone (O, n= 8) and together with 
SR48968 at 10-12 mol (A, n=8 )
B) Application of NKB alone (O, n= 8) and together with 
SR48968 at 10-10 mol (■, n= 8)
C) Application of NKB alone (O, n=8) and together with 
SR48968 at 10"8 mol ( • ,  n=8 )
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Fig 4.3.3. Changes in synovial blood flow during topical 
application of NKB to the knee joint capsule alone, and 
with an NK1 antagonist, FK888 at different doses: Values 
are mean ±SEM.
A) Application of NKB alone (O, n = 8) and together 
with FK888 at 10" 12 moi (A, n= 8 )
B) Application of NKB alone (O, n= 8) and together with 
FK888 at 10-10 mol (■, n= 8 )
C) Application of NKB alone (O, n= 8) and together with 
FK888 at 10"8 mol ( • ,  n=8 )
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Fig 4.3.4. Changes in synovial blood flow during topical 
application of NKB to the knee joint capsule alone, and 
with an NK1 and NK2 antagonist, FK224 at different 
doses: Values are mean ±SEM.
A) Application of NKB alone (O, n= 8) and together with 
FK224 at 10-12 mol (A, n=8 )
B) Application of NKB alone (O, n= 8) and together with 
FK224 at 10‘10 mol (■, n=8 )
C) Application of NKB alone (Q, n= 8) and together with 
FK224 at 10-8 mol ( • ,  n=10 )
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Fig 4.3.5. Changes in synovial blood flow during topical 
application of NKB to the knee joint capsule, alone (O, mean 
±SEM, n=8) and co-application with SR48968 and FK888, both at 
dose of 10-8 moi? (■ 5 mean ±SEM, n=8)
4.3.5 D ISC U SSIO N
There is little data published about NKB and its effect on 
different organs. NKB in the rat the knee joint potently and dose 
dependently increased blood flow. An effect which was highly 
significant (pO.OOOl one way Anova). This vasodilatation is transient 
and like other neurokinins lasts only a maximum of two minutes. 
Maximum vasodilatation was 105.7±13.6 % increase from base line 
which showed the greatest effect of the three neurokinins.
SR48968 at doses of 10"12 and 10"10 mol enhanced the effect of 
NKB on blood flow, this becoming significant at 10“ 1° mol (p= 0.01, 
n=8). This enhancement could be due to a dual effect of the antagonist 
which will be discussed later. SR48968 at 10"8 mol slightly but 
significantly reduced the NKB effect on blood flow (p=0.038, two 
way Anova). This reduction indicates involvement of NK2 receptors in 
this response. FK888 failed completely to inhibit NKB at doses of 10“ 
12 and 10“10 mol and slightly but non significantly reduced its effect at 
10"8 mol. As FK888 is a specific NK1 antagonist, NKB appears to 
mediate its effects via other neurokinin receptors.
Application of FK224 at doses of 10-12 and 10"10 mol dose 
dependently inhibited NKB which at 10” mol was significant 
(p=0.012, n=8). At 10"8 mol FK224 strongly and significantly 
(pO.OOOl, n=8) blocked NKB effects on blood flow and even at 10“9 
mol NKB failed to dilate blood vessels. These data strongly suggest 
that NKB mediates its effects via both NK1 and NK2 receptors. In 
view of the finding with FK888, NK1 receptors in the rat knee joint 
may be a subtype of NK1 receptor and also the NK2 receptor could be 
a NK2b receptor.
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These finding were verified by application of both FK888 and 
SR48968 mol, which significantly and dose dependently reduced the 
effect NKB on blood flow which supports the FK224 findings.
With regard to these data, it could be concluded that NKB may 
mediate its effects on blood flow via an atypical NK1 receptor and a 
subtype of NK2 receptor. Complete inhibition by FK224 indicates that 
there is no other neurokinin receptor in the rat knee joint and the 
significant reduction in blood flow by co- administration of FK888 and 
SR48968 indicate lack of NK3 receptors in the rat knee joint. In the 
literature the only report about the existence of peripheral NK3 
receptors indicates that there are found in the rat portal vein 
(Mastrangelo etal 1987).
4.3.6 GENERAL DISCUSSION
All three neurokinins dose dependently and significantly 
induced vasodilatation in the rat knee joint, and these response were 
significantly different from each other. The rank order of potency was 
NKB > SP > NKA (fig. 4.3.6). There is no significant difference 
between SP and NKB at lower doses, but at higher doses the difference 
is highly significant and NKB overall demonstrates a potent effect on 
blood flow. It could be that SP has a hypotensive effect at the highest 
doses but NKB does not.
Three distinct neurokinin receptors exist for these three 
neurokinins, and subdivision of these receptors were also found. These 
three neurokinins are capable of activating these receptors, but with 
different affinities and potencies (Regoli et al 1987b). The mechanism
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Fig 4.3.6 Changes in synovial blood flow during topical 
application o f SP ( • ,  mean ±SEM , n=35), NKA (A, mean ±SEM, 
n=14), NKB (■ , mean ±SEM , n=8), to the knee jo in t capsule
is via activation of a second messenger (Phosphatidyle inositol 
hydrolysis) with differing potency (Nakjima et al 1992).
Application of three different antagonists demonstrated different 
effects. SR48968 at 10"12 mol failed to inhibit the vasodilatation 
induced by three neurokinins, and even slightly increased the SP effect 
on blood flow.
SR48968 at 10” 10 mol enhanced effects of neurokinins on blood 
flow instead of attenuating vasodilatation, which was significant with 
NKB. SR48968 at 10"8 mol significantly enhanced the SP vasodilator 
effect.
These data suggest that SR48968 has dual effect on rat knee 
joint blood flow: a specific effect on NK2 receptors which blocked the 
vasodilator effect mediated by NK2 receptors and an indirect effect 
which potentiated the neurokinin effect on blood flow. In the presence 
of NK2 receptors the inhibitory effect of SR48968 overcomes its 
indirect effects. The mechanism underlying the indirect effect is not 
clear. It may activate other mechanisms and release other vasodilator 
agents, or the receptors may have a regulating and interfering effect on 
each other, and blocking one receptor type may influence other 
receptors type and potentiates their responses. The effect of SR48968 
which is not a specific antagonist for SP, shows clear potentiation of 
the vasodilator effect of SP.
For both NKA and NKB there appears to be both an antagonistic 
and a potentiating effect of SR48968, which by potentiation of 
neurokinins and competitive inhibition of their receptors, altogether 
shows a very weak antagonistic effect. SR48968 is a potent antagonist
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for NK2a receptors but has also effects on NK2b receptors, (Advenier 
et al 1992a). The weak response to NKA in the rat knee joint suggests 
the existence of NK2b receptors in this area. These finding were 
confirmed by others in rat peripheral tissues and NK2b receptors have 
been reported in rat smooth muscle (Maggi et al 1993a).
FK888, which is a selective NK1 antagonist, like SR48968 
increased neurokinin effects on blood flow, which could be due to an 
indirect effect as described before. FK888 showed a weak antagonistic 
effect on SP, which could partially be due to interaction with the 
indirect effect of FK888 and also due to a subtype of NK1 receptor 
which was confirmed with application FK224.
FK224, a NK1 and NK2 receptor antagonist, completely 
blocked the effect of SP on blood flow which reveals that SP also 
mediates its effects via NK2 receptors. Significant but not complete 
reduction of SP increased blood flow by combination of FK888 and 
SR48968 again verifies that a subtype of NK1 receptor and NK2b 
receptor which mediates SP induced vasodilatation.
The NKA data revealed that this peptide mediates its 
vasodilatation via NK2 receptors, but as the SP and NKA data 
suggest, this receptor may be of the NK2b receptor subtype.
Complete block of NKB induced vasodilatation by FK224 and a 
combination of FK888 and SR48968 suggests that there are no NK3 
receptors in the rat knee joint and that NKB mediates its effects by 
acting at both NK1 and NK2 receptors. Thus it is possible that a 
subtype of NK1 receptor and the NK2b receptor mediate the effects of 
all the neurokinins on the rat knee joint.
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These experiments revealed that SP, NKA and NKB exert their 
effects via both NK1 and NK2 receptors and activation of only 
one of those receptors by one of these neurokinins may be 
necessary to show its full effects on blood flow. Blocking of one 
neurokinin receptor type by a specific antagonist would not 
reduce that neurokinin's effect on blood flow because the other 
receptor type will remain active and thus be able to show the 
agonist's full effect. It is possible that to achieve a full response 
by the agonist does not require occupation of all the receptors 
(depend on the nature of the receptor and the agonist). Partial 
receptor occupation would be enough to achieve to the highest 
response, therefore blocking of one receptor type neurokinins 
would not be enough to reduce the neurokinin's effect on blood 
flow. Thus there would not be a significant change in blood flow 
in compared to the effect of the neurokinin on its own. To 
effectively block the neurokinin's effect on blood flow blockade 
of both neurokinin receptors is necessary, as observed in these 
experiments.
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SECTION FOUR
PHYSIOLOGICAL ROLE OF NEUROKININS 
IN THE REGULATION OF 
SYNOVIAL BLOOD FLOW
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4.4.1 SU M M A RY
1) Experiments were performed on Male wistar rats to clarify 
physiological role of the tachykinins in regulating synovial blood flow.
2) Laser Doppler Imaging (LDI) was used to investigate 
changes in blood flow.
3) FK888 (an NK1 antagonist), SR48968 (an NK2 non-peptide 
antagonist), and FK224 (an NK1 and NK2 antagonist), at three 
different doses and also phenoxybenzamine (an al&  a2 adenoceptor 
antagonist) were used in these experiments.
4) Neither FK888 nor SR48968 on their own significantly 
influenced joint blood flow
5) Co-administration of FK888 and SR48968 significantly and 
dose dependently reduced basal blood flow, which showed -20% 
reduction from control at 10"® mol.
6)FK224 significantly, but less potently, reduced basal blood
flow
7) Phenoxybenzamine administration resulted in -30% increase 
in basal blood flow. This effect was reduced by 60% during co­
administration with of antagonists FK888 and SR48968 at 10“® mol.
8) In the denervated knee joint, co-administration of FK888, and 
SR48968 at 10“® mol showed a 6% increased basal blood flow which 
did not significantly differ from vehicle treatment.
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9) Phenoxybenzamine-mediated vasodilatation was not inhibited 
by co-administration with FK888 and SR48968 at 10“8 mol in the 
denervated knee.
10) These data suggest that SP and perhaps other neurokinins 
are normally released from sensory nerve ending and participate in 
regulating vascular tone and thus basal blood flow.
4.4.2 INTRODUCTION
Neurokinins are present in unmyelinated sensory fibres in the 
both central and peripheral nervous systems ( chapter 1, and chapter 4, 
sec 4.1, 4.2, 4.3), and such fibres also innervate the rat knee joint 
(Konttinen et al 1990).
Experiments described earlier (chapter 4, sec 4.1, 4.2, 4.3) 
showed the presence of neurokinin receptors as there is a potent 
vasodilator effect with exogenous application of neurokinins to the rat 
knee joint however whether SP and other neurokinins have a role in 
regulating synovial perfusion is unknown at present and it was 
investigated in this study.
4.4.3 MATERIAL AND METHOD
Experiments were performed on male Wistar rats (~350-500g). 
Two groups of rats were used, an intact group and a knee joint 
denervated group. The procedure of terminal anaesthesia and 
experimental procedures in the intact group were described earlier in 
section 4.1. In the denervated group, five rat were anaesthetised with 
hypnorm and diazepam and the medial aspect of knee joint denervated, 
as described in chapter two. After allowing one week to elapse for
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degeneration and depletion of sensory nerve fibres, the same
procedures used in the intact group, were repeated on this group of 
rats. Three different antagonists FK224, FK888, SR48968 at three 
different doses 10“ 12 mol5 10“ 10 mol, 10“8 mol and
phenoxybenzamine an a  1 and o2 receptor antagonist at a dose of 10"6 
mol were used in these experiments . Statistical analysis of the data 
was performed. The comparisons between mean values was by 
Student's t test (see 4.1.3)
4.4.4 RESULTS
Effect of antagonist: Saline and the vehicle for the neurokinin 
antagonists on their own did not have any significant effect on basal 
blood flow. (0.2±1.4%, n=44, and 0.7±2.2%, n=29 increase from base 
line perfusion, respectively) and also did not show any significant
difference with each other (p=0.85, two tail t test) ( fig. 4.4.1).
Application of SR48968 on its own at different doses produced 
variable and non-significant effects on blood flow. SR48968 at 10“ 12 
mol slightly increased blood flow (0.64±3.1%, n=27, T test), and a 10“ 
10 and 10“8 mol slightly decreased blood flow (-0.6±2.2%, n=22 and 
-1.3±2.8%, n-22, respectively), but none of these responses differed 
significantly from the vehicle effect (10“12 p=0.8, 10“10 p=0.8, 10“8 
p= 0.9, respectively, paired two tail t test) (fig. 4.4.1)
Application of FK888 on its own at different doses like 
SR48968, produced variable but non-significant responses on blood 
flow. At 10“ 12 mol FK888 slightly and non significantly decreased 
blood flow (-2.7±2.9%, n=28) and at 10“ 10 and 10“8 mol did not 
produce any significant effect on basal blood flow (1.5 ± 3.1, n=36 and
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-2.1±2.6%, n=40, respectively)(10"12 p=0.3, 10”10 p= 0.9, 10”8 p= 
0.3, respectively, paired two tail t test) (fig. 4.4.2).
Application of FK224 on its own reduced blood flow and this 
reduction occurred at all doses. At 10” 12 mol FK224 reduced blood 
flow (-5.3±4%, n=14) but this reduction of blood flow was not 
significant (p=0.3, n=14) compared to vehicle. At 10"10 mol FK224 
significantly reduced blood flow (-8.3±2.2% p = 0.01, n=28, paired t 
test). FK224 at 10“8 mol also significantly reduced blood flow (- 
5.9±2.1 p=0.03, n=25, T test) (fig. 4.4.3).
Co-application of FK888 and SR48968 dose dependently 
reduced basal blood flow at all doses. The 10" 12 mol dose non 
significantly reduced blood flow (-6.3±4.8%, p = 0.24, n=24, t test). At 
10”10 mol this became significant (-12±3.3% p=0.002, n=24, t test) 
and more so at 10"8 mol (-19.9±2.7 p=0.0001, n=38, t test) (fig. 4.4.4a 
& b).
In the denervated rat knee co-application of FK888 and 
SR48968 (10-8 mol) failed to reduce basal blood flow and actually 
produced a small but non-significant increase in flow (6.8±4.5%, 
p=0.38, n=29)(fig. 4.4.5)
Application of phenoxybenzamine (10"6 mol) significantly 
increased basal blood flow (31.3±6.2%, p= 0.001, n=12) in the normal 
joint but when phenoxybenzamine was co-administered with FK888 
and SR48968 the increase in blood flow was substantially and 
significantly (P=0.001, n=30, t test) attenuated. In the denervated joint 
the response to the same dose of phenoxybenzamine was reduced 
(16.8±11.7%, p= 0.33 n=8). but this reduction was not significant
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Fig 4.4.1. Changes in synovial blood flow during topical 
application of saline, vehicle for the neurokinin antagonist and 
SR48968 in different doses to the knee joint capsule. Values are 
mean ±SEM.
Saline (n=44), vehicle (n=29), SR48968 at 10-12 (n=27), SR48968 
at 10"10 (n=22), SR48968 at 10"8 (n=22), there were not any 
significant difference between different treatments.
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Fig 4.4.2. Changes in synovial blood flow during topical 
application o f saline, vehicle for the neurokinin antagonist and 
FK888 in different doses to the knee joint capsule. Values are 
mean ±SEM.
Saline (n=44), vehicle (n=29), FK888 at 10-12 (n =28), FK888 at 
10-10 (n=36), FK888 at 10-8 (n=40), there were not any significant 
difference between different treatments.
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Fig 4.4.3. Changes in synovial blood flow during topical 
application o f saline, vehicle for the neurokinin antagonist and 
FK224 in different doses to the knee jo int capsule. Values are 
mean ±SEM.
Saline (n=44), vehicle (n=29), FK.224 at 10-12 (n=14, FK224 at 
10-10 (n=28), FK.224 at 10-8 (n=25). * means differs significantly, 
from vehicle. For significant value see text
Fig 4.4.4a: Laser Doppler perfusion images of rat knee joints.
A) colour-coded system for showing perfusion values .
B) Control perfusion image of the knee joint.
C) Co-application of FK888 & SR48968 both at 10“8 mol. 
There is a significant reduction in basal blood flow.
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Fig 4.4.4b. Changes in synovial blood flow during topical 
application o f saline, vehicle for the neurokinin antagonist and 
both SR48968 + FK888 in different doses to the knee jo int capsule. 
Values are mean ±SEM.
Saline (n=44), vehicle (n=29), SR48968 + FK888 at 10-12 (n=24, 
SR48968 + FK888 at 10-1° (n=24), SR4896S + FK888 at 10‘8 
(n=38). * means differs significantly, from vehicle . For significant 
value see text
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Fig 4.4.5. Changes in synovial blood flow during topical 
application o f saline, and both SR48968 + FK888 both at 10~8 mol 
alone and with phenoxybenzam ine (10"6 mol) to the normal and 
denervated knee joint capsule . Values are mean ±SEM.
Saline (■ , n=44), SR48968 + FK888 (» ,  n=29),
phenoxybenzam ine (■ , n=12), SR48968 + FK888 with
phenoxybenzam ine (H , n=38). * means differs significantly from 
vehicle . For significant value see text
compared to vehicle (fig. 4.4.5). Contrary to the normal joint, co­
administration of phenoxybenzamine and FK888 and SR48968 (10~8 
mol) gave a response (22.78±12.86%) which did not differ 
significantly (p=0.14, n=5, t test) from phenoxybenzamine alone (fig. 
4.4.5).
4.4.5 DISCUSSION
As the vehicle neurokinin for the antagonists contained alcohol, 
it could be argued that a part of the vascular response to the 
antagonists was due to alcohol, but application of vehicle alone to the 
knee joint did not show any effect on basal blood flow. The vehicle 
applied to the knee joint had the highest alcohol concentration which 
was used with the 10"8 mol dose of antagonist in these experiments, 
but even so, it had as little effect on blood flow as application of 
saline.
Previous experiments confirmed that SP acts at both NK1 and 
NK2 receptors, and as SP mediates its effect on blood vessels via these 
receptors three different antagonists, FK888, FK224 and SR48968 
were used to antagonise its action on the vascular bed.
Neither FK888 nor SR48968 at the three doses used influenced 
synovial perfusion compared to vehicle, which suggests that in the 
previous experiments (section 4.1, 4.2, 4.3) the results were solely due 
to the effect of the antagonists on blood flow.
FK224 reduced basal blood flow at all three doses but this was 
significant only at the 10"10 and 10“8 mol doses (p=0.01, n=28 and 
0.03, n=25).
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Co-administration FK888 and SR48968 at the three doses 
potently and dose dependently reduced blood flow, the greatest 
reduction being 19.9±2.6%. Blood pressure was monitored in these 
experiments to confirm that these effects are not due to a systemic 
hypotensive effect of the antagonists. Application of both antagonists 
to the knee joint did not show any effect on blood pressure even at the 
highest doses.
These two series of data suggest that there is a basal release of 
SP in the normal knee joint which produces vasodilatation and 
participates in regulating blood vessel tone via NK1 and NK2 
receptors, and thus blocking these receptors reduces basal blood flow.
To confirm these findings, phenoxybenzamine 10"6 mol applied 
to the knee joint produced a 31.3±6.2% increase in basal blood flow, 
but it did not show any significant effect on systemic blood pressure. 
Co-administration of FK888 and SR48968 (10“8 mol) with the same 
dose of phenoxybenzamine reduced the vasodilator effect of
phenoxybenzamine on its own (by more than 60%) (10.4±0.5%) which 
was highly significant (fig. 4.4.5).
These findings suggest that there is normally sympathetic vaso­
constrictor tone which is offset by the vasodilator action of
neurokinins and basal blood flow shows a balance between the
sympathetic vasoconstrictor and neuropeptidergic vasodilator
influences.
As SP and other neuropeptides exist in sensory nerve endings, to 
check that this action was mediated by sensory neurokinins, in five rats
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the medial aspect of joint was surgically denervated and one week later 
the above experiments repeated.
In the denervated knee, co-administration of FK888 & SR48968 
(10“8 mol) produced a 6.8±4.5% increase in perfusion, which was not 
significantly different from the effect of the vehicle. The lack of effect 
of these antagonists is indicative of the absence of neurokinins in the 
denervated joints
In these rats phenoxybenzamine-induced vasodilatation did not 
change significantly with co-administration of antagonists, which also 
indicates the absence of neurokinins.
These finding all indicate that SP and perhaps other neurokinins 
are normally released from sensory nerve ending without apparent 
activation of these fibres and to some extent offset sympathetic 
vasoconstrictor ’’tone”. This implies that these neurokinins have an 
important regulatory function in vascular function in rat knee joints 
and perhaps in other vasculature beds.
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CHAPTER FIVE
EFFECTS OF INFLAMMATION 
AND
NERVE DEPLETION 
ON
SYNOVIAL BLOOD FLOW
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5.1 SU M M A RY
1) Experiments were performed to evaluate the effect of 
different models of inflammation on neurokinin-mediated 
vasodilatation
2) Laser Doppler imaging (LDI) was used to investigate changes 
in blood flow.
3) Carrageenan-induced acute inflammation increased basal 
blood flow and enhanced the vascular response to SP.
4) Capsaicin was utilised to induce chronic nerve depletion and 
was acutely applied to the knee joint. Chronic capsaicin treatment 
increased basal blood flow and also altered SP-induced vasodilatation.
5) Injection of different doses of capsaicin into the knee joint 
produced an acute vasoconstriction at all doses, followed by a dose 
dependent vasodilatation. This secondary effect could be due to the 
release of vasodilator mediators from sensory nerve endings.
6) Capsaicin in chronic application substantially attenuated SP- 
induced vasodilatation and with acute application dose dependently 
attenuated the SP effect on blood flow.
7) Adjuvant was applied to induce chronic inflammation. 
Adjuvant significantly reduced basal blood flow in the first week but 
this abated by the third week. Temperature and knee diameter 
increased in the first week after administration.
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8) Adjuvant altered and attenuated the SP effect on blood flow, 
which was consistent across the three weeks.
9) A contralateral inflammatory effect of the adjuvant was 
revealed in these experiments. An increase in the temperature and 
diameter and alteration of the SP effect on blood flow was observed in 
the contralateral knee joint.
10) These data suggest that different agents can induce 
neurogenic inflammation and the response to neurokinins is 
completely altered in different models of inflammation. This alteration 
may contribute to the process of inflammation.
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5.2 IN F L A M M A T IO N  IN T H E  JO IN T S
5.2.1 INTRODUCTION
Recent studies have identified an important contribution of the 
nervous system to inflammation and inflammatory disease. In 
particular, substances released from the peripheral terminals of small 
diameter primary afferent fibres and from sensory nerve endings have 
been implicated in several major components of inflammation and in 
inflammatory models in the rat (Basbaum et al 1991). Inflammation in 
fact is a major component of the body's defence mechanism, but the 
initiating factors in chronic inflammatory disease such as arthritis in 
synovial joints remain unclear (Scott et al 1994). The acute 
inflammatory process is characterised by three main stages :
1) vasodilatation and increased blood flow to an area.
2)Increased vascular permeability with leakage of plasma from 
the micro-circulation.
3)Migration of phagocytic leukocytes from the micro­
circulation into the surrounding tissue.
Acute inflammation may also be an initiating factor in chronic 
inflammatory disease (Scott et al 1994).
In the inflamed joint many events and changes appear in the 
affected area, and there is an alternative response to different 
neurokinins. For example in the acutely inflamed joint enhancement of 
SP induced protein extravasation has been reported (Scott et a l 1992).
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However there is relatively little known about neurokinin receptors 
and their response in acute and chronic models of joint inflammation.
It would be expected a priori that the best screen test for 
evaluation of neurokinin receptors and their role in the different stage 
of inflammation would be based on experimental models of arthritis. 
In this study three different models of inflammation were induced in 
the rat knee joint. Acute inflammation can be induced by intra-articular 
injection of carrageenan and chronic inflammation by freunds 
adjuvant. Application of capsaicin into the knee joint caused depletion 
of sensory nerves. These models of inflammation were used to assess 
the responsiveness of blood vessels to neurokinins in these conditions.
5.3 SECTION ONE 
ACUTE INFLAMMATION INDUCED BY: 
CARRAGEENAN
5.3.1 Introduction: The Algae chondrus crispus is the main 
source of carrageenan. The term carrageenan was first used by Stanford 
in 1862 but a polysaccharide with simpler properties had been isolated 
and described previously by Schmids in 1844 (Rosa 1972). Later 
material with similar composition and physical properties has been 
isolated from other type of seaweeds, but carrageenan was restricted 
to polysaccharide extracted from Algae chondrus and Gigatina Stella.
Carrageenan is a sulphated polysaccharide which has been 
fractionated with potassium chloride into two separate components: k
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carrageenan is the part which acts under influence of potassium ions 
and X carrageenan is insensitive to the potassium ion. k  has 40% and X 
has 60% of unfractioned carrageenan. k  carrageenan is composed of 
sulphated D galactose and 3, 6 anhydro- D -galactose with a branch 
component with a molecular weight between 1.8-3.2 xlO^ and X 
carrageenan is composed almost entirely of sulphated D galactose with 
molecular weight between 4-7* 10^. The ability of carrageenan to 
induce inflammation is related to the chemical structure of galactose, 
the configuration of the unit plays no apparent role, and the compound 
has a wide spectrum of interference with biological systems. The use 
of carrageenan as an irritant was first introduced in 1962 (Lam & 
Ferrell 1989a);. carrageenan induces acute oedema and a chronic 
granolumatous response which characterised by an influx of 
polymorphonuclear leukocyte in the synovial fluid and accompanied 
by the proliferation of synovial membrane and the carrageenan 
induced acute inflammatory response is mediated by several mediators 
released in the area (Willoughby & Dirosa 1971). The time course of 
Carrageenan induced oedema has been described in the presence of 
different phases of development of oedema (Vanarman et a l 1965; 
Vinegar et al 1969). Overall, carrageenan is a well established agent 
to induce acute inflammation.
5.3.2 MATERIALS AND METHOD
Two groups of rats were selected: group 1 was used as a control 
and group 2 had an inflamed knee. 0.2 ml of 2% carrageenan was 
injected into the knee joint 24 hours prior to the experiments under a 
general anaesthetic (0.1 ml to the posterior and 0.1 ml to the anterior 
region) (see Chapter 2). SP was administered in a bolus at different
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doses to the inflamed and intact knee joints. LDI imaging and data 
analysis were as described previously (chapters 1&2)
5.3.3 RESULTS AND DISCUSSION
Carrageenan alone induced acute inflammation and significantly 
(p=0.01, n-20, t test) increased basal blood flow which confirm the 
finding of Lam & Ferrell (1993a)(fig. 5.1a & b). Application of SP at 
different doses in the inflamed knee joint significantly and dose 
dependently (P=0.001, n=20, 2way anova) increased blood flow in 
comparison to the effect of SP in the normal rat knee (fig. 5.2). Lam 
and Ferrell (1989a) demonstrated that the inflammatory response to 
carrageenan is mediated by neurokinin receptors and blocking 
neurokinin receptors strongly attenuated its inflammatory response. 
Lam and Ferrell (1989a) also suggested a lack of sympathetic 
influence on articular blood vessels in carrageenan-induced 
inflammation. It has been shown that in carrageenan inflammation 
within the synovial capsule, the general metabolism of chondrocytes is 
temporarily depressed and it is suggested that the factors produced in 
the inflammatory response produce intracellular structural 
abnormalities and altered membrane function (Byres et al 1985). 
Overall this enhanced response to the application of SP could result 
from reduced sympathetic tone, hyper-sensitivity of the inflamed joint 
to the exogenous applied SP or alteration of neurokinin receptors in 
carrageenan-induced acute inflammation.
110
,v'
s c
Fig 5 .1a:  Laser Doppler perfusion images of rat knee joints.
A) colour-coded system for showing perfusion values
B) Basal perfusion images o f the rat knee jo ints in control 
(intact) knee.
C) knees after 24 hours after carrageenan treatment, show a 
higher basal perfusion in com pared to control knees.
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Fig 5.1b. Flux reading o f (volts) first control scan in normal knees 
(n=35, P=0.01) and carrageenan-treated knee (n=20). * means 
carrageenan flux value differs significantly from normal flux value.
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Fig 5.2. Changes in synovial blood flow during topical application 
of SP to the knee joint capsule, in the normal knee (O, mean 
±SEM, n=35) and carrageenan pre-treated knee ( • ,  mean ±SEM, 
n=20)
5.4 SE C T IO N  T W O : C H R O N IC  IN F L A M M A T IO N
ADJUVANT MONOARTHRITIS
5.4.1 Introduction:
The mechanisms underlying the formation and development of 
chronic inflammatory diseases such as rheumatoid arthritis are still 
uncertain. In order to study the pathogenesis of these disorders, a 
number of experimental models of arthritis have been designed 
(Gardner, 1960). Of these, injection of Freund’s complete adjuvant into 
the joint capsule induces an unilateral monoarthritis (Grubb, et al 
1988). Ajuvant was described over 40 years ago (Stoerk et al 1954) as 
an agent for induction of arthritis. Adjuvant was made of a variety of 
dead mycobacteria, usually mycobacterium tuberculosis and M 
butiricum or M pheleiy suspended in vegetable or mineral oil. Corinea 
bacterium and nocardia asteroides have also been used to induce 
arthritis (Billingham and Davies 1979). The concentration of 
mycobacteria in the vehicle suspension can influence the arthritis 
which develops and so it was necessary for the optimum concentration 
of mycobacteria to be determined. The time course of adjuvant- 
induced arthritis has been described by several investigators such as 
Newbold (1963) and Billingham and Davies (1979). It is clear from 
the literature that the inflammatory syndrome is essentially the same 
whatever the laboratory, and that rat strains have recovered from later 
phases of disease after 21 days. The time of onset of inflammation 
varies between 3-13 days in different reports. Baugartner et al. (1974) 
have described five phases in the course of adjuvant arthritis, starting 
with acute local inflammation within 1 to 4 days so by day 7 to 12
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there is a remission of inflammation which later changes to a very 
extensive inflammation and osteogenesis by day 12-28. Finally at day 
35, the last stage with associated permanent deformity with minimal 
inflammation occurs. Adjuvant inflammation is produced by several 
different factors and the presence of adjuvant is a trigger for activation 
of a multi-factorial process involving the lymphatic system, 
immunological mechanisms (fig. 5. 3), histological processes and 
lysosomal enzyme activation (Handling 1984).
Freunds adjuvant-induced arthritis is being increasingly used as 
a model of chronic inflammation. Examination of synovium from 
adjuvant treated rats shows a reduction in synovial neuropeptidergic 
nerves when compared with normal samples (Konttinen et al. 1990) 
and similar findings have also been seen in patients with rheumatoid 
arthritis (Gronblad et al. 1988; Mapp et al 1990). The tachykinin 
substance P (SP) is present in afferent nerve terminals (Hockfelt, et al, 
1975) and is released in response to electrical antidromic stimulation 
of their fibres (Yaksh, 1988). The role of synovial nerves in the 
development of various forms of acute inflammation has previously 
been reported (Lam & Ferrell, 1991b) and it is thought that their 
effects may be mediated by local release of SP which is known to be 
an initiating factor for inflammation in this region. By using the 
technique of laser Doppler perfusion imaging (LDI), it has been 
possible to examine these neurogenic and neuropeptidergic effects on 
joint blood flow (Lam & Ferrell, 1993a). These experiments showed 
that topical application of SP to the exposed joint surface produced a 
potent vasodilatation although this particular effect was found to be 
transient. Intra-articular injection of carrageenan, an agent known to
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induce acute joint inflammation, attenuated the neurogenic 
vasoconstrictor response but enhanced the SP-mediated vasodilatation 
(Lam 8l Ferrell, 1993). In the experiments described below Freund's 
Adjuvant induced a monoarthritis which was followed for three weeks 
to follow up any eventual changes of the response to SP in both the 
ipsilateral and contralateral knees
5.4.2 MATERIAL AND METHODS
Thirty male Wistar rats from an in-house colony (aged 170 days- 
approx. 330 g in weight) were used in this study. The animals were 
deeply anaesthetised by Hypnorm (fentanyl citrate 0.315 mg/ml and 
fluanisone 10 mg/ml, Janssen: 0.1 ml/300g i.m.) and diazepam (2.5 
mg/kg, i.p). The width of the knee joint was measured by a digital 
micrometer (Motoyo instruments, Japan) and temperatures were 
measured by a digital thermometer (Harvard USA). The skin over the 
knee joint was shaved and 0.2 ml of Freund's complete adjuvant 
(Sigma) was injected into the synovial cavity of the right knee joint 
(0.1 ml into the posterior region and 0.1 into the anterior region). The 
animals were allowed to recover and the inflammatory response was 
assessed by measurement of knee diameter and temperature at one, 
two and three weeks post injection. Comparison between mean 
diameters and temperature was by a two-tail paired student t-test.
For the terminal blood flow experiments, the 30 animals were deeply 
anaesthetised by i.p. injection of urethane (2g/kg, Sigma). Here, 10 
animals were examined at one and three weeks post injection and a 
further 10 normal rats were used as controls. An ellipse of skin 
overlying the joint was excised to expose the medial aspect of the
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knee. SP (Cambridge Research Biochemicals) was warmed (37°C) 
prior to administration as a bolus applied to the exposed surface of the 
joint in a volume of 0.1 ml (doses ranged from 10“13 to 10"8 mol). 
Warmed (37°C) physiological saline (0.9% NaCl) was regularly 
applied to the knee joint surface to prevent tissue dehydration. Relative 
changes in synovial blood flow (voltage difference of test minus 
control) were monitored by a laser Doppler perfusion imager in both 
the normal group and the adjuvant treated group. Image analysis and 
statistics were as described in chapter 2.
5.4.3 RESULTS
5.4.3.1 Inflammatory response and basal joint perfusion
Injection of Freund’s adjuvant into the rat knee caused a 
considerable increase in knee diameter at one week post-injection 
which abated by the third week (Fig. 5 4). At week 1, the adjuvant- 
treated knee width increased by 1.797±0.544 mm (mean ± S.E.M.) 
which compared to week 0 was significantly different (P=0.013, n=9, 
two-tailed paired t-test) from control knees which increased in size due 
to growth of the rats. By week 3, the inflamed knee had only increased 
by 1.195 ±0.35 mm from the week 0 level and this was found to be not 
significantly different (P=0.315; n=8 for adjuvant animals and n =10 
for untreated animals, two tail t test) from a normal knee which had 
grown by 0.744 ±0.11 mm over the three week period. Knee joint 
temperature also significantly increased at week 1 in injected 
compared to control knees and also at week 2 and week 3 the knee 
temperature in adjuvant treated was significantly higher than at the 
start (P=0.001, n=9, t test) (fig. 5.5). The contralateral knee did show
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Fig 5.4, Changes in knee jo in t diameter at one and three weeks in 
response to intra-articular injection o f Freund's adjuvant (blue 
column, n=9) compared to normal (untreated, black column, 
n=10). * * means differs significantly at week one. P=0.013
week 0 weekl week2 \veek3
Fig 5.5. Changes in jo in t tem perature at three weeks in response to 
intra-articular injection o f Freund's adjuvant. W eek 0 refers to the 
experimental starting day. (control and week 1, n=10, and week 2, 
11=9, week 3 n=9). * means week 1 differs significantly from week 
0. For significant value see text
a significant (P=0.043, n=9) increase in diameter at week one and a 
significant (pO.Ol, n-9, t test) increase in temperature.
Freund's complete adjuvant was found to have no significant 
effect on ankle diameter and temperature over the 3 weeks (P>0.05; n 
=15 for each group tested, t test) thereby confirming an absence of a 
systemic effect of the adjuvant (fig. 5.6 a & b).
One week after induction of arthritis, a marked reduction in joint 
perfusion occurred as revealed by a fall in the LDI flux values 
measured at the beginning of each experiment. Perfusion then returned 
back towards control levels by the third week (Fig. 5.7)
5.4.3.2 Neurokinin-mediated vasodilatation
Substance P, when applied topically to the exposed surface of 
normal knee joints, showed a significant dose-dependent augmentation 
of joint blood flow (PO.OOl; n =10, anova) culminating in a peak rise 
of 45.1±8.6% with the 10~9 mol dose. Figs. 5.3, 5.8 show that 
adjuvant treatment, however, completely abolished this hyperaemia 
and in some instances a constrictor response to SP could be observed. 
At week 1, SP had no significant effect on synovial blood flow 
(P=0.511; h=10, anova) but by the third week of inflammation 
vasoconstriction was recorded (PO.OOl; n=9); both groups of animals 
were found to be significantly different from the control rats 
(PO.OOl). A fall in articular perfusion of approximately 40% occurred 
when 10"8 and 10“ 12 mol doses of SP were administered to the joint 
but the intermediate doses produced less of an effect.
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Fig 5.6: Changes in ipsilateral (blue column) ankle 
diameter (A) and temperature (B) at three weeks in 
response to knee joint intra-articular injection of Freund's 
adjuvant compared to the contralateral (black column) 
ankle, week 0 refers to the experiments starting day. 
(n=15). There is not any significant difference between the 
two ankle (ipsilateral and contralateral, adjuvant treated 
knee joint) both in diameter and temperature within the 
three week and also compared to week 0.
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Fig 5.7. Alteration in basal blood flow at one and three weeks 
following intra-articular injection o f Freund's adjuvant (mean ± 
SEM, n=10 for both control, week 0, and week 1 data and n=9 for 
week 3 group). ** refers to significant difference between week 0 
and week 1, and week 3 and week I. P=0.001
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Fig 5.8adm ages showing changes in perfusion o f normal and 
adjuvant-treated knees in response to application o f substance P 
(SP) Perfusion is encoded using a six colour scale covering 0- 
10V. Control images indicate a substantial reduction of 
perfusion in adjuvant treated knees at week 1 which recovers by 
week 3. However, in adjuvant-treated knees there is no 
vasodilator response to SP at either weeks 1 or 3.
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Fig 5.8b Changes in synovial blood flow during topical application 
o f SP to the jo int capsule in normal (O , mean ±SEM, n=10), in 
adjuvant induced chronically inflamed knees at week one ( • ,  mean 
±SEM , n=10), and week three (A , mean ±SEM , n=8). The 
sequence o f doses administered was randomised.
Application of NKA and NKB (both at 10‘10 mol) to the 
surfaces of the exposed normal knee produced a 10.3±4.2% and 
32.4±16.7% vasodilatation respectively. Adjuvant treatment at week 
three, however, completely abolished this hyperaemia and in some 
instances a vasoconstrictor response to these neurokinins was observed 
(Figs. 5.9 A) and this was significantly different from the control 
response (p<0.0001, n=7, t test). Application of 5 hydroxytryptamine 
(5HT 10~11 mol) to the exposed normal and adjuvant treated joint did 
not show any significant (p> 0.05, n=7, t test) effect on basal blood 
flow and application of 10“ 12 mol of adrenaline (epinephrine) to the 
normal and adjuvant treated joint showed an acute vasoconstriction 
effect which in adjuvant treated knee was slightly and significantly 
(P<0.05, n=7) greater than the normal knee (Fig. 5.9B).
5.4.4 DISCUSSION
Injection of Freund's complete adjuvant into rat knee joints 
caused a considerable increase in diameter and temperature of the joint 
and this was used as an index of the magnitude of the inflammatory 
response. Since no discernible change in ankle diameter occurred in 
any of the rats, it is clear that inflammation was localised to the knee 
and hence a polyarthritic model was avoided. Despite this observation, 
the contralateral knee could not be used as a control as it is known that 
an experimentally-induced monoarthritis causes bilateral changes in 
peptide content of synovial fluid (Bilevicuite et al., 1993). This effect 
could result in a modification of basal blood flow in the contralateral 
knee thereby masking any possible neurogenic or peptidergic 
responses. Indeed, the contralateral knee did show a small but 
significant increase in diameter and a significant increase (p<0.01) in
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Fig 5.9 A and B: Changes in synovial blood flow during 
topical application of NKA and NKB both doses at 10" 
mol, 5HT at a dose 10"! 1 mol and adrenaline at a dose 10" 
12 mol in the normal knee joint (black column, mean 
±SEM, n=7) and at three weeks in the chronic adjuvant 
treated knee (blue column, mean ± SEM, n=7). * and ** 
refers to significant difference between the effect of NKA, 
NKB and adrenaline on blood flow in the normal knees 
with those in adjuvant treated knees. For significant value 
see text
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Fig 5.10 A and B: Changes in knee joint diameter and 
temperature over three weeks in response to intra-articular 
injection of paraffin (vehicle of Freund's adjuvant , dark 
column) compared to contralateral knee (control, white 
doted column), week 0 refers to the experimental starting 
day. (n=5). There is not any significant difference between 
the two knees both in diameter and temperature within 
three weeks.
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temperature, suggesting that a mild, perhaps neurogenically-mediated, 
inflammatory response had occurred, confirming the unsuitability of 
the contralateral knee as an internal control. Injection of the paraffin 
alone (a necessary part of the control studies, since paraffin is the 
vehicle for Freund,s adjuvant) did not show any significant effect in 
knee diameter and temperature compared to un injected knee, 
verifying that the response to the to adjuvant is due to its active 
component (p > 0.05, n=5, t test)(fig. 5.10 a&b).
One week after adjuvant treatment, chronically inflamed knees 
exhibited a fall in basal blood flow which subsequently returned 
towards normal two weeks later. This initial fall in perfusion is 
probably real and not due to an inability of the laser to detect blood 
flow in the enlarged knee. The swelling of the joint is not due to a 
thickening of the capsule but may be ascribed to accumulation of 
tissue fluid which does not significantly affect the penetrative power of 
the laser beam. In addition, blood vessels on the surface of the 
adjuvant arthritic knee are still visible to the naked eye and therefore 
should be detectable by the LDI system. The monoarthritis model 
produces a localised lesion with little systemic disturbance and treated 
animals are found to be normotensive. Thus, the hypoperfused knee 
observed one week post adjuvant injection cannot be ascribed to 
circulatory disturbances which might occur in the more severe 
conventional adjuvant polyarthritic model. Microscopic inspection of 
the arthritic knees suggested that the hypo perfusion might to some 
extent be the result of localised areas of tissue necrosis and possible 
blood vessel ablation.
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Differences between the arthritic and control rats could not be 
ascribed to differences in the reproducibility of measurements as basal 
flux values at week 1 in arthritic rats show lower variability than the 
measurements obtained in control rats or at week 3 (fig. 5.7). In 
addition, flux readings obtained prior to administration of SP were 
found to be stable throughout the experiments. The LDI technique is 
suitable for comparison of rats at different ages as the scan area can be 
increased to accommodate the larger knee joint in the older animals. 
Interestingly, comparison of flux values between animals of different 
ages revealed no significant differences in perfusion, suggesting that 
there is no alteration of vascularity of the joint as a function of age.
As articular cartilage is dependent for its nutritional requirements 
on synovial perfusion (McKibbin & Maroudas, 1979), then this initial 
reduction in joint blood flow could cause the integrity of the joint to 
deteriorate and lead to degenerative changes. It has previously been 
shown that adjuvant-induced inflammation in the rat knee joint 
abolishes sympathetic vasoconstriction and the neuropeptidergic 
vasodilator response to SP at one week (McDougall, et al 1994). The 
investigation outlined here has shown that these alterations are not 
transitory but persist three weeks post-injection of adjuvant, even 
though the inflammatory process appears to be abating by the third 
week.
Topical application of SP to the exposed surface of rat knees elicited a 
dose-dependent dilatation in normal rats which was maximal at 10"9 
mol. Chronically inflamed joints were unresponsive to SP for the 
whole three weeks of the study and in some instances even showed 
vasoconstriction. This finding suggests that the SP receptors are either
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radically transformed or possibly inactivated by the inflammatory 
process. Previous work has shown decreased binding of Bolton-Hunter 
labelled SP in chronically inflamed rat knee joints (Walsh, et al, 1993) 
supporting the view that a variation in either receptor expression or 
decreased efficacy of the receptor has occurred. In addition, it is 
possible that enzyme systems which degrade neuropeptides such as SP 
are altered by the inflammatory process. Adjuvant monoarthritis is 
known to cause an increased SP content of dorsal root ganglia (Smith, 
et al, 1992) and this increased amount of neuropeptide is transported 
toward the periphery in the axoplasmic flow (Donnerer, Schuligoi & 
Stein, 1992). It may be this accumulation of SP at the periphery which 
is contributing to the modification of the SP receptors either by toxic 
means or via a down regulatory mechanism. Experiments on another 
group of adjuvant treated knees revealed that the vasodilator response 
of the inflamed knee joint to NKA and NKB was like SP also reversed, 
whereas the responses to application of 5HT and adrenaline were not 
altered in the adjuvant treated knee compared to the normal joint and 
even showed a significantly stronger effect of adrenaline in the 
absence of natural neurokinin effects.In blood vessels the response to 
5HT is variable, the overall effect varying according to the size of the 
vessels (Rang & Dale 1992). Using LDF it has been shown that 5HT at 
10“ 11 mol produces vasodilatation in the rat knee joint ( Lam & 
Ferrell, unpublished data). However in the present experiments this 
dose showed only a small effect on blood flow in the normal knee 
which was not changed significantly in the adjuvant treated knee, but 
the response was small and made it difficult to assess the effect of 5HT 
on its own. As 5HT has a variable effect on systemic blood pressure 
(Rang & Dale 1992) higher doses of 5HT could have caused blood
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pressure changes and affect the results. In future experiments it would 
need a full dose response curve for 5HT to assess its effect on knee 
joint blood flow whilst monitoring blood pressure.
These results indicate that in the adjuvant treated knee all 
neurokinin receptors are modified and that this modification does not 
necessarily affect other receptor types in the joint.
Acute inflammatory responses induced by intra-articular 
injection of carrageenan show nerve-mediated vasoconstriction to be 
attenuated but the dilator effects of SP to be greatly enhanced (Lam & 
Ferrell, 1993a), whereas adjuvant induced inflammation altered both 
SP mediated vasodilatation and sympathetic vasoconstriction 
(McDougall et al. 1994). Combined with the findings of the present 
study, it would appear that the integrity of sympathetic transmission 
and neurokinin receptor activation in rat knee joints declines as 
inflammation becomes more chronic. Loss of these neurovascular 
controls could contribute to degenerative changes which commonly 
accompany chronic inflammatory joint diseases.
5.5 CONTRALATERAL EFFECT OF 
ADJUVANT MONOARTHRITIS
5.5.1 Introduction: The contralateral effect of neurogenic 
arthritis began to be recognised some years ago. Axotomy of the nerve 
to one muscle of the frog induced sprouting and synapse formation by 
the homologous intact nerve on the opposite side and this has since 
been observed in three different muscles, the cutaneous pectoralis
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(Rotshenker 1979), the sartorious (Ring et al 1983), and piriformis 
(Elizade et al. 1983), Similar events also occurred in mammals and it 
was found that in the intact muscle of the normal rat, spouting and 
synapse formation in an ongoing process which can be enhanced by 
contralateral axotomy (Rotshenker & Tai M. 1985). Bilevicuite et al 
(1993) showed bilateral changes in synovial fluid neuropeptide content 
to monoarthritis.
Allnatt et al (1990) reported that sapheneous nerve injury and 
degeneration in one rat leg suppressed the ability of the contralateral 
nerve to evoke plasma extravasation, which indicated that there is a 
neuronic contralateral effects in the body organs. Kidd et a l (1989) 
reported that synovial damage resulted in acute inflammation in the 
damaged joint and in a neurogenically mediated infiltrate of 
inflammatory cells in the contralateral joint.
Neuropeptides are known to have an important role in the 
inflammatory process (Marzou et al 1989; Scott et al 1994). They can 
share and interact with the neuropeptide’s second messengers and so 
can connect certain immunological stimuli to the biosynthesis of 
inflammatory mediators (Marzou et al 1989). In addition there has 
been a report describing the contralateral effect of monoarthritis on the 
spinal cord (Mapp et al 1993), but to date little work has been done 
on the effect of ipsilateral arthritis on the vascular response of the 
contralateral joint to tachykinins.
In section 5.3 it was reported that administration of adjuvant 
caused significant increase in temperature of the contralateral knee and
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to further investigate this matter, the experiments described in this 
section were carried out.
5.5.2 MATERIAL AND METHOD
Experiments were performed on two groups of rats, an intact 
group as control and an adjuvant treated group. Freund's adjuvant was 
injected into the knee joint to induce chronic monoarthritis and the 
temperature and width of the knee joint measured as an assessment of 
the inflammatory response at 1, 2 and 3. weeks. In addition, the 
response of the contralateral knee to SP at different doses was 
examined. In these experiments the contralateral effect of adjuvant was 
studied at the third week. The method of induction arthritis and 
measurement of temperature and width was the same as described in 
5.3.2. and LDI imaging and data analysis performed, as described 
previously in chapter 2.
5.5.3 RESULTS
At week 1 the knee width significantly increased in the contra­
lateral knee, compared to week 0 (control) (p=0.043 N=9), but there 
was no significant difference in diameter of the contralateral knee 
between week 2 or week 3 compared to week zero. The temperature in 
the contralateral knee significantly increased at weeks 1,2 and 3 
compared to control (week 0) (p<0.05, n=9, t test) (Fig. 5.11).
Topical application of SP to the contralateral knee was 
performed at week 3. As shown in fig. 5.12 the vasodilator effect of SP 
on the blood flow was significantly attenuated and shifted the dose 
response curve to the right (p=0.01, n=9, anova).
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Fig. 5.11: Changes in contralateral knee joint temperature at three 
weeks in response to intra-articular injection o f Freund's adjuvant 
compared to week 0. week 0 refers to the experimental starting 
day. (n=9). * refers to significant difference between week 1, 2 and 
3 with week 0. For significant value see text
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Fig 5.12: Changes in synovial blood flow during topical 
application of SP to the joint capsule in normal (O, mean ±SEM, 
n=10), and in contralateral knees at week three of the adjuvant 
treated animals ( • ,  mean ±SEM, n~9),
In the control group temperature and diameter changes over 
three weeks were not significant and increased knee diameter due to 
the natural growth at week three was not significant compared to week 
0 (p> 0.05, n=5, t test)(fig. 5.13).
5.5.4 DISCUSSION
The temperature in the contralateral knee was significantly 
increased at all three weeks compared to control values, (P<0.05, 
n=9). Knee diameter at week 1 was significantly increased compared 
to week zero (p=0.01, n=9), but it abated by week 2 and week 3 and 
there was not any difference between values obtained at these weeks 
and the corresponding control values.
The attenuation of the effect of SP on blood flow by ipsilateral 
inflammation was not as strong on the contralateral side but it was 
significant compared to control. The changes in the temperature and 
diameter and attenuation of the SP effect on blood flow suggest a 
neurogenic symmetrical effect. In the control group no significant 
changes in temperature and diameter of the joint were seen over three 
weeks. Measurement of ankle diameter and temperature in the 
ipsilateral and contralateral sides over three weeks did not show any 
significant (n=15, P> 0.05) changes compared to week zero suggesting 
that the results cannot be explained by a purely systemic effect of the 
adjuvant. A functional relationship seems to exist between the sensory 
nerve fibres in the periphery and neuropeptides in the dorsal horn of 
the spinal cord. These peptides are therefore well placed to mediate a 
symmetrical response by a putative central reflex (Mapp 1993). The 
proposal is that after nociceptor activation secondary to joint damage,
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Fig 5.13 A and B: Changes in knee joint diameter and 
temperature at three weeks compared to week 0. Both 
knees are intact (right knee, doted column left knee lined 
column), week 0 refers to the experimental starting day. 
(n=5). There is not any significant difference between two 
knee both in diameter and temperature within three weeks.
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preganglionic sympathetic neurones in the autonomic cell column of 
the spinal cord are selectively activated. These neurones project across 
the spinal cord to their counterparts on the other side and joint damage 
could therefore results on both sides (Kidd et al 1989). Considering 
these finding and the existence of similar response to SP on the 
contralateral and at the ipsilateral knees, a neurogenic contralateral 
effect of adjuvant monoarthritis could be a possible explanation.
5.6 SECTION THREE 
INFLAMMATION INDUCED BY 
CAPSAICIN
5.6.1 Introduction: Capsaicin is the pungent ingredient which 
is found in a wide variety of red peppers of the genus capsaicin. 
Chemically it is a derivative of vanillyl amid, 8 methyl-n- vanillyl 6- 
no- nonamide (fig. 5.14) with a molecular weight of 305.42. Hot 
peppers have been known to humans since prehistoric times, but it has 
only recently been realised that capsaicin, a pure pepper substance, 
exerts a long term sensory receptor blocking action and capsaicin has 
now become well established as an important probe for sensory 
neurones (Holzer 1991).
Two effects of capsaicin can be differentiated: firstly an action 
which is grossly selective for thin afferent neurones of mammalians 
species, with short lasting stimulation followed by desensitisation, and 
secondly a transient depression with no long lasting consequences for 
the cell which is seen in most species (Holzer 1991). Capsaicin leads
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Fig 5.14: Chemical structures of capsaicin and
resiniferatoxin
to a depolarisation of thin primary afferent neurones and the majority 
of SP containing afferents are depleted by capsaicin. CGRP and 
neurokinin containing neurones are also deplete by capsaicin ( Holzer 
1991), but the monoamine system is not damaged by capsaicin in the 
CNS and spinal cord and even slightly increases the amount of 
monoamine in these cells. In the rat, application of capsaicin on the 
sciatic nerve leads to a 34% reduction of cell bodies in the dorsal rout 
ganglia (DRG) and 32-40% reduction of unmyelinated fibres but 
capsaicin does not have any effect on myelinated fibres (Jansco and 
Lawson 1990; Ferrell eta l 1992 ).
Capsaicin’s action on sensory neurones is mediated by a specific 
recognition site with the pharmacological properties of a receptor. 
These receptors activate Ca++ and Na+ ion channels and produce a 
stimulatory effect (Bevan and Szolcsany 1990)(fig. 5.15). This effect 
on ion channels is distinct from the voltage dependent cation channel 
in the cell membrane and taken together capsaicin stimulates sensory 
neurones which increases conductance and induces depolarisation. 
Calcium influx is induced by this mechanism and intracellular calcium 
concentration increases with consequent activation of intracellular 
enzymes and neuro-transmitter release (Holzer 1991).
Both excitation and desensitisation are dependent on extra 
cellular calcium concentration and the L type of voltage sensitive 
calcium channel (Maggi et al 1989).
Capsaicin also has a direct action on metabolism and cellular 
proliferation. This effect is dose dependent, but the mechanisms by 
which it stimulates DNA synthesis is not yet clear (Mutacci et al.
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Fig 5.15: Scheme of action for capsaicin. From Bevan S. & 
Szolcsanyi 1990
1990). Subsequently Capsazepine was discovered and found to be 
competitive antagonist for capsaicin (Dray 1992)
In this study capsaicin was used to induce acute inflammation 
and chronically deplete nerve fibres. Chronic capsaicin treatment was 
used to deplete knee joint nerve endings to examine the tissue and 
vasculature response to SP. Acute capsaicin was used to release 
neurokinins and thereby induce neurogenic inflammation. The 
neuropeptidergic response was examined in both cases to elucidate the 
effect of neurokinins on the rat knee joint vasculature.
5.6.2 PART ONE 
CHRONIC CAPSAICIN TREATMENT
Capsaicin, is known to cause depletion of neuropeptides such as 
SP from sensory nerve fibres and is neurotoxic when locally applied to 
nerves (Holzer, 1991). Unmyelinated but not myelinated nerve fibres 
supplying the rat knee joint are depleted after intra-articular injection 
of capsaicin (Ferrell, Lam and Montgomery, 1992). Thus capsaicin 
pretreatment of the joint could reveal the effect of SP, and also 
neurokinin receptor antagonists on knee joint vasculature.
5.6.2.1 MATERIALS AND METHODS:
Two groups of male Wistar rat were used in these experiments, 
an intact group and capsaicin-treated group. Degeneration of the 
nerves supplying the knee was induced by intra-articular injection of 
0.2 ml of 2% capsaicin (Sigma) into the rat knee 5-7 days prior to the
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start of experiments. Previous work has shown that this period is 
sufficient to obtain a significant reduction in unmyelinated fibres 
(Ferrell et al, 1992).To control and compare with an intact group, 10 
rats were injected with 0.2 ml of the capsaicin vehicle (ethanol, 
cremaphor EL in 0.9% saline). SP (Cambridge Research 
Biochemicals) was administered as a bolus applied to the surface of 
the joint in a volume of 0.1 ml. Phenoxybenzamine (10"6 mol) and 
FK888 and SR48968 (both 10-8 moi? ^  n k i  & NK.2 antagonist 
respectively) also were used in these experiments. Warmed (37°C) 
physiological saline solution (0.9% Na Cl) was regularly applied to the 
knee joint surface to prevent tissue dehydration. Arterial blood 
pressure was measured by cannulation of a carotid artery, connection 
to a pressure transducer (Elcomatic EM751) and monitoring the 
transducer output on a pen recorder (Lectromed Multitrace 4). 
Experimental set-up and image analysis was as described in chapter 2
5.6.2.2 RESULTS
Although the images suggest a higher basal blood flow in 
capsaicin-treated as opposed to vehicle-treated knees (fig. 5.16b), the 
mean voltage signals (±SEM) corresponding to each group (4.95±0.52 
and 4.15±0.35 V respectively) did not differ significantly between the 
two groups (P=0.21, two sample t-test; n=12 and 15 knees 
respectively). The heterogeneity of perfusion in the knee joint capsule 
is clear from the images in figure 5.16 and analysis of two separate 
square areas (an array of 4 by 4 measurement points) in the same knee 
of control rats, one at the upper border and one at the lower border of 
the joint, showed significant (P=0.0014; n=47 paired measurements)
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10pmol SP
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Fig 5 16: Laser Doppler perfusion images o f rat knee 
joints.
A) colour-coded system for showing perfusion values
B) Images o f knees from two rats, one pre-treated with 
capsaicin, the other with vehicle, prior to any intervention.
C) The same knees as in B immediately after topical 
application o f 10 pmol o f  substance P (SP) to both knees. 
The vehicle-treated knee shows significant vasodilatation, 
but this is much less evident in the capsaicin-treated knee.
differences in the LDI signals of 2.2±0.11 V and 2.82±0.16 V 
respectively.
The responsiveness of articular blood vessels to neuropeptides 
was assessed by examination of the dose/response relationship to SP 
which was administered directly to the joint in a volume of lOOpl. It 
was clear that SP produced significant vasodilatation in the both 
normal and vehicle-treated knee but had much less effect in capsaicin- 
treated knees (fig. 5.16.b& c). There was not any significant difference 
(P=0.27,vehicle n=10, intact n=35, two tail anova) between intact and 
vehicle treated rats in their response to SP.
This difference in response was observed across a range of 
doses of SP (fig. 5.17A) and two-factor ANOVA revealed a significant 
dose-dependent effect (P=0.026) and a very significant difference 
between intact and capsaicin-treated knees (P<0.0001; n=35 & n=12 
knees, respectively). Application of phenoxybenzamine (10-6 mol) in 
the 2% capsaicin treated knee slightly but non significantly reduced 
blood flow. Phenoxybenzamine in the intact knees, increased basal 
blood flow by 30% and the difference between these groups was 
highly significant (p <0.001,n=26, paired t test) (fig. 5.18).
Application of both FK888 and SR48968 (both 10"8 mol) in the 
2% capsaicin pre-treated knee decreased basal blood flow but this did 
not differ significantly compared to the intact group. Co-application of 
phenoxybenzamine with FK888 and SR48968 in the 2% capsaicin pre­
treated knee, slightly decreased basal blood flow as in the intact knees 
but the difference was not significant (p >0.05, n=17, t test ) (fig. 
5.18).
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Fig 5.17A. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, in normal knees 
(O, mean ±SEM, n=35) and in 2% capsaicin pre-treated 
knees ( • ,  mean ±SEM, n=12)
Fig 5.17B Percentage change in mean arterial blood flood 
in response to topical application of SP to the joint capsule 
in normal knee (mean ± SEM, O, n=5) and in 2% 
capsaicin pre-treated knees ( • ,  mean ±SEM, n=12). There 
is not any significant difference on blood pressure between 
different treatments.
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Fig 5.18. Changes in synovial blood flow during topical 
application o f saline, and SR48968 + FK888 both at 10"8 mol 
alone and with phenoxybenzam ine (10’° )  to the normal and 2% 
capsaicin pre-treated knee jo int capsule . Values are mean ±SEM  
and for normal and capsaicin treated knees are:
Saline (■ , n=44, and 57), SR48968 + FK888 (■ , n=29 and 17), 
phenoxybenzam ine (■ , n=12 and 26), SR48968 + FK888 with 
phenoxybenzam ine (■ , n=38 and 9). * means differs significant.
As capsaicin could have induced a mild synovitis, in addition to 
its neurotoxic effects, it is possible that the attenuated vasodilator 
response to SP in capsaicin-treated knees could be attributed to more 
rapid uptake of SP in these joints. Rapid uptake of SP by synovial 
capillaries could then give rise to systemic vasodilatation and 
consequent transient hypotension, which has been observed at SP 
doses greater than 1 nmol (Lam and Ferrell, 1993b). This was checked 
in the present study by monitoring arterial blood pressure whilst 
applying different doses of SP to vehicle-treated and capsaicin-treated 
knees. As shown in fig. 5.17B, mean arterial blood pressure remained 
relatively steady across a range of doses and there was no difference in 
the blood pressure response to SP between vehicle and capsaicin- 
treated knees (P=0.228, one factor ANOVA, n=5).
In addition, repeated scans following SP administration showed 
that significant differences from pre-SP administration only occurred 
in the scan immediately following SP administration. This was true for 
capsaicin pre-treated rats, indicating that the time course of the dilator 
response to SP in this group was similar to that occurring in the vehicle 
group.
5.6.2.3 DISCUSSION
The present experiments have revealed that SP-mediated 
vasodilatation is substantially reduced in knees pre-treated with 
capsaicin.
The effect of topically applied SP on joint blood flow was of 
interest as capsaicin treatment shifted the SP dose/response curve to 
the right. This is in accordance with previous work where it was shown
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that increased vascular permeability induced by SP was vastly 
attenuated by pre-treatment of the joint with capsaicin (Lam and 
Ferrell, 1989b). Application of phenoxybenzamine in capsaicin pre­
treated knees slightly but non significantly reduced blood flow, while 
phenoxybenzamine in the intact knee induced an increase of more than 
30% in blood flow, possibly due to the effect of peptidergic control of 
blood flow in the absence of sympathetic tone. This effect on blood 
flow was reduced to near zero in the capsaicin pre-treated knee 
because of elimination of peptidergic neurones due to capsaicin. Also 
application of neurokinin antagonists (FK888 & SR48968) in the 
capsaicin-treated knee slightly reduced blood flow compared with the 
intact knee which demonstrated the lack of efficacy of sensory 
neuropeptides. This observation also verifies previous findings which 
indicated that in the capsaicin treated knee sympathetic post ganglionic 
fibres are resistant to the neurotoxic effect of capsaicin (Karimian et 
al 1995). Capsaicin inhibits the action of exogenous SP by a 
mechanism unrelated to the integrity of the afferent nerve fibres 
innervating the knee joint and peripheral nerve section has no effect on 
this inhibition (Lam & Ferrell 1989b). It has also shown that the 
inhibitory effect of SP is not primarily due to depletion of mediator 
cell such as mast cell (Lam Sc Ferrell 1989b). Such findings suggest 
that capsaicin is capable of modifying post-junctional receptor- 
mediated effects of SP, in addition to its known neurotoxic effects. The 
blood pressure recordings indicate that this is a true effect and not 
simply a consequence of more rapid uptake of SP by capsaicin-treated 
joints leading to arterial hypotension at lower doses of SP.
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5.6.3 P A R T  T W O
ACUTE CAPSAICIN TREATMENT 
(NEUROGENIC INFLAMMATORY MODEL)
In the literature, capsaicin is described as inducing a variety of 
responses via different mechanisms, and therefore the development of 
responses to capsaicin may be altered by chronic or acute application 
of this agent. Acute capsaicin treatment excites primary afferent 
neurones and cause depletion of neurokinins from sensory nerve 
endings and consequently neurogenic inflammation develops. In these 
experiments the effect of acute capsaicin treatment in the rat knee joint 
was studied to investigate its effect on blood flow and the vascular 
responses to SP.
5.6.3.1 MATERIALS AND METHODS:
Two groups of rats were deeply anaesthetised (see chapter 2). 
Group one was the control and group two the capsaicin-treated rats. 
0.1 ml of capsaicin at different doses was injected into the anterior 
capsule of the rat knee joint some minutes before the recordings SP 
was used in these experiments to evaluate if there is any change of 
response to SP in acute capsaicin treatment. Systemic blood pressure 
was monitored by carotid artery cannulation to assess the effect of the 
drugs on blood pressure. LDI imaging, data analysis was as described 
previously (chapter 2)
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5.6.3.2 R E SU L T S
5.6.3.2.1 The effect of capsaicin on blood pressure: Injection 
of 0.1 ml saline into the anterior capsule produced a transient fall in 
blood pressure returning to normal in a few seconds. Injection of 0.1 
ml capsaicin vehicle alone to the anterior capsule caused a 21 ±8% 
(n=5) fall in blood pressure which lasted a maximum of 30 sec and 
returned back to normal.
Infusion of 0.1 ml of 0.02% and 0 .2% capsaicin into the rat knee 
joint did not have any significantly different effect on blood pressure 
compared to vehicle (n=5). Infusion of 2% capsaicin into the joint 
caused an 18±6% (n=5) increase in blood pressure which returned to 
normal within ten minutes .
5.6.3.2.2 The effect of capsaicin in the knee joint: Capsaicin 
induced a potent and dose dependent vasoconstriction which lasted a 
minimum of 40 minutes, whilst the vehicle did not show any 
significant effect (p> 0.05 n=5)(fig. 5.19A). Intra-articular injection of 
0.02% capsaicin (0.1 ml) caused almost 40% (n=8) reduction in blood 
flow (fig. 5.19 B) which lasted 40 minutes and an increase in blood 
flow following this vasoconstriction. Intra-articular infusion of 0.2% 
capsaicin induced a 75% (n=8) reduction in knee blood flow which 
was stable for a period of 40 min followed by vasodilatation (fig. 5.20 
A, n=8). Intra-articular application of 2% capsaicin induced a greater 
than 50% (n=5) reduction in blood flow which was stable, constant 
and irreversible (fig. 5.20 B).
5.6.3.2.3 Application of SP: SP at different doses was applied 
in conjuction with capsaicin.. All different capsaicin doses attenuated
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5.19 A and B: Time course and changes in synovial blood 
flow during intra-articular injection of capsaicin vehicle 
(fig A: n=5, p>0.05) and 0.02% acute capsaicin (fig B: 
n=8)
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5.20 A and B: Time course and changes in synovial blood 
flow during intra-articular injection of 0 .2% acute 
capsaicin (fig A: n=8) and 2% acute capsaicin (fig B: 
n=8)

the effect of SP on blood flow. In the 0.02% capsaicin pre-treated 
group, SP at lower doses induced a slight but non- significant increase 
in baseline blood flow and with the highest concentration produced a 
sharp reduction of blood flow, but the difference between SP doses 
was not significant. The response to SP was significantly different 
(P=0.004, n=8, two way anova) from the control group dose response 
curve and this curve was shifted to the right (fig. 5.21 a ).
The effect of SP on 0.2% capsaicin pre-treated knees was 
attenuated compared with the control group and the dose response 
curve was significantly shifted to the right (PO.OOl, n=8, two way 
anova). This attenuation was more potent than in the 0.02% pre treated 
group but the difference between the two treatment was not significant 
(fig. 5.21 B). In the 2% capsaicin pre-treated group, the effect of SP 
doses was completely attenuated and SP did not show any effect on 
blood flow. The attenuation of the SP effect on blood flow was 
significant compare to the control group (P< 0.001, n=10, anova). The 
effect of different doses of SP on blood flow was not significantly 
different between the capsaicin treated groups and SP did not show a 
significant effect on blood flow (fig. 5.21c).
5.6.3.3 DISCUSSION
These experiments revealed the different effects of capsaicin. 
Intra-articular application of capsaicin induces a dose dependent 
vasoconstriction in which lasted a minimum of 40 minutes at all doses. 
Intra-articular injection of saline, 0.02% and 0.2% capsaicin, caused a 
transient effect on blood pressure which probably is due to the 
nociceptive effect of the needle and the capsule distention by the
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Fig 5.21A. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, in normal knees 
(O ,mean ±SEM, n=35 and at 0 .02% acute capsaicin 
treated knees (A mean ±SEM, n=8). Difference is 
significant p=0.004 ANOVA
Fig 5.21b. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, in normal knees 
(O ,mean ±SEM, n=35 and at 0.2% acute capsaicin treated 
knees (■ mean ±SEM, n=8). Difference is significant 
p<0.001 ANOVA
Fig 5.21c. Changes in synovial blood flow during topical 
application of SP to the knee joint capsule, in normal knees 
(O ,mean ±SEM, n=35 and at 2% acute capsaicin treated 
knees ( •  mean ±SEM, n=10). Difference is significant 
p<0.001 ANOVA
% 
ch
an
ge
 
in 
blo
od
 
flo
w
5 0 i
A
30 -
1 0 -
- 1 0 -
-30 TT T
-13 -12 -11 -10 -9 -8
50 -I
30 -
10  -
- 1 0 “
-30
9 8-13 -12 -10-11
-30 H---------- 1---------- 1---------- 1---------- 1---------- 1---------- 1
-*3 -12 -11 -10 -9 -8
log dose SP (mol)
infused fluid. Distension of the proprioceptive afferents, such as those 
in the joint capsule, are known to be able to reflexly influence blood 
pressure (W.R. Ferrell personal communication). Intra-articular 
injection of 2% capsaicin causes a transient increase in blood pressure 
which lasts for few minutes and returns backs to normal within 10 min. 
In general capsaicin did not have a significant long term effect on 
systemic blood pressure. Intra-articular injection of vehicle for the 
capsaicin did not show any significant effect on the vascular bed and 
over 40 min blood flow was constant and similar to control base line 
levels. Therefore vasoconstriction of the knee is the major and local 
effect of capsaicin on blood flow. This vasoconstrictor effect was 
followed by a marked vasodilatation which only occurred with the first 
two concentrations of capsaicin (0 .02% and 0 .2%).
The vasoconstrictor effect described above could be a 
hyperactivity of sympathetic tone due to influx of calcium ions 
through the calcium channels activated by capsaicin or could be due to 
depletion of neuropeptides which have an effective role in offsetting 
sympathetic sympatetic vasoconstrictor tone (see chapter 4.4). 
Vasoconstriction is irreversible in the 2% capsaicin-treated knee joint 
over the time course of experiment.
As articular cartilage is critically dependent on synovial fluid 
formation for its nutrition (McKibbin and Matoudas 1979). This long 
lasting vasoconstriction followed by a marked and dose dependent 
vasodilatation could be due to the effect of capsaicin on unmyelinated 
sensory neurones and the release of neurokinins (Holzer 1991) and 
calcitonin gene related peptide (CGRP) which is a potent vasodilator 
(Hughes et ai 1994)
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In all cases following intra-articular application, capsaicin reacts 
with unmyelinated capsaicin-sensitive neurones and produces two 
separate reactions. In the first stage capsaicin desensitises and 
inactivates these neurones with an apparent vasoconstrictor effect 
possibly due to enhanced sympathetic tone. In the second stage release 
of neurokinins and CGRP from these neurones will have a vasodilator 
effect.
The capsaicin treated joint attenuated the SP vasodilator effect 
dose dependently. The lowest attenuation was in the 0.02% capsaicin 
pre-treated knee, which shifted the dose response curve to the right and 
significantly reduced the SP effect on blood flow. The highest 
attenuation due to SP was in the 2% capsaicin treated knee. Here the 
SP induced vasodilator effect was totally abolished and in fact there 
was no response to different doses of SP and the attenuating effect of 
0 .2% capsaicin was between these two.
These effects of SP in the acute capsaicin treated knee was 
similar to the chronic capsaicin treated group, and demonstrated a 
attenuated response to the exogenous neuropeptide, which could be 
due to the insensitivity of the neurokinin receptors. As SP is an 
inflammatory agent and capsaicin supresses its inflammatory effect 
(Lam & Ferrell 1989b), it could be used for treatment of arthritis and 
reduce its inflammation and pain by topical application of capsaicin 
cream (Deal et al. 1991) These data suggest that a long lasting acute 
vasoconstriction, changes in neuronal sensitivity and subsequent 
release of neurokinins are initiating factors for neurogenic 
inflammation. These finding support previous work (Jansco et al.
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1967), but have been visualised, for the first time, using the LDI 
technique.
5.7. GENERAL DISCUSSION
Three different models of inflammation were studied in these 
experiments, Carrageenan, a galactose fraction, induces acute 
inflammation by activating immune cells and releasing different 
inflammatory mediators. Acute oedema develops in the injected area 
and there is also alteration of membrane function. Carrageenan 
induced inflammation and significantly enhanced the vasodilator effect 
of SP on blood flow. SP-containing neurones and SP receptors seem to 
have an important effect in development of inflammation as evidenced 
by the enhanced vasodilator response to SP (fig. 5.22).
Capsaicin which is selectively neurotoxic for sensory 
unmyelinated fibres, was used to induce inflammation. With chronic 
capsaicin treatment, which causes sensory nerve ablation, SP did not 
show any effect on blood flow, and capsaicin modified receptors 
which mediates the effect of SP. When capsaicin was acutely applied 
to the joint at different doses, a short period vasoconstriction appeared 
followed by a larger dose dependent vasodilatation at lower 
concentrations of capsaicin. This demonstrated the effect of capsaicin 
on sensory neurones and on the release of vasodilator mediators or loss 
of vasoconstrictor tone.
Adjuvant activates immunological, histological, lysosomal and 
lymphatic systems to induce chronic arthritis. This inflammation also
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Fig 5.22: Changes in synovial blood flow during topical 
application o f SP to the jo int capsule in normal (O , mean ±SEM, 
n=10), carrageenan induced inflamm ation ( • ,  mean ±SEM , n=20), 
0.2% acute capsaicin (H, mean ±SEM , n=8), and in chronic 
adjuvant treatm ent week 3 (A , mean ±SEM , n=9). The sequence of 
doses adm inistered was randomised.
attenuated SP-induced vasodilatation and thus altered tissue response 
to SP. Adjuvant also demonstrated a contralateral inflammation 
accompanied by elevation of temperature. An increase in joint 
diameter and an alteration of the effect of SP on blood flow also
occurred. Such marked differences in response to SP suggests
fundamental differences in the mechanisms of inflammation in each 
model. It cannot be assumed that chronic inflammation is simply an
extended acute inflammatory response. Although acute capsaicin
administration induces acute inflammation in skin, in the joint marked 
vasoconstriction occurred, masking any inflammatory response. Thus, 
capsaicin cannot be used to investigation ipsilateral neurogenic 
inflammation, whereas in carrageenan-induced acute inflammation a 
marked vasodilatation occurs which demonstrates a different route to 
achieve acute inflammation. Chronic capsaicin treatment, causing 
nerve depletion, seems to mimic some of the adjuvant responses, 
certainly at week 1. This similarity may be due to the depletion of 
nerves in the synovium of adjuvant arthritic rats (Kontinen 1990), but 
these were only investigated at one week. It would be interesting to 
follow capsaicin-treated rats to 3 weeks post injection and examine the 
response of the synovial vasculature to SP (fig. 5.22).
The three agents produced a inflammation with altered 
neurokinin responses showing that they may play a role in the 
induction of these inflammatory responses. Neurokinins could provide 
clues to unlocking the mysteries of arthritis .
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6 G E N E R A L  C O N C L U SIO N :
Joint nutrition is critically dependent on the synovial circulation 
and joint activity and blood flow regulation are closely related. The 
existence of calcitonin gene-related peptide (CGRP) and neurokinins 
has been found in sensory nerve endings and these have important 
actions in blood flow regulation.
In this thesis different aspects of the effect of these 
neuropeptides on blood flow has been studied. An interesting finding 
in these experiments was the protein extravasation effect of CGRP, 
which could be a contributory factor in joint inflammation.
The finding that NK1 and NK2 receptors mediate the effect of 
neurokinins on blood flow in the rat knee joint and that their actions 
are altered in the different models of arthritis considered here, suggests 
that these peptides may be involved in the inflammation. The enhanced 
SP-induced vasodilatation in carrageenan-induced inflammation 
contrasts with vasoconstrictor response to SP in adjuvant arthritis and 
suggests that chronic inflammation is not simply a continuation of an 
acute inflammatory response, and they have different pathways, 
though they can interact.
These experiments, for the first time revealed the contribution of 
neurokinins in the regulation of normal basal blood flow. It is possible 
that there is continual release of neurokinins from sensory nerve 
endings even in the absence of application of noxious stimuli.
Future experiments are indicated to continue work on different 
models of inflammation over longer periods to determine how long
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neurokinin responses are altered and also establish the contribution of 
other agents, e.g. prostaglandins and nitric oxide and their interaction 
with neurokinins in the development of inflammation. Also of interest 
would be the extent to which neurokinins influence basic perfusion in 
acute and chronic inflammation. Recently discovered specific NK3 
antagonists could give a clear clue in the investigation of the 
neurokinin effect on knee joint blood flow in the normal knee and 
inflamed knee.
In the normal knee joint over 60% of nociceptors are silent. 
However, activation of these receptors by different mechanisms (e.g.: 
chemical or physical factors) is followed by the release of 
neuropeptides (Otsuka & Yashioka 1993, Me Carson 1994), which 
results in protein extravasation and vasodilatation in the area, and 
stimulates nociceptors to a greater discharge frequency such that a 
vicious circle then develops. Up to this level of inflammation the three 
models of inflammation have similar signs but beyond this, depending 
on the nature of the agent, will develop different effects and changes in 
the joint such as alteration in the response to SP. The involvement of 
these sensory nerve fibres in joint inflammation is suggested by 
observation that in both capsaicin and Adjuvant treated knees there is a 
reduced response to SP and in both cases there is known to be 
depletion of unmyelinated nerve fibres (Ferrell et al 1992, Konttinen et 
al 1990). However such similarities in signs, the future course of 
inflammation and the methods of therapy depend on the initiating 
factor and individual treatments are required, but in all of these 
inflammatory models neuropeptides play a major role .
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